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Preface 
The thesis presented here, shows the work I have completed for obtaining a 
doctoral degree of Natural Science in Biology. The experimental work was carried out in 
the Laboratory of Cell Migration, Institute of Physiology II, Westfälische Wilhelms-
University of Münster. The supervisor on my project was Prof. Dr. med. Albrecht Schwab 
and as a representative from the Faculty of Biology, Prof. Dr. phil. nat. Wolf-Michael 
Weber, Institute of Animal Physiology, Department of Biology, University of Münster.  
 
The main focus of my thesis is the role of TRPC1 and TRPC6 channels in the 
response of pancreatic stellate cells (PSCs) to hypoxia and their importance for cell 
migration. The aim of Chapter 1 is to familiarize the reader with the role of PSCs in the 
development and progression of pancreatic cancer. The importance of cell migration is 
discussed in relation to PSC function, and the role of Ca2+ signalling for this process is 
highlighted. In the end of chapter 1, an introduction to TRP channels role as sensors, 
modifiers and transduction/effectors of the tumour microenvironment is outlined leading 
to the main aim and hypothesis of the thesis (described in Chapter 2). In Chapter 3, 
experimental materials and methods are outlined. This is followed by the major results 
discovered, described in Chapter 4. These findings are discussed in Chapter 5. Chapter 6 
contains concluding remarks and perspectives of scientific findings presented in this study  
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Nikolaj Nielsen  
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Summary 
Pancreatic cancer is characterized by the presence of an excessive amount of 
connective tissue, primarily formed by pancreatic stellate cells (PSCs). This leads to a 
hypoxic tumour microenvironment that activates PSCs such that they secrete various 
growth factors, chemokines and matrix components. This stimulates PSC migration 
towards the tumour area as well as mutual growth factor/cytokine signalling with cancer 
cells. Thus, the ability of PSCs to migrate is recognized as a consequence of their activated 
state and as a requirement for efficient communication with cancer cells. Moreover, cell 
migration is a Ca2+-dependent process that implicates the activity of transient receptor 
potential (TRP) channels. Many TRP channels are part of receptor signalling cascades, and 
are thereby essential components of the transduction and effector mechanisms 
underlying cellular responses to microenvironmental cues such as hypoxia. Furthermore, 
there is growing evidence supporting a role of TRP channels in sensing and modifying the 
(tumour) microenvironment. This is in particular evident for members of the TRPC family. 
However, the role of TRPC channels in the response of PSCs to hypoxia is unclear.  
In the current study, the TRPC1 and TRPC6 channel showed the highest expression 
of all TRPC channels in murine PSCs. It was therefore postulated that these particular 
channels could play a role in regulating the responses of PSCs to hypoxia. Their role in PSC 
migration was investigated using primary cultured PSCs isolated from WT, TRPC1-/- and 
TRPC6-/- mice. Hypoxia was shown to increase WT mPSC motility, activate secretion of 
autocrine stimulants and enhance calcium signaling. In contrast, similar effects were not 
observed for TRPC1-/- and TRPC6-/- mPSCs. Hypoxia-mediated increase of TRPC1 
expression in mPSCs was coupled to elevated cell motility, potentially via a sensor 
mechanism that is also important for correct cell size regulation. TRPC6 channels are part 
of a modifier mechanism due to their requirement for efficient autocrine stimulation 
under hypoxic conditions through growth factor/cytokine secretion. Moreover, by 
mediating increased calcium influx during hypoxia they activate Ca2+ sensitive effector 
proteins of the cellular migration machinery, evidencing a role in a transduction/effector 
pathway. Overall, these data show for the first time that the Ca2+ permeable TRPC1 and 
TRPC6 channels are important for the response of mPSCs to hypoxia by affecting their 
migratory behaviour. 
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German Resumé 
Ein charakteristisches Merkmal des Pankreaskarzinoms ist die übermäßige 
Produktion von Bindegewebe, an der primär Pankreassternzellen (PSZ) beteiligt sind. 
Hierdurch entsteht ein hypoxisches Mikromilieu im Tumorgewebe, welches zu einer 
Aktivierung von PSZ und damit zu einer vermehrten Bildung von Wachstumsfaktoren, 
Chemokinen und Matrixkomponenten führt. Dies fördert die Migration von PSZ in das 
Tumorgewebe und ermöglicht eine Kommunikation mit den Karzinomzellen. Somit kann 
die Fähigkeit zur Migration als Folge der Aktivierung der PSZ und als eine Voraussetzung 
zur effizienten Kommunikation mit den Krebszellen angesehen werden. Zellmigration im 
allgemeinen ist ein Ca2+-abhängiger Prozess, welcher TRP-Kanäle (transient receptor 
potential) impliziert. Viele Mitglieder der TRP-Kanal-Familie sind Teil von Rezeptor-
Signalkaskaden, die die Antworten auf Stimuli aus der zellulären Umgebung vermitteln. 
Auch wenn es vereinzelte Hinweise für eine Beteiligung von TRP-Kanälen an der 
Detektion extrazellulärer Stimuli aus dem Tumor-Mikromilieu gibt, konnte ihre Rolle bei 
der Reaktion von PSZ auf hypoxische Bedingungen bisher nicht geklärt werden. 
In der vorliegenden Arbeit konnte gezeigt werden, dass TRPC1 und TRPC6 die am 
stärksten exprimierten TRP-Kanäle in murinen PSZ (mPSZ) darstellen. Um ihre Rolle bei 
der Zellmigration zu klären, wurden mPSZ aus WT, TRPC1-/- und TRPC6-/- Mäusen isoliert. 
Hierbei konnte gezeigt werden, dass Hypoxie die Motilität, die Sekretion autokriner 
Stimuli und das Ca2+-Signaling von WT mPSZ erhöht. Im Gegensatz hierzu konnten diese 
Effekte in TRPC1-/- und TRPC6-/- mPSZ nicht beobachtet werden. Die durch  Hypoxie 
herbeigeführte Erhöhung der TRPC1 Expression in den WT Zellen wird dabei 
möglicherweise über einen Sensor-Mechanismus vermittelt, der ebenfalls an der 
Regulation der Zellgröße beteiligt ist. TRPC6-Kanäle scheinen dagegen an der effizienten 
autokrinen Stimulation durch Wachstumsfaktor- und der Zytokin-Sekretion unter 
hypoxischen Bedingungen beteiligt zu sein. Darüber hinaus führt die TRPC6-vermittelte 
Ca2+-Mobilisierung unter Hypoxie zur Aktivierung von Effektor-Proteinen der 
Zellmigration. Zusammenfassend konnte in dieser Arbeit zum ersten Mal gezeigt werden, 
dass der Ca2+-permeable TRPC1- und TRPC6-Kanal maßgeblich das Migrationsverhalten 
von mPSZ unter hypoxischen Bedingungen beeinflussen. 
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Introduction 
1.1 Anatomy and Function of the Pancreas 
The primary function of the pancreas is to aid in the digestion of food through 
secretion of enzyme-rich pancreatic juice. Humans secrete approximately 1-2 l pancreatic 
juice per day. The pancreas is located in the upper abdomen, has a recognizable pinkish 
color and forms a lobular structure. It contacts the concave side of the duodenum and the 
spleen, thereby maintaining an intimate connection with vital blood vessels and organs. It 
is comprised four regions: head, neck, body and tail (figure 1.1) (Aumüller et al., 2014; Lee 
et al., 2012). The pancreas acts as both an exocrine and an endocrine gland. The 
endocrine glands, referred to as the islets of Langerhans, secrete hormones that regulate 
glucose metabolism. These include among others, Insulin, glucagon, somatostatin and 
pancreatic polypeptide, which are secreted from β-, α-, δ- and F-cells, respectively. A 
normal human pancreas contains between 500.000 to several millions islets, each 
measuring between 50 and 300 μm in diameter (Boron and Boulpaep, 2005). The 
exocrine pancreas is composed of lobules each made up of acini (clusters of acinar cells) 
surrounding a central lumen whereto the acinar cells release their digestive enzymes via 
zymogen granules (figure 1.1). These enzymes include proteases, amylases, nucleases and 
lipases, which are mostly secreted as inactive precursor proteins. The acini lumen feeds 
into an intercalated duct and groups of acini are further drained by larger interlobular 
ducts that empty into a main duct connected to the lumen of the gastrointestinal tract 
(Boron and Boulpaep, 2005). Food digestion can stimulate digestive enzyme release 
through both neural (cholinergic) or hormonal (predominantly CCK, released from the 
duodenum) activity. In the duodenal lumen, enteropeptidase cleaves the pancreatic 
protease trypsinogen into active trypsin, which in turn catalyses the activation of all other 
pancreatic proteases.  
The two primary functions of the pancreatic duct cells are to (a) secrete fluid that 
acts as a vehicle for the transport of secreted enzymes and (b) secrete HCO3- that is 
important for neutralizing gastric acid and provides the optimal pH environment for the 
digestive enzymes (Boron and Boulpaep, 2005; Lee et al., 2012). Pancreatic stellate cells 
(PSCs) are also residing in the exocrine pancreas (described in section 1.3). They are 
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Figure 1.1. The Anatomy of Pancreas. (A) Placed deep in the abdominal cavity, the pancreas is 
situated close to many vital organs and blood vessels. It is anatomically divided into a head, 
neck, body and tail (adapted from http://www.pancreaticcancerindia.com). (B) The pancreas 
can be divided into an exocrine and endocrine component. The endocrine component, 
consisting of islets of Langerhans, functions to secrete hormones that regulate carbohydrate 
metabolism. The exocrine component consists of clusters of acinar cells (known as acini)  that 
secrete numerous digestive enzymes into the acinar lumen that feeds into ductules. In the 
normal pancreas, quiescent PSCs are found in the periacinar and periductal space of exocrine 
areas, where their long cytoplasmic processes encircle the acinar and duct cells. PSCs 
participate in various physiological as well as pathophysiological processes in pancreas biology 
(Omary et al., 2007).  
mostly present in the periacinar space were they encircle the base of the acini, but they 
can also be found in perivascular and periductal regions of the pancreas (figure 1.1) (Apte 
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et al., 1998; Bachem et al., 1998; Omary et al., 2007). These cells play a role in regulating 
and controlling tissue homeostasis in both physiological as well as pathophysiological 
processes, including pancreatic cancer (Apte and Wilson, 2011; Bachem et al., 2008; 
Duner et al., 2011; Vonlaufen et al., 2008b). 
 
1.2 Pancreatic Ductal Adenocarcinoma 
Tumours arising from the epithelium of the exocrine pancreas are the most 
common type of pancreatic cancer and account for well over 95% of all pancreatic 
cancers. Of these, pancreatic ductal adenocarcinoma (PDAC) is the most common type, 
making up 90% of all exocrine tumours (Klimstra, 2007; Matthaios et al., 2011). PDAC 
tumours can be sub-grouped according to their localisation in the pancreas. 65% originate 
in the head of the pancreas, 30% in the body and tail and 5% can occur within the whole 
pancreas (Ryan et al., 2014). PDAC is not a common cancer type compared to that of lung, 
breast, prostate and colorectal cancer. In 2015, PDAC is projected to rank 10-12th in 
incidence rates worldwide (Ferlay et al., 2015; Siegel et al., 2015), which is lower than the 
previous years where it ranked 9-10th in 2009 in the United States (Jemal et al., 2009) and 
7th in 2012 in European countries (Ferlay et al., 2010; Ferlay et al., 2013). Despite its low 
ranking in incidences, PDAC is the fourth most common cause of cancer related death in 
the world among men and women (Ferlay et al., 2015; Malvezzi et al., 2014; Siegel et al., 
2015). Moreover, a recent projection of cancer incidence and death for 2020 and 2030 
estimated that pancreatic cancer will surpass breast, prostate and colorectal cancers by 
2030 to become the second leading causes of cancer-related deaths (Rahib et al., 2014). 
In total, PDAC has one of the worst prognoses of all cancers, with an overall 5-year 
survival rate of less than 5% and on average patients live for only 6 months after 
diagnosis. It therefore represents one of the most lethal cancers, where mortality is 
essentially equal to incidence (Hidalgo, 2010).  
 
1.2.1 Clinical Manifestation and Risk Factors  
The lethal nature of PDAC is due to its aggressive growth and the rapid 
development of distant metastasis. Moreover, symptoms of PDAC are mostly present at 
only an advanced stage, making diagnosis and treatment extremely difficult (Hidalgo, 
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2010; Maitra and Hruban, 2008; Oettle, 2014). The only potentially curative treatment so 
far is surgical resection followed by adjuvant chemotherapy, but less than 20% of patients 
are able to undergo surgery (Barugola et al., 2009; Jones et al., 2014). Additionally, 
surgical resection only prolongs the 5-year survival by 10% because of comorbidity or 
because the tumour has already become metastatic. 85% of these patients will therefore 
experience relapse and subsequent cancer-related death. Virtually all patients do not 
survive past 7-10 years of surgery (Alexakis et al., 2004; Carpelan-Holmstrom et al., 2005).  
PDAC occurs primarily in elderly people and the aging European population means 
the incidence is very likely to increase (Malvezzi et al., 2014). Nevertheless, age is not the 
only risk factor for developing PDAC, as other factors include multiple genetic syndromes 
(section 1.2.2), a family history of cancer, as well as modifiable risk factors (reviewed in 
(Becker et al., 2014; Maisonneuve and Lowenfels, 2010)). Cigarette smoking represents 
the most prominent environmental risk factor of developing PDAC (Lowenfels and 
Maisonneuve, 2006), along with others such as diabetes, obesity, chronic pancreatitis and 
alcohol abuse (Fedeli et al., 2014; Maisonneuve and Lowenfels, 2010; Raimondi et al., 
2009) as well as lack of sufficient physical activity (Eheman et al., 2012; Raimondi et al., 
2009). Currently, no standards exists for screening and evaluating these high-risk patients 
(Bruenderman and Martin, 2014). To combat the mortality rates of PDAC, more effort is 
required to understand PDAC development and progression together with methods of 
early prevention, diagnosis and treatment of patients with advanced disease. Better 
screening and identification of early pancreatic cancer lesions can also improve the 
detection of patients suitable for surgical resection (Esposito et al., 2014; Haugk, 2010). 
 
1.2.2 Characterisation and Molecular Pathogenesis of PDAC 
Pancreatic intraepithelial neoplasia  represents the best characterised histological 
indicator used to designate and identify proliferative duct lesions during progression of 
PDAC from normal duct epithelium to infiltrating cancer (figure 1.2) (PanIN) (Hruban et 
al., 2001; Hruban et al., 2000; Klimstra and Longnecker, 1994; Maitra et al., 2003). 
Intraductal papillary mucinous neoplasm (IPMN) and mucinous cystic neoplasm (MCN) 
are also associated with invasive PDACs (reviewed in (Hruban et al., 2007)). However, 
these lesions account for only ~5% of all primary pancreatic tumours (Visser et al., 2008). 
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Figure 1.2. Progression Model of Pancreatic Ductal Adenocarcinoma. (A) Representative 
histopathological images illustrating the progressive abnormality changes from normal duct 
epithelium to PanIN-1 A/B, PanIN-2, PanIN-3 and to invasive PDAC (adapted from (Mihaljevic 
et al., 2010)). (B) A schematic drawing of the histopathological PanIN features of normal duct 
epithelium progression to infiltrating cancer (left to right). Underneath are given some of the 
main known mutagenic events occurring during PDAC progression together with novel tumor 
markers (see text). The length of the arrows indicates the occurrence of the events, some at 
early and some at later stages (adapted from (Duner et al., 2011; Maitra et al., 2003). 
All precursor lesions found for PDAC (PanIN, IPMN and MCN) are fundamental for early 
detection and treatment of patients (Becker et al., 2014; Haugk, 2010).  
 PDAC is a fundamentally genetic disease caused by alterations in cancer associated 
genes. In the past two decades we have witnessed an explosion in our understanding of 
PDAC, with a number somatic mutations being identified and mapped (Esposito et al., 
2014; Maitra and Hruban, 2008; Maitra et al., 2006). These mutagenic abnormalities 
occur in parallel with PanIN lesions (figure 1.2) (Maitra et al., 2003). Overall, PanIN is 
driven by the expression of an oncogenic form of the K-RAS gene, which was the first 
genetic abnormality found in PDAC progression and is present in more than 90% of PDAC 
A 
B 
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tumours (Hruban et al., 1993). Telomere shortening is also one of the first events that 
occurs in PDAC development and is found in more than 95% of all PanIN lesions (van Heek 
et al., 2002). Other important tumour suppressor, oncogenes and maintenance genes 
implicated in PanIN progression include P16/CDKN2A, Cyclin D1, SMAD4, P53, HER-2/neu 
and BRCA2 (some depicted in figure 1.2 B) (Reviewed in (Haugk, 2010; Mihaljevic et al., 
2010; Ottenhof et al., 2011). Each affects several central core signalling pathways 
important to fulfil the following hallmark criteria for tumour development defined by 
Hanahan and Weinberg (Hanahan and Coussens, 2012; Hanahan and Weinberg, 2011): (1) 
self-sufficiency in growth signals, (2) insensitivity to antigrowth signals, (3) evasion of 
apoptosis, (4) limitless replicative potential, (5) angiogenesis, and (6) invasion and 
metastasis (Hanahan and Weinberg, 2000; Mihaljevic et al., 2010). Several other genes 
have been found to be up- and down regulated (Biankin et al., 2012; Grutzmann et al., 
2004; Jones et al., 2008). This has made it clear that PDAC is highly heterogeneous 
partially explaining the difficulties in treatment (Oettle, 2014; Ottenhof et al., 2011). 
A representative group of novel PDAC tumour markers in different PanIN lesions are 
depicted in figure 1.2 B (PSCA, Mesothelin, Fascin, and 14-3-3). These genetic fingerprints 
or transcriptional profiles have allowed the identification of specific subtypes of PDAC 
(classical, quasimesenchymal (QM-PDA) and exocrine-like), which have different 
prognoses and distinct drug responses (Collisson et al., 2011)  
 
1.3 Pancreatic Stellate Cells – Key Players in PDAC 
Progression and Metastasis 
One of the most pronounced features compared to other cancers is the abundant 
deposition of connective tissue (fibrosis) surrounding the tumour also known as the 
desmoplastic reaction in PDAC (Apte et al., 2004; Vonlaufen et al., 2008b). This stroma 
content can form up to 90% of the total tumour mass in PDAC and correlate with its 
biological and clinical aggressiveness, chemo resistance and limited availability in drug 
delivery (Erkan et al., 2012; Mahadevan and Von Hoff, 2007; Schober et al., 2014). It is 
widely accepted that activated pancreatic stellate cells (PSC) are responsible for this 
reaction (Apte et al., 2004). This has increased the understanding of PDAC development 
and progression together with other general aspects of the tumour microenvironment 
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(TME) and its host cells in cancer progression (e.g. fibroblasts, macrophages and other 
immune cells or endothelial cells) (Brabek et al., 2010; Gupta and Massague, 2006; 
Hanahan and Weinberg, 2011; Joyce and Pollard, 2009). The tumour is now recognized as 
a continuously evolving organ and as the cancer progresses, the surrounding TME 
changes in parallel into an activated state (Gatenby and Gillies, 2008). This occurs mainly 
through continuous communication and mutual signalling between the cancer and 
stroma cells together with extracellular matrix (ECM) production and remodelling (Li et 
al., 2007b; Shimoda et al., 2010). This aspect in tumour progression is intimately related 
to the influence of PSCs in PDAC progression. Second, the physical and biochemical 
properties of the TME have an influence on PSC activation and PDAC progression (e.g. 
pressure, ECM components, stiffness, topography, acidity and hypoxia) together with 
oxidative stress and its metabolites including reactive oxygen species (ROS), ethanol, 
acetaldehyde and hydrogen peroxide (Feig et al., 2012; Kikuta et al., 2006; Masamune et 
al., 2002; Masamune et al., 2010). Overall, cancer progression can be viewed as an 
orchestra of multiple players. 
  
1.3.1 The History and Characterization of Pancreatic Stellate Cells  
The term “Stellate cell” was first used for isolated hepatic stellate cells (HSC) 
identified by Karl Wilhelm Kupffer although he classified these cells as phagocytes 
(Kupffer, 1876). In 1971, Wake identified these cells as HSC (Wake, 1971) and an 
agreement was made to use this as a standard name in 1996 (Ahern et al., 1996). PSC is 
the counterpart to HSC and was first reported in mice by Watari in 1982 (Watari et al., 
1982) and later in human and rat (Ikejiri, 1990). However, the major impact in the 
understanding of fibrosis and desmoplasia in PDAC was first made after the development 
of the isolation and culture procedure for mammalian PSCs (Apte et al., 1998; Bachem et 
al., 1998) and the establishment of a human PSC line (RLT-PSC) (Jesnowski et al., 2005). 
This in vitro tool has provided valuable knowledge on PSC function and their pronounced 
influence on PDAC progression (Vonlaufen et al., 2010). A historical timeline with the 
most important milestones in the understanding of PDAC and PSC is shown in figure 1.3. 
In the normal pancreas, resident PSCs are located in the periacinal spaces adjacent   
to acinar cells and comprise 4-7% of all pancreatic cells. Here they maintain normal tissue 
integrity and homeostasis via tight regulation of extracellular matrix (ECM) turnover 
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Figure 1.3. Major Milestones in Pancreatic Stellate Cell and PDAC Biology. (A) The key 
milestones in PSC and PDAC biology shown in a timeline with relation to following: (1) The 
implementation of the “seed and soil” hypothesis, (2) introduction of cancer hallmarks, (3) 
introduction of the TME to the cancer hallmarks, (4) discovery of TRP channels (5) to date only 
published papers on ion channels/receptors in PSCs (outlined in the text).  (B) Illustration of 
the increasing research interest of the TME influence on tumour biology, PSCs role in PDAC 
development and progression, and ion channels related to cancer.  
through the secretion of metalloproteinases (MMPs) and tissue inhibitors of MMPs 
(TIMPs) (Phillips et al., 2003a). Additionally, PSCs determine the proper formation and 
differentiation of acini during normal development through effective β1-integrin cell 
adhesion to the basement membrane (Arcangeli et al., 2014; Riopel et al., 2013). In their 
quiescent stage PSCs can be characterised and identified by abundant Vitamin A droplets 
in their cytoplasm together with the expression of desmin and glial fibrillary acidic protein 
(GFAP). During pancreatic injury or PDAC, PSCs are activated, lose their lipid droplets and 
transform into an activated myofibroblast-like phenotype expressing α-smooth muscle 
actin (α-SMA). Of note, this transformation is also spontaneously induced by in vitro 
isolation and culturing of primary PSCs (Apte et al., 1998; Bachem et al., 1998).  
 
1.3.2 Pancreatic Stellate Cell Activation 
Upon activation, PSCs subsequently acquire the following functional capabilities: (1) 
increased proliferation rate, (2) higher migration activity, (3) excessive production of ECM 
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components as well as ECM modulators including MMP and TIMPs, and (4) secretion of 
proinflammatory growth factors and cytokines (Bachem et al., 2005; Phillips et al., 
2003b).  
Several in vitro and in vivo studies of mice, rat and human PSCs have identified a 
number of intra- and extracellular effector molecules that are secreted by PSCs. Many 
also originate from PDAC cells (section 1.3.3.2). These include numerous growth 
factors/cytokines, oxidative stress and ROS which exert both paracrine and autocrine 
effects (figure 1.4). Platelet-derived growth factor (PDGF) and transforming growth factor 
β1 (TGF-β1) are the two most established activators that lead to increased proliferation, 
ECM production, MMP secretion and cell migration of PSCs (Apte et al., 1999; Apte et al., 
2012; Luttenberger et al., 2000; Masamune et al., 2009; Phillips et al., 2003b; Schneider 
et al., 2001; Tahara et al., 2013; Tang et al., 2012). PDGF is also a potent chemoattractant 
for PSCs (Hild, 2015; Phillips et al., 2003b). Other factors include hepatocyte growth factor 
(HGF), vascular endothelial growth factor (VEGF), connective tissue growth factor (CTGF), 
epidermal growth factor (EGF) fibroblast growth factor (FGF), interleukin (IL)-6, IL-8, IL-10, 
IL-15 and monocyte chemoattractant protein 1 (MCP-1) (Eguchi et al., 2013; Habisch et 
al., 2010; Masamune et al., 2009; Masamune et al., 2008a; Mews et al., 2002). PSCs also 
respond differently to a range of inflammatory cytokines. For example, tumour necrosis 
factor α (TNF-α) stimulates proliferation and collagen production, IL-10 stimulates 
collagen production, whereas IL-6 inhibits both functions (Mews et al., 2002).  
In connection to this, the mitogen-activated protein kinase (MAPK) and the 
phosphatidylinositol-3-kinase (PI3K) pathway has been identified to be among the key 
signalling pathways of cytokine-related PSC activation (Jaster, 2004; Masamune and 
Shimosegawa, 2009). PDGF-induced PSC migration is regulated by the PI3K-Akt pathway 
(Masamune et al., 2003a; McCarroll et al., 2004), while PDGF-induced PSC proliferation is 
mediated via the extracellular signal regulated kinase (ERK1/2) pathway (Jaster et al., 
2002; Masamune et al., 2003a). Oxidative stress and its metabolites including ROS, 
ethanol, acetaldehyde and hydrogen peroxide induce activation of the MAPK pathway in 
PSC through ERK1/2, p38 kinase and c-jun amino terminal kinase (JNK), transcription 
factor activator protein-1 (AP-1) as well as the two upstream signalling molecules PI3K 
and protein kinase C (PKC) (Kikuta et al., 2006; Masamune et al., 2002; Masamune et al., 
2010). Additionally, the Rho-Rho kinase (ROCK) pathway is involved in the activation of 
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PSC through the reorganization of actin cytoskeleton (Masamune et al., 2003b) and 
activation of the Indian hedgehog (IHH) pathway, which promotes PSC migration 
(Shinozaki et al., 2008). In contrast, the nuclear hormone receptor peroxisome 
proliferator-activated receptor γ (PPAR-γ) pathway been implicated in PSC inhibition 
through a repression of PSC proliferation and α-SMA expression (Galli et al., 2000). 
 
1.3.3 Pancreatic Stellate Cells in the (PDAC) Microenvironment  
Sustained PSC activation leads to disturbance of the normal balance between ECM 
production and degradation promoting fibrogenesis. This occurs primarily through 
elevated expression of collagens (I, III, V), fibronectin and laminin in activated PSCs (Apte 
et al., 1999; Bachem et al., 1998; Wehr et al., 2011) (figure 1.4). Consequently, PSCs are 
present and activated within these hypoxic and fibrotic areas of PDAC as demonstrated 
by co-localisation studies with the hypoxia inducible factor 1-α (HIF-1α) and carbonic 
anhydrase 9 (Couvelard et al., 2005; Eguchi et al., 2013). More, PSC-produced collagen I 
and V promote the malignant phenotype of PDAC (Apte et al., 2004; Armstrong et al., 
2004; Berchtold et al., 2015; Vaquero et al., 2003; Wehr et al., 2011). In return ECM 
components influence PSC activity: fibrinogen, which is highly present in PDAC, induces 
collagen I, IL6, IL8, MCP-1, VEGF production in PSCs (Masamune et al., 2009). Additionally, 
the ECM can serve as a reservoir for numerous proteins and growth factors/cytokines, 
which are released during ECM turnover to promote PSC and PDAC cell activity. In 
connection to this, studies suggest that activated PSCs rather that PDAC cells are the main 
players in ECM turnover: PSCs are major sources of MMP and TIMP secretion (MMP-2, 9, 
12 and 13) (Bachem et al., 2005; Erkan et al., 2009; Phillips et al., 2003a; Yoshida et al., 
2004). For example, MMP-2 secretion exceeds by far that of cancer cells (Ellenrieder et 
al., 2000; Farrow et al., 2009; Schneiderhan et al., 2007). As general changes in ECM 
mechanics are related to promoting cancer progression (Werfel et al., 2013), this adds 
weight to the participation of PSCs in driving PDAC progression. Although targeting MMPs 
showed promising results only a few years ago (Alves et al., 2001), the inhibition of MMPs 
in cancer and stroma cells in later studies actually increased migration, questioning the 
potential of MMPs in cancer therapy (Friedl and Wolf, 2009a; Kessenbrock et al., 2010; 
Mierke, 2012).  
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Figure 1.4. Pancreatic Stellate Cell Activation and Mutual Signalling with PDAC Cells. PSC can 
be activated or further stimulated by various paracrine stimulants released from PDAC cells 
(blue text), inflammatory immune cells or injured acinar/duct cells. Activated PSCs in turn 
secrete growth factors/cytokines (red text) and ECM components mediating stimulatory and 
survival effects on PDAC cells either directly or through a desmoplastic reaction. Activated 
PSCs can recruit/activate neighbouring PSCs and inflammatory immune cells. In this manner, a 
positive mutual stimulatory loop is maintained and an aggressive PDAC microenvironment 
formed. Additionally, PSCs can be activated by exogenous factors including oxidative stress or 
hypoxia caused by the desmoplastic reaction. Finally, PSCs are cable of autocrine stimulation 
perpetuating their own activity. Major PSC processes stimulated by PDAC cells and vice versa 
are given in blue and red boxes, respectively. Modified from (Tang et al., 2012) and (Duner et 
al., 2011). 
1.3.3.1 Hypoxia – A Major Feature in PDAC and PSC Activation  
Tumour compression, solid stress and high interstitial fluid pressure observed in 
PDAC promote intracellular oxidative stress pathways in PSCs (Asaumi et al., 2007; 
Kharaishvili et al., 2014), which leads to elevated secretion of TGF-β1 and collagen I 
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(Watanabe et al., 2004). In addition, cell stress appears to participate in the early stages 
of fibrogenesis and oncogenesis by activating PSCs, with hypoxia playing a major role in 
this process (Erkan et al., 2009; Rebours et al., 2013). Hypoxia-mediated PSC activation 
involve elevated migratory activity together with expression and secretion of collagen I, 
fibronectin, CXCL12, TGF-β1, FGF, CTGF, VEGF and MMPs expression. This facilitates a 
favourable TME for PDAC progression, migration and invasion (Eguchi et al., 2013; Erkan 
et al., 2009; Ide et al., 2006; Masamune et al., 2008a). Additionally, hypoxia-mediated 
secretion of VEGF by PSCs promotes angiogenesis in PDAC (Erkan et al., 2009; Masamune 
et al., 2008a) correlating with the degree of fibrosis (Kuehn et al., 1999) (figure 1.4). 
Hypoxia also favours the metabolic cooperation between stroma and cancer cells and the 
induction of chronic inflammation (Icard et al., 2014). Specifically, continuous secretion of 
proinflammatory cytokines (IL-1, 6, 8, 10 and MCP-1) in hypoxia-activated PSCs, together 
with that of PDAC cells, leads to recruitment and infiltration of immune cells. This gives 
rise to chronic tumour inflammation and an immune suppressive TME that accelerates 
tumour progression (Clark et al., 2007; Landskron et al., 2014; Lunardi et al., 2014; 
Wormann et al., 2014; Yang et al., 2013; Yu and Kim, 2014). For example, IL-8 and MCP-1 
expression by PSCs may modulate the recruitment and accumulation of inflammatory 
cells in the pancreas and may play a role in perpetuating a state of inflammation in the 
TME (Andoh et al., 2000; Wehr et al., 2011). Even so, the molecular mechanisms behind 
the hypoxia-mediated stimulation of PSC are still yet to be elucidated. In summary, this 
supports the statement that PSCs establish a TME that favour PDAC progression and 
survival. Thus this is largely achieved through close mutual signalling between PSCs and 
PDAC cells (figure 1.4) (Apte and Wilson, 2011; Habisch et al., 2010; Tang et al., 2012; 
Vonlaufen et al., 2008b). This partnership was highlighted in a recent review, where a 
collection of all available in vitro and in vivo data demonstrated a close bi-directional 
interaction between PSCs and PDAC cells (Haqq et al., 2014) 
 
1.3.3.2 PSCs Mutual Signalling with PDAC Cells  
PDAC cells stimulate PSC proliferation, migration, matrix and MMP synthesis 
through secretion of PDGF, TGF-β1 and FGF-2 (Apte et al., 2004; Bachem et al., 2005; 
Bachem et al., 2008; Vonlaufen et al., 2008a). In return, PSCs stimulate pancreatic cancer 
cell proliferation, migration, invasion/metastasis and decrease cancer cell apoptosis to 
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enhance cancer survival (Bachem et al., 2005; Bachem et al., 2008; Hwang et al., 2008). 
For instance, enhanced CTGF secretion from hypoxia-activated PSCs induces invasion of 
PDAC cells (Eguchi et al., 2013) and inhibition of CTGF improves chemotherapy responses 
without increasing drug delivery (Neesse et al., 2013). Hwang et al. found that 
conditioned media from PSCs induces PDAC resistance to gemcitabine and radiation 
(Hwang et al., 2008), although Mantoni et al. could not confirm these observations. 
Instead, they found that under both in vitro and in vivo settings PSCs radioprotect PDAC 
cells via a  β1-integrin-dependent signalling pathway (Mantoni et al., 2011). Further, 
PDAC cells stimulate PSCs to secrete VEGF promoting angiogenesis (Erkan et al., 2009; 
Masamune et al., 2008a) and the induction of COX-2 expression in PSC (Yoshida et al., 
2005), which is coupled to autocrine stimulation in PSCs (Aoki et al., 2007). Also 
sphingosine-1-phophate (S1P) activates PSCs to generate MMP-9, which increases PDAC 
cell migration and invasion in vitro. Following knock down of the S1P signalling pathway in 
PSCs, reduced pancreatic tumour growth and metastasis in an orthotopic PDAC model (Bi 
et al., 2014).  
Moreover, a direct interaction between PSC and PDAC cells has been observed. Co-
culture of PSC with PDAC cells significantly increased PDAC cell proliferation compared to 
regular co-culture systems using conditioned media. This activation was thought to be 
due to direct cell contact-activated notch signalling (Fujita et al., 2009). Overall, this 
supports the existence of an active and close cooperation between PSCs and PDAC cells in 
facilitating PDAC progression. In vivo studies in genetically engineered mouse models 
(GEMM) (12 in total, reviewed in (Hruban et al., 2006; Mazur and Siveke, 2012) have 
confirmed these observations. 
GEMMs mimic the natural development and progression of PDAC more than 
standard xenograft and orthotopic PDAC models (Hruban et al., 2006; Mahadevan and 
Von Hoff, 2007; Mazur and Siveke, 2012). Co-injection of PSCs and PDAC cells into an 
orthotopic mice model developed larger tumours with extensive desmoplasia, elevated 
tumour progression and increased regional invasion and distant metastasis compared to 
PDAC cells injected alone (Bachem et al., 2008; Hwang et al., 2008; Vonlaufen et al., 
2008a). Additionally, in a xenograft model PSCs accelerated tumour progression of PDAC 
through elevated secretion of MMP-2 (Schneiderhan et al., 2007). Sonic hedgehog (SHH) 
signalling is absent in the normal pancreas but upregulated in PDAC. In PDAC SHH elicits 
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paracrine effects on PSC differentiation and motility, contributing to the formation of 
desmoplasia by increased collagen I and fibronectin production (Bailey et al., 2008). 
Inhibition of SHH signalling in a GEMM reduced desmoplasia with subsequent increase in 
gemcitabine uptake due to improved vascularization of the tumour (Olive et al., 2009). 
Others found a prolonged survival in a GEMM trough SHH inhibition (Feldmann et al., 
2008). The contribution of PSCs in later stages of PDAC has been highlighted by their 
ability to co-metastasize to distant organs. Xu et al. showed in an orthotopic mouse 
model that PSCs were able to intravasate/extravasate to and from blood vessels and by 
that accompany PDAC cells to distant metastatic sites (Xu et al., 2010). This observation 
points to a possible role of stroma cells in guiding invasive cells through the ECM (Friedl 
and Alexander, 2011; Friedl and Wolf, 2009a) and in creating cell tracks for the cancer 
cells to follow (Gaggioli et al., 2007). Thus, all models have brought valuable knowledge to 
the understanding of PDAC and function of PSCs. 
Consequently, the mutual interplay of PSCs with PDAC cells falls into the context of 
the long known “seed” and “soil” hypothesis in shaping the TME, with PDAC cells being 
the seed and PSCs shaping the soil for PDAC to progress (Gupta and Massague, 2006; 
Paget, 1889; Sleeman et al., 2012). PSCs are therefore acknowledged as a villain rather 
than as a friend in PDAC progression, and thus represent a potential therapeutic target 
together with PDAC cells in PDAC patients. 
 
1.3.4 Autocrine Stimulation in PSCs 
Notably, in addition to responding to paracrine exogenous stimulants in PDAC, 
several lines of evidence also point toward PSCs acting as mediators of autocrine 
stimulation that perpetuate their own activity. This leads to the hypothesis, that when 
activated by an exogenous factor, PSCs are capable of existing in a persistently activated 
state even in the absence of the initial trigger factors that drive pancreatic fibrogenesis 
(Apte et al., 2012; Bachem et al., 2006). This is observed in PSC secretion of TGF-β1. PSCs 
express TGF-β1 receptors and respond to TGF-β1 by increased matrix synthesis and 
reduced proliferation (Bachem et al., 2006; Schneider et al., 2001; Shek et al., 2002). 
Additionally, autocrine stimulation loops have been identified in activated PSCs involving 
TGF-β1, IL-1, IL-6 and cyclooxygenase-2 (COX2) through Smad3 and ERK(1/2) dependent 
pathways (Aoki et al., 2006a; Aoki et al., 2007; Aoki et al., 2006b; Kruse et al., 2000), 
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activin A, which is a member of the TGF-β superfamily (Ohnishi et al., 2003) and the 
peptide endothelin-1 (Klonowski-Stumpe et al., 2003) (figure 1.4). Furthermore, pro-
oxidant compounds and ROS secreted from injured acinar/duct cells or inflammatory 
immune cells can stimulate PSCs to generate and secrete ROS as an auto- and paracrine 
stimulant (Apte et al., 2000; Masamune et al., 2008b). Thereby, production of ROS can 
perpetuate PSC activity. This is coupled to NADPH oxidase function. NAPDH oxidase 
inhibition, in turn, was shown to decrease PSC proliferation and production of IL-1 and 
collagen. Moreover, NAPDH oxidase inhibition abolished the transformation of isolated 
PSCs, supporting the hypothesis that oxidant production by PSCs might serve as a 
paracrine/autocrine stimulator during transformation (Asaumi et al., 2007; Masamune et 
al., 2008b). PDGF, TGF-β1, IL-1 and angiogensin II were also found to induce ROS 
production in PSCs (Cao et al., 2014; Masamune et al., 2008b).  
 
1.4 Cell Migration 
One common feature of stroma cells are their ability to migrate enabling them to 
reach the tumour site and recruit more cells to the tumour area (Hanahan and Coussens, 
2012; Kalluri and Zeisberg, 2006). In the context of PDAC, the increased number of 
activated PSCs in fibrotic areas can be a result of: (i) stimulated attraction of PSCs by 
PDAC cells, (ii) stimulated attraction of PSCs by resident PSCs and (iii) stimulation of PSC 
proliferation. One major acquired capability in PSC transformation from quiescent to 
activated state is their elevated motility. It is now widely accepted that PSC migration is a 
consequence of their activated state and a requirement for their communication with 
PDAC cells (Phillips et al., 2003b).  
 
1.4.1 Basic Principles of Cell Migration 
Common for all mammalian cell migration modes is a polarized morphology along 
the axis of movement, which is a prerequisite for directed cell migration and makes it 
easy to distinguish between the front and rear end (figure 1.5). This polarization is 
particularly evident when cells are migrating on a two-dimensional (2D) surface (Keren et 
al., 2008; Nabi, 1999; Weihuang et al., 2015). The basic principle for polymerizing actin 
filaments at the front and contractile at the rear end has been defined for 2D migration 
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(Lauffenburger and Horwitz, 1996) however the majority of cells migrate in a three-
dimensional (3D) environment (Friedl and Wolf, 2009b). Recently a 5-step migration 
process has been defined for this migration mode by Friedl and colleagues, for both single 
and collective migration (Friedl and Wolf, 2009b; Ilina and Friedl, 2009; Lauffenburger and 
Horwitz, 1996; Schmidt and Friedl, 2010; Wolf and Friedl, 2011). Additionally, evidence 
suggests that cell migration is affected by ECM dimensionality by differences in structural 
organization including density, stiffness and orientation (Doyle et al., 2013; Grinnell, 
2008; Keren et al., 2008). Although the basic principles are fulfilled (cells migrating along 
or through tissue structures), each cell type exerts migration in different contexts using 
distinct molecular repertoires and extracellular guidance (Friedl and Wolf, 2009a). 
Different components of the cellular migration machinery, including focal adhesions and 
receptors, are therefore active and expressed at either the cell front or rear end. This 
makes directed migration possible, as observed for neutrophils migrating towards a 
chemotactic gradient (Damann et al., 2009; Lindemann et al., 2013). Thus, coordinated 
cytoskeletal dynamics are fundamental and obligatory for any kind of cell motility 
(Anderson et al., 2008; Le Clainche and Carlier, 2008; Pollard and Borisy, 2003).  
Studies from the last 15 years have shown increasing evidence that the plasma 
membrane itself and the ion transport across this structure play important roles in cell 
dynamics and migration including  numerous of Na+, K+ and Ca2+ channels (Keren, 2011; 
Komuro and Rakic, 1998; Schwab et al., 2012; Schwab et al., 2007; Stock et al., 2013). This 
prediction is supported by the discussion of integrin-dependent and -independent 
migration that questions the importance of focal adhesions in cell migration (Friedl and 
Wolf, 2009a; Lammermann et al., 2008; Schmidt and Friedl, 2010). Ion channels are not 
only important for creating a correct intracellular milieu for cell polymerization, but they 
are also regulated by the cytoskeleton components (Dreval et al., 2005; Mazzochi et al., 
2006; Nolz et al., 2006; Sasaki et al., 2014). Data concerning the role of ion channels in 
PSC function are currently virtually non-existent, emphasizing the need for further 
investigation. 
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Figure 1.5. The Central Role of Ca2+ Signalling in Cell Migration. (A) Ca2+ channels play 
important roles in remodelling and setting Ca2+ homeostasis in migrating cells. Numerous 
effectors in the migration machinery are Ca2+ dependent regulating several downstream 
pathways implicated in cell migration e.g. focal adhesion turnover and cytoskeleton dynamics. 
(B) Ion channels set and regulate the intracellular front/rear Ca2+ gradient. The lower [Ca2+] at 
the front makes it possible for migrating cells to fine-tune their molecular repertoire and 
migration direction to extracellular guidance cues through locally elevated Ca2+ flickers. 
1.4.2 Calcium-dependent Signalling in Cell Migration 
Given that cell migration is a Ca2+-dependent process (Komuro and Kumada, 2005; 
Pettit and Fay, 1998), the role of ion channels in setting and regulating the intracellular 
Ca2+ homeostasis is of critical importance, giving a higher intracellular [Ca2+] at the rear 
end than in the front of migrating cells (Brundage et al., 1991; Schwab et al., 1997). This in 
part mediates a polarization along the axis of movement, allowing different components 
of the cellular migration machinery to be expressed or to be functional at the cell front or 
rear end including focal adhesions, receptors and ion channels (Broussard et al., 2008; 
Eddy et al., 2000; Schwab et al., 2012; Stock et al., 2013). For instance, the increased Ca2+ 
concentration at the cell end is related to myosin II contraction and cleavage of focal 
adhesion, which subsequently causes retraction of the rear end (Eddy et al., 2000; 
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Palecek et al., 1998). In addition, the front/rear Ca2+ gradient can be superimposed by 
locally elevated Ca2+ zones and short-lived Ca2+ flickers that play a role in regulating the 
directionality of migrating cells (figure 1.5) (Fabian et al., 2008; Tsai and Meyer, 2012; Wei 
et al., 2009). In this way, cells are able to fine-tune their molecular repertoire to 
extracellular guidance cues and the local microenvironment (Friedl and Wolf, 2009a). 
Numerous components of the cellular migration machinery and intracellular signalling 
pathways are Ca2+ sensitive. They can affect cytoskeletal remodelling, focal adhesion 
turnover, matrix degradation, leading edge guidance and localized cell volume changes 
(Falke and Ziemba, 2014; Schwab et al., 2012).  
A rise of [Ca2+]i can trigger the dynamic formation of lamellipodia through Rac1, 
thereby increasing migration or inducing stress fibres through RhoA activity, which in turn 
inhibits cell migration (Etienne-Manneville and Hall, 2002; Singh et al., 2007; Tian et al., 
2010). Ca2+ signalling induces; (i) contraction of the actomyosin network (Yang and Huang, 
2005); (ii) activation of calpain (Jang et al., 2010) required for ECM matrix modelling by 
regulating MMP2 and 9 activity (Monet et al., 2010; Sukumaran et al., 2013), and 
regulation of focal adhesion turnover (Giannone et al., 2004; Giannone et al., 2002; 
Lawson and Maxfield, 1995; Schafer et al., 2012; Svensson et al., 2010; Wells et al., 2005); 
and (iii) induction of localized changes of the cell volume of migrating cells (Happel et al., 
2013; Schneider et al., 2000; Schwab et al., 1995; Watkins and Sontheimer, 2011). These 
examples demonstrate that cell migration is Ca2+-dependent signalling process, which can 
be linked to both Ca2+ influxes through plasma membrane channels and/or Ca2+ release 
from internal Ca2+ stores. Thus far, data concerning Ca2+ signalling in PSCs are essentially 
lacking, counting to date only 4 published papers. Won et al. has shown that Ca2+ 
signalling is elevated in activated compared to quiescent PSCs together with increased 
expression of numerous surface receptors coupled to intracellular Ca2+ signalling (Won et 
al., 2010). Haanes et al. and Hennigs et al. have shown P2-receptor-mediated calcium 
signalling in activated PSCs (Haanes et al., 2012; Hennigs et al., 2011) and recently, the 
transient receptor potential (TRP) channel family member TRPV4 has been implicated in 
reactive calcium responses in high fat and alcohol activated PSCs (Zhang et al., 2013).  
Evidence for the role of ion channels involved in the mechanisms underlying cancer 
development, progression and tumour-stroma interaction is accumulating (figure 1.3 B) 
(Arcangeli, 2011; Fraser and Pardo, 2008). Specifically TRP channels have increasing 
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interest during the last 15 years due to their role in setting Ca2+ homeostasis as discussed 
in my recently published review (Nielsen et al., 2014).  
However, the molecular mechanisms by which they affect PSC migration as well as 
the mutual communication with PDAC cells are still elusive. TRP channels are interesting 
since they are able to sense and respond to microenvironmental changes occurring during 
cancer development and progression giving rise to increased migratory activity in stroma 
cells (Nielsen et al., 2014).  
 
1.5 TRP Channels in Migration and as 
Microenvironmental Sensors, Modifiers and Effectors 
1.5.1 TRP Channel Family 
The first discovery of TRP channels was made in Drosophilia melanogaster (Montell 
and Rubin, 1989) and 5 years later the first human homologue, TRPC1 followed (Wes et 
al., 1995; Zhu et al., 1995). 
TRP channels are expressed ubiquitously in numerous excitable and non-excitable 
tissues (Kunert-Keil et al., 2006; Pedersen et al., 2005) implicating them in multiple 
hereditary, chronic and acquired diseases (Nilius and Szallasi, 2014). The TRP family can 
be classified and divided into seven main subfamilies based of amino acid sequence 
homology: the TRPC (`Canonical´) family, the TRPV (`Vanilloid´) family the TRPM 
(`Melastatin´) family, the TRPP (`Polycystin´) family, the TRPML (`Mucolipin´) family, the 
TRPA (`Ankyrin´) family, and the TRPN (`NOMPC´) family. These can further be divided 
into subgroups based on the mode of activation and function (for review see (Nilius and 
Owsianik, 2011; Pedersen et al., 2005). Most TRP channels are non-selective cation 
channels that are permeable to Ca2+ and Na+ (PCa/PNa = 1–10). Nonetheless, most studies 
dealing with TRP channels in cell migration related the functional impact of TRP channels 
to their Ca2+ permeability (Owsianik et al., 2006).  
 
1.5.1.1 TRP Channel Function 
TRPC, TRPM and TRPV channel families are attractive candidates for probing the 
TME because some of their members are exquisitely sensitive to components of the TME. 
For example, TRPC channels are part of G protein-coupled receptor (GPCR) and receptor 
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tyrosine kinase (RTK) signalling cascades mediating receptor-operated calcium entry 
(ROCE) (Ambudkar and Ong, 2007), and members of the TRPM family such as TRPM2 are 
activated by oxidative stress that is frequently encountered in tumours (Ray et al., 2012; 
Takahashi et al., 2012a; Tochhawng et al., 2013). GPCR activation leads to the activation 
of phospholipase C (PLC), which cleaves phosphatidylinositol 4,5-bisphosphate (PIP2) into 
diaglycerol (DAG) and inositol-1,4,5 triphosphate (IP3). DAG induces ROCE by activating 
TRPC3/6/7 channels and IP3 can give rise to Ca2+ release from intracellular stores into the 
cytosol. This elevation in cytosolic Ca2+ induces store-operated calcium entry (SOCE) 
(Clapham, 2003; Minke and Cook, 2002) through TRPC1/2/4/5 channels or the STIM/ORAI 
complex, with STIM being the endoplasmatic reticulum (ER) Ca2+ sensor and ORAI the 
Ca2+-selective Ca2+ entry channel (Cahalan, 2009; Soboloff et al., 2012; Soboloff et al., 
2006; Sours-Brothers et al., 2009).  
TRP channels, besides forming homotetramers, can form heterotetramers with 
other subgroup members making their functional characterization even more complex 
(Pedersen et al., 2005). A dynamic assembly between TRPC1-STIM1-ORAI1 has been 
reported to be essential for SOCE and SOC function (Jardin et al., 2008; Ong et al., 2007; 
Rao et al., 2010; Sours-Brothers et al., 2009). However, a recent study shows evidence 
that TRPC1 and ORAI1 constitute distinct SOC and Ca2+ release-activated Ca2+ channels, 
both gated by STIM1 in response to store depletion (Cheng et al., 2011). This implies that 
the composition and expression of SOC channels is very complex and highly cell type and 
tissue specific (Ambudkar and Ong, 2007; Cahalan, 2009). 
 
1.5.1.2 TRP Channels in Cell Migration and Interaction Partners 
A substantial amount of data connects TRPC, TRPV and TRPM channels to cell 
migration of stroma and cancer cells, reviewed in Nielsen et al. Predominantly, it is 
assumed that the impact of most TRP channels on cell migration is due to their ability to 
mediate transduction/effector Ca2+ responses following the activation by growth factor or 
chemoattractant receptors (GPCR and RTK) (Nielsen et al., 2014).  
Sustained growth factor signalling in PSCs and PDAC cells culminates in the 
activation of the TME with induction of tumour-promoting inflammation, ECM 
production/remodelling, sustained proliferation, angiogenesis and migration/invasion 
(Apte and Wilson, 2011; Tang et al., 2012; Vonlaufen et al., 2008b) (figure 1.4). These 
1.5 TRP Channels in Migration and as Microenvironmental Sensors, Modifiers and Effectors 
 
21 
 
processes have been linked to TRP channels as regulators of tumour and stroma cell 
migration in general, highlighting the huge diversity and contribution of TRP channels in 
the cancer–stroma interplay (figure 1.6) (Nielsen et al., 2014). TRP mediated Ca2+ entry 
further leads to the initiation of (local) intracellular Ca2+ signalling cascades important for 
cell migration. These include among others the PI3K pathway, ERK1/2, Akt/protein kinase 
B pathway, MAPK and the Ras-homologue-(Rho)-GTPases, which almost all depend on 
Ca2+ and affect cell migration (Falke and Ziemba, 2014). Importantly, these pathways are 
linked to PSC activation (described in section 1.3.2). Nonetheless, the connection of PSC 
activation and migration to TRP channel function is unknown.  
TRP channels also interacts with the migration machinery by a reciprocal interplay 
with the cytoskeleton (Clark et al., 2008). TRPV1 and TRPV4 channels directly interact 
with actin and microtubules synergistically regulating cell migration in human 
hepatoblastoma and neuroblastoma cells (Goswami et al., 2006; Goswami et al., 2010). 
TRPM7 affects actomyosin contractility and cell adhesion in both human breast and 
neuroblastoma cells (Clark et al., 2006; Middelbeek et al., 2012) and TRPC6 is needed for 
actin polymerization in KC-stimulated neutrophils (Lindemann et al., 2013).  
However, TRP channels themselves can also be regulated by the cytoskeleton. An 
intact actomyosin cytoskeleton are required for interaction of human endogenous 
expressed TRPC1 with the calcium sensor STIM1 (Lopez et al., 2006) and actin 
depolymerisation with calculin A induces the internalization of several TRPC channel 
members and blocks calcium entry in human neutrophils (Itagaki et al., 2004). Further, a 
disruption of the actin cytoskeleton in the neuroblastoma cells and in endothelial derived 
breast cancer cells are linked to impaired TRPV4-mediated currents and TRPV4 trafficking 
to the plasma membrane (Fiorio Pla et al., 2008; Fiorio Pla et al., 2012; Goswami et al., 
2010). This reciprocal regulation mostly occurs through larger protein complexes where 
the TRP channels are linked to the actomyosin either directly or via scaffold proteins 
(Clark et al., 2006; Smani et al., 2013; Tang et al., 2000; Vandebrouck et al., 2007).  
As stated in my review, TRP channels also functionally cooperate with other ion 
channels relevant for cell migration (Schwab et al., 2012). TRP-mediated calcium influx 
supply Ca2+-sensitive channels such as KCa3.1, KCa2.3, CaCC (ANO/TMEM16) or ClC-3 with 
Ca2+ needed for their activation (Chantome et al., 2013; Cuddapah et al., 2013; Jacobsen 
et al., 2013; Turner and Sontheimer, 2013; Wanitchakool et al., 2014). In turn, TRP 
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Figure 1.6. Major Mechanisms of the Tumour–Stroma Interplay in Cancer Progression.  
Illustration of major mechanisms underlying tumour invasion and metastasis involving cancer 
cells (blue), stroma cells (red) or both (red/blue). During tumour progression, cancer and 
stroma cells undergo a close mutual interaction with each other through continuous growth 
factor signalling, as observed between PSCs and PDAC cells. This shapes the TME and induces 
hypoxia, cellular oxidative stress, inflammatory responses, angiogenesis and ECM 
production/remodelling, all well-known characteristics of PDAC. At some point all these 
characteristics are connected to cell migration. Additionally, implicated TRP channel families 
and STIM/ORAI proteins are indicated. The contribution of TRP channels in PSC-PDAC interplay 
is unknown (modified from (Nielsen et al., 2014)). 
channels rely on the activity of K+ channels that hyperpolarize the cell membrane 
potential in order to maintain the electrochemical driving force for Ca2+ entry (Gao et al., 
2010; Hammadi et al., 2012). Such cooperative mechanisms has been needed for efficient 
migration, invasion and metastases of different cell types (Chantome et al., 2013; 
Chimote et al., 2013; Cuddapah et al., 2013; Hammadi et al., 2012; Kuras et al., 2012; 
Siddiqui et al., 2012; Turner and Sontheimer, 2013).  
Consequently, this enables regulation of TRP channels at multiple levels, as 
interference of these macromolecular complexes/transportomes can affect all its 
1.5 TRP Channels in Migration and as Microenvironmental Sensors, Modifiers and Effectors 
 
23 
 
members together with downstream effectors involved in cell migration (Nielsen et al., 
2014).  
 
1.5.2 TRP Channels as Sensors and Effectors of the Tumour 
Microenvironment 
The membrane localization of TRP channels enables them to act as multifunctional 
cellular sensors to the dynamic changing TME during tumour progression in both stroma 
and cancer cells (reviewed by (Nielsen et al., 2014). TRP channel activation therefore 
spans between diverse intra- and extracellular stimuli that are either of physical (e.g. 
mechanical stress, osmotic pressure or temperature) or chemical nature (e.g. growth 
factors/cytokines, environmental irritants, pH, pO2, ROS, hypoxia, ADP ribose (ADPr)). 
Further, these parameters can alter TRP channel expression and function in both stroma 
and cancer cells. For example, TRP channel expression is frequently dysregulated in both 
stroma and cancer cells during cancer progression strongly correlating with tumour 
aggressiveness, thus representing valuable diagnostic and/or prognostic markers 
(Bodding, 2007; Dhennin-Duthille et al., 2011; Nielsen et al., 2014; Ouadid-Ahidouch et 
al., 2013; Prevarskaya et al., 2007; Santoni and Farfariello, 2011). However, the 
implication of TRP channels in PSC activation and functions related to mechanisms in 
PDAC is completely unknown.  
 
1.5.2.1 TRP Channels as Mechanosensors and Modulators of the TME 
By being major modulators in PDAC, PSCs must respond to the dynamically 
changing TME. Stretch, stiffness, osmotic stress and high interstitial fluid pressure are 
some of the characteristic in the TME of PDAC known to activate PSCs (Asaumi et al., 
2007; Kharaishvili et al., 2014), possibly through TRP channels via a mechanoregulatory 
sensor pathway (Kuipers et al., 2012). For example, in fibroblasts and smooth muscle cells 
TRPC1 and TRPC6 channels were activated by mechanically and osmotically induced 
membrane stretch, respectively (Fabian et al., 2012; Spassova et al., 2006), and in 
proportion to cell polarity, substrate stiffness mediate the activation of TRPC1 mediated 
SOCE in human bone osteosarcoma cells (Weihuang et al., 2015). Moreover, hypoosmotic 
and pressure induced membrane stretch activates TRPC5 channels in neurons (Gomis et 
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al., 2008). Among the TRPV and TRPM family, TRPV2 is activated by stretch in aortic 
myocytes (Muraki et al., 2003) and TRPV4 is activated by osmotic cell swelling in several 
mammalian cells (Liedtke et al., 2000). TRPM3 show a putative role in kidney and brain 
cells and TRPM4 in smooth muscle cells, respectively (Dietrich et al., 2006; Earley et al., 
2004; Grimm et al., 2003). 
TRP channels also play a role in ECM modelling and migration. TRPC2 down-
regulation attenuated migration and invasion of Rat thyroid cells through decreased 
secretion of MMP2 (Sukumaran et al., 2013). More importantly, in vitro and in vivo 
inhibition of TRPC3 in renal fibroblast decreased collagen production and MMP2/9 and 
TIMP1 secretion through ERK1/2 signalling preventing ECM modelling and fibrosis (Saliba 
et al., 2014). Further, siRNA- mediated TRPV2 silencing in prostate cancer cells down-
regulates the expression of MMP2, MMP9 needed for migration and invasion (Monet et 
al., 2010). These findings point to the possible influence of TRP channels in PSCs 
bidirectional modelling of and adaptation to the changing TME. 
 
1.5.2.2 TRP Channels in Hypoxia and Oxidative Stress 
TRP channels can act as sensors and effectors of hypoxia- and oxidative stress-
related stimuli by increasing their expression and/or activity (reviewed by (Numata et al., 
2013; Shimizu et al., 2014; Takahashi et al., 2012b; Takahashi and Mori, 2011). The 
ensuing cell responses often involve elevated migratory activity and/or production and 
secretion of growth factors/cytokines (figure 1.7) (Bauer et al., 2012; Chigurupati et al., 
2010; Nielsen et al., 2014; Yamamoto et al., 2008) many of which are involved in the 
mutual signalling between PSCs and PDAC cells and in the autocrine stimulation of PSCs. 
Specifically, the functional expression of TRPC1, TRPC6 and TRPM2 channels have been 
coupled to hypoxia sensitivity and oxidative stress (reviewed in (Dietrich et al., 2014; 
Dietrich and Gudermann, 2014; Faouzi and Penner, 2014; Nesin and Tsiokas, 2014). As 
described in section 1.3.3.1, PSCs are capable of responding to hypoxia and oxidative 
stress stimulation. Roles of TRP channels in these processes are therefore very likely. 
However, up to now there is only limited information about the influence of tumour 
hypoxia and oxidative stress on TRP channel function in general. 
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Figure 1.7. Multiple TRP Channel Sensor and Effector Functions in the Tumour 
Microenvironment. Illustration of major hypoxia and cellular oxidative stress-dependent 
mechanisms in cancer and stroma cells involving TRP channels. These mechanisms are 
connected to higher cell activity through elevated motility and/or cytokine/chemokine 
secretion. In cancer and stroma cells, TRP channels can have both a sensor function for extra-
/intracellular stimuli mediating cellular responses and an effector function by increased 
expression and activation to induce cytokine/chemokine production in these cells. Further, 
hypoxia and oxidative stress can lead to up-regulation of TRP channels (e.g. TRPC1, TRPC3 and 
TRPC6) and mediate the production of ROS and ADPr.  For the sake of clarity, this sketch does 
not include all signalling pathways mentioned in the text. Neither are all microenvironmental, 
growth factor- and chemokine-activated pathways involved in increased activation or 
expression of TRP channels included (modified from (Nielsen et al., 2014)). 
So far, only the TRPA1 channel has been shown to sense pO2 directly in murine and 
sensory neurons (Takahashi et al., 2011). Other TRP channels function indirectly as 
oxygen sensors through increased expression and/or activity (see (Numata et al., 2013) 
for a review). This is mostly under the control of hypoxia sensitive transcription factors 
such as HIF-1α, which control the expression of various of hypoxia responsive genes such 
as growth factors/cytokines, enzymes, transporters and ion channels (Elvidge et al., 2006; 
Lum et al., 2007; Schofield and Ratcliffe, 2004; Tatum et al., 2006; Webb et al., 2009). 
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Concerning TRP channels, hypoxic pulmonary vasoconstriction involves the activation of 
TRPC1 and TRPC6 in mediating elevated [Ca2+]i in both, human, rat and mice smooth 
muscle cells (Tang et al., 2010; Weissmann et al., 2006; Xu et al., 2014; Yang et al., 2015). 
Further, the TRPC1-STIM1-ORAI1 complex is needed for hypoxia-induced SOCE in 
pulmonary arterial smooth muscle cells of both rats and mice (Lu et al., 2008; Ng et al., 
2012). In glioblastoma, an elevated expression of TRPC6 channels was found compared to 
normal brain tissue and demonstrated to be coupled to hypoxia through a notch 
signalling pathway. Furthermore, suppression of TRPC6 greatly inhibited hypoxia 
stimulated glioblastoma cell migration and invasion, possibly by inhibiting actin–myosin 
interactions (Chigurupati et al., 2010).  
Notably, hypoxia facilitates the production of ROS in cancer, which leads to 
oxidative cellular stress and increased activity of present cells (Cook et al., 2004; 
Tochhawng et al., 2013; Yang et al., 2013). TRPM2 and TRPC3 channels serve as a sensor 
for oxidative stress in B-lymphoblasts helping the cells to reach or orient within the 
tumour (Roedding et al., 2012), and hypoxic stress induces the expression of TRPM2 
channels in cardiac fibroblasts leading to increased proliferation and ECM production 
(Takahashi et al., 2012a). Furthermore, ROS can be generated as a result of growth factor 
stimulation of RTKs/GPCRs, thereby transmitting signals to induce cellular changes 
necessary for cell activity by affecting Ca2+-sensitive effector molecules (Hurd et al., 2011; 
Ray et al., 2012; Tochhawng et al., 2013). Consequently, this suggests a role of TRP 
channels in the coupling between ROS and Ca2+ ions as stress-response messengers 
(figure 1.7) (Numata et al., 2013; Shimizu et al., 2014). In the pancreatic cancer cell line 
(BxPC-3), the stress responsive protein sirtuin 6 (SIRT6) promotes inflammation by 
enhancing the production of ADPr. In return, ADPr activates Ca2+ responses through 
TRPM2, promoting the secretion of the pro-inflammatory proteins IL-8 and TNF-α 
enhancing cell migration (Bauer et al., 2012). Moreover, the ectoenzyme CD38 mediates 
increased cADPr and ADPr generation from NAD (for a review, see (Malavasi et al., 2008)). 
ADPr binds to the TRPM2 channel leading to Ca2+ influx, which enhances the intracellular 
chemoattractant signal enabling chemotaxis of both tumour and stroma cells (Partida-
Sanchez et al., 2007; Vaisitti et al., 2011). Another important factor in inflammatory cell 
responses is the NAPDH oxidase-mediated generation of ROS. In granulocytes, the 
inflammatory process of NADPH oxidase-mediated superoxide production is related to 
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TRPC1, TRPC3, TRPC6 and ORAI1 channels (Brechard et al., 2008) and in lung endothelial 
cells to TRPC6 activity (figure 1.7) (Weissmann et al., 2011). NADPH oxidase activity in 
ROS production is relevant for PDAC and cancer in general (Cao et al., 2014; Yang et al., 
2013). Moreover, its activity is regulated by growth factors in pancreatic cancer 
(Edderkaoui et al., 2011) and in the activation of PSCs (Asaumi et al., 2007; Masamune et 
al., 2008b). TRP channels could therefore indirectly play a role in PSC activation through 
NAPDH oxidase activity regulation.  
Similarly, ROS and stress promote TRP-dependent cytokine/chemokine production, 
emphasizing the role of TRP channels in modulatory mechanisms of the TME and cell 
activation. Activation of TRPM2 channels underlie enhanced cytokine/chemokine 
production in activated T-lymphocytes (Melzer et al., 2012), monocytes and neutrophils 
(Knowles et al., 2011; Wehrhahn et al., 2010; Yamamoto et al., 2008). The 
lipopolysaccharide-mediated Ca2+ entry via TRPV2 channels activates RAW264 
macrophages to produce IL-6 and TNF-α (Yamashiro et al., 2010). In vascular endothelial 
cells the reactive nitrogen oxide, NO, activates TRPC5 channels inducing production of 
NO, resulting in a positive feedback cycle of receptor-activated Ca2+ and NO signalling 
(Takahashi et al., 2012b; Yoshida et al., 2006). In contrast to stimulatory effects, the 
overexpression of a dominant-negative mutant of TRPM4 or elimination of TRPM4 using 
RNAi in Jurkat T-cells induced elevated Ca2+ signalling with increased IL-2 production 
(Launay et al., 2004). Similar observations were found in mouse T-cells, affecting cell 
motility and IL-2 as well as IL-4 production (Weber et al., 2010). In turn, TRP channel 
activity itself can be regulated by cytokines. The transformation of fibroblasts into 
myofibroblast depends on TRPC6 channel expression (Davis et al., 2012). This process is 
similar to the TGF-β-mediated activation of PSCs (section 1.3.2.1). TGF-β stimulation 
induced elevated TRPC6 channel expression by p38/MAPK signalling leading to elevated 
Ca2+ signalling in WT fibroblast, whereas Trpc6−/− fibroblasts showed no induction of 
αSMA positive stress fibers (activation marker) and reduced migration (Davis et al., 2012).  
Thus, TRP channels modulation of secretion of growth factors/cytokines may 
constitute an important element in securing the following processes within the TME of 
PDAC: (i) regulation of mutual signalling between PSCs and PDAC cells, (ii) recruitment of 
additional stroma cells, (iii) regulation of (directed) cell migration and (iv) regulation of 
autocrine/paracrine stimulation pathways in PSCs.   
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Figure 1.8. Major Mechanisms of TRP Channels in Cell Functions Coupled to the 
Microenvironment. TRP channels are important components of cellular responses to the 
microenvironment and vice versa. This interplay can be divided into three major mechanisms. 
(1) Direct/indirect sensor mechanism to extracellular stimuli such as hypoxia (pO2), acidosis or 
cell stress. (2) Modifier mechanism of the microenvironment by being involved in secretion of 
growth factors/cytokines which can mediate both autocrine and paracrine stimulating effects. 
(3) Mediating cellular transduction/effector responses to stimulants. 
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In summary, the transmembrane localization of TRP channels puts them in an ideal 
position to function as multifunctional cellular sensors to the microenvironment strongly 
influencing both intracellular functions and modification of the microenvironment. TRP 
channels can thereby function as central intermediary regulators in transferring 
information in outside-in and inside-out directions. This can be divided into three major 
mechanisms implicating a (i) sensor-, (ii) modifier- and (iii) transduction/effector 
mechanism (see figure 1.8).  
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Project Aim 
2.1 Hypothesis, Objective and Strategy 
The close cooperation between PSCs and PDAC cells is a typical feature of PDAC, 
which depends on intense mutual growth factor/cytokine signalling to control activity of 
both cell types. This creates a TME with distinct physical and chemical properties that are 
permissive for tumour progression. Key properties include hypoxia, acidosis and an 
abundance of growth factors, all of which stimulate PDAC and PSC migration. It is widely 
accepted that PSC migration is a consequence for their activated phenotype. 
Cell migration is a Ca2+-dependent process that implicates the activity of TRP 
channels. There is growing evidence supporting a role of TRP channels in sensing and 
modifying the TME together with being essential cellular components of the transduction 
and effector cascades of cellular responses to the TME.  
Owing to the hypoxic milieu of PDAC and the major contribution of this factor to 
malignancy and treatment resistance, the understanding of the responses of PSCs to 
hypoxia is of paramount significance. Mounting evidence supports direct or indirect 
participation of PSCs and correlates with their high occurrence in this context. Thus, it is 
very likely that TRP channels also play a critical role in the function of PSCs.  
This led to the hypothesis that PSCs’ response and adaptation to hypoxia can be 
regulated by TRPC1 and/or TRPC6 channels affecting the activated migratory phenotype 
of PSCs. One possibly mechanism is through altered TRPC1/6 mediated Ca2+ influx. A link 
between hypoxia and TRPC1/6 channels has already been found in various cell types. 
Furthermore, the TRPC1 and TRPC6 channel represent selective candidates of SOCE and 
ROCE, respectively.  However, the exact mechanism how PSCs react to hypoxia together 
with the involvement of TRP channels in PSC activation and function remains elusive. 
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Figure 2.1. Possible Roles of TRPC1 and TRPC6 Channels in the Hypoxia-Mediated Activation of 
PSCs. TRPC1 and/or TRPC6 can influence PSCs activation by hypoxia in different ways. (1) A 
sensor mechanism leads to increased expression and/or activation upon hypoxic stimuli, (2) 
they modulate the microenvironment by being involved in production of growth 
factors/cytokines stimulating PSCs in autocrine ways, and (3) they mediate 
transduction/effector responses to stimulants secreted by PSCs and PDAC cells.  
The current study was planned with aim to decipher the roles of TRPC1 and TRPC6 
channels in regulating PSC responses and adaptations to hypoxia. Following hypothesis 
was predicted and set to be tested: 
 
TRPC1 and/or TRPC6 channels are key components in sensing microenvironmental 
changes, thereby regulating PSC responses related to pancreatic cancer 
 
In accordance with this hypothesis the following mechanisms were identified as 
potentially responsible for a role of TRPC1/6 channels in PSC activation (figure 2.1): 
 
? TRPC1/6 channels can function as microenvironmental effector-sensors by their 
involvement in downstream sensory mechanisms of pO2 (e.g. HIF-1α) leading to 
elevated expression and/or activation (mechanism ① in figure 2.1). 
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? TRPC1/6 channels are modifiers of the microenvironment by regulating hypoxia-
triggered secretion of growth factors/cytokines that stimulate PSCs in an autocrine 
manner (mechanism ② figure 2.1). 
 
? TRPC1/6 channels are effectors of intracellular transduction pathways triggered by 
growth factors/cytokines secreted by PSCs or PDAC cells (mechanism ③ figure 
2.1).  
 
All pathways (1-3), consequently lead to increased migratory activity 
 
The ability of PSCs to migrate is a consequence of their activated state and could be 
used as a parameter for the experiments. In order to test the hypothesis and the 
potential involvement of the three underlying mechanisms, the migratory activity of 
primary cultured PSCs isolated from WT, TRPC1-/- and TRPC6-/- mice was characterised.  
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Materials and Methods 
3.1 Materials 
3.1.1 Media 
Table 3.1: Basic Media 
Media Producer/Manufacturer 
DMEM/F12* Sigma 
DMEM* Sigma 
RPMI 1640 Sigma 
GBSS PAN Biotech 
DPBS PAN Biotech 
FCS-Gold GE Healthcare 
Penicilin/Streptomycin Biochrom 
 
* When not stated otherwise, cell culture media includes 10% FCS-Gold and 1% 
Penicilin/Streptomycin. 
 
3.1.2 Chemicals and Kits 
Table 3.2: Chemicals and Kits 
Chemical or Kit Producer/Manufacturer 
Agarose SERVA 
APS (Ammoniumpersulfate) Sigma-Aldrich 
BCA Pierce® Protein Assay Kit Thermo Scientific 
BCECF-AM Life Technologies 
Boric Acid Merck 
Bromophenolblue Sigma 
Chloroform Sigma 
(CMAC, t-BOC-Leu-Met) Molecular Probes 
Collagen I, Bovine Biochrom AG 
Collagen III, human BD Biosciences 
Collagen IV, mouse BD Bioscience 
Collagenase P Roche 
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Complete mini Roche 
Dimethyloxalglycine (DMOG) Frontier Scientific 
Dimethyl Sulfoxide (DMSO) Sigma 
DTT (Dithiothreitol) Boehringer 
DNase Ambion 
dNTP-mix (10mM/dNTP) VWR 
EDTA SERVA 
Fibronectin BD Biosciences 
Fura-2-AM Invitrogen 
KC (murine), CXCL1 Biolegend 
Laminin Sigma-Aldrich 
Murine KC Pepro tech 
PDGF (recombinant human PDGF-BB) Biolegend 
Phos-STOP Roche 
PVDF membrane Millipore, Immobilon®-P 
Reverse transcriptase (RT) Assay Roche 
SB 225002 Calbiochem 
Super Signal West pico Luminol Kit Thermo Scientific 
Super Signal West Femto Luminol Kit Thermo Scientific 
SYBR® Gold nucleic acid gel stain Invitrogen, Molecular Probes 
Taq DNA Polymerase Segenetic 
Taq DNA Polymerase Buffers Qiagen 
TRAM-34 Sigma-Aldrich 
Triton X-100 Roth 
Trizol® Reagent Invitrogen 
TWEEN® 20 Roth 
2xSsoFastTM EvaGreen® Super mix Bio-Rad 
6x Loading dye New England BioLabs 
1-Oleoyl-2-acetyl-sn-glycerol (OAG) Sigma-Aldrich 
100 bp DNA Ladder New England BioLabs 
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3.1.3 Instruments 
Table 3.3: Instruments 
Instruments Producer/Manufacturer 
Axio Cam mRm Zeiss 
Axiovert 200 Zeiss 
Bio photometer Eppendorf 
Bottle neck top filter, 0.22 μm, polystyrene Corning 
C1000 Thermal cycler, cFX 96TM Real-Time 
system 
Bio-Rad 
Camera XC-ST70CE Hamatsu 
Camera XC-77CE Hamatsu 
Cell culture dish, glasbottom, 35 mm, 
CellviewTM 
Greiner bio-one 
Cell strainer Corning 
ChemiDocTM XRS Gel documentation system Bio-Rad 
Electrophoresis Power PAC 3000 Bio-Rad 
Fresco 21 centrifuge Thermo Scientific 
Galaxy 14S incubator (hypoxia) New Brunswick 
HERA Cell 150 incubator Heraeus 
Inkubator 1000 Heidolph 
Master Cycler Eppendorf 
Microplate reader Thermo Max 
Microscope Axiovert 40C Zeiss 
Microscope Axiovert 25C Zeiss 
Microwave Amica Internation GmbH, Germany 
Milliex-GF Filter unit, 0.22 μm, PVDF 
membrane 
Millipore 
Multifuge 1 S-R Heraeus 
Polychromator System Visichrome 
Seahorse Extracellular Flux analyzer, XF96  Bioscience 
Seahorse XF96 Prep station  Bioscience 
SPOT camera RT se Diagnostic 
Thermo mixer Eppendorf 
Tissue culture dish, 100x20 mm Corning 
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Tissue culture flask, T25, 12,5 cm2 Corning 
Trypsin Biochrom 
Unimax 1010 shaker Heidolph 
 
3.1.4 Oligonucleotides 
Table 3.4: Oligonucleotides for PCR and Quantitative Real-time PCR 
Oligo Name Sequence (5’-3’) Ref. 
TRPC1_forward (1) TGGGCCCACTGCAGATTTCAA (Dietrich et al., 2005) 
TRPC1_reverse (1) AAGATGGCCACGTGCGCTAAGGAG (Dietrich et al., 2005) 
TRPC1_forward (2) GCAACCTTTGCCCTCAAAGTG (Liu et al., 2007) 
TRPC1_forward (2) GGAGGAACATTCCCAGAAATTTCC (Liu et al., 2007) 
TRPC1_forward (3) CATGGAGCATCGTATTTCAC (Varga-Szabo et al., 2008) 
TRPC1_reverse (3) GAGTCGAAGGTAACTCAGAA (Varga-Szabo et al., 2008) 
TRPC2_forward ACTTCACTACATATGATCTGGGTCAC (Storch et al., 2012) 
TRPC2_reverse CACGTCCAGGAAGTTCCAC (Storch et al., 2012) 
TRPC3_forward 
AGCCGAGCCCCTGGAAAGACAC (Dietrich et al., 2005; Weissmann 
et al., 2011) 
TRPC3_reverse CCGATGGCGAGGAATGGAAGAC (Dietrich et al., 2005; Weissmann 
et al., 2011) 
TRPC4_forward 
GGGCGGCGTGCTGCTGAT (Dietrich et al., 2005; Weissmann 
et al., 2011) 
TRPC4_forward 
CCGCGTTGGCTGACTGTATTGTAG (Dietrich et al., 2005; Weissmann 
et al., 2011) 
TRPC5_forward GCTGAAGGTGGCAATCAAAT (Storch et al., 2012) 
TRPC5_forward AAGCCATCGTACCACAAGGT (Storch et al., 2012) 
TRPC6_forward 
GACCGTTCATGAAGTTTGTAGCAC (Dietrich et al., 2005; Weissmann 
et al., 2011) 
TRPC6_forward 
AGTATTCTTTGGGGCCTTGAGTCC (Dietrich et al., 2005; Weissmann 
et al., 2011) 
TRPC7_forward CCCAAACAGATCTTCAGAGTGA (Storch et al., 2012) 
TRPC7_forward TGCATTCGGACCAGATCAT (Storch et al., 2012) 
Hprt_forward TCCTCCTCAGACCGCTTTT (Storch et al., 2012) 
Hprt_reverse CCTGGTTCATCATCGCTAATC (Storch et al., 2012) 
β2M_forward GCTATCCAGAAAACCCCTCAA (Hill et al., 2013; Johnsen et al., 
3.2 Mouse Strains 
 
36 
 
2006) 
β2M_reverse CATGTCTCGATCCCAGTAGACGGT (Hill et al., 2013; Johnsen et al., 
2006) 
 
* All oligos were purchased from Metabion.  
**Hprt1 (Hypoxanthin phosphoribosyltransferase 1) and β-2M (β-2 microglobulin)  
 
3.2 Mouse Strains 
mPSCs were isolated from 8-12 months old male/female 129Sv/C57BL/6J WT, 
TRPC1-/- (Dietrich et al., 2007), and TRPC6-/- mice (Dietrich et al., 2005). All animal 
experiments were approved from the State Agency for Nature, Environment and 
Consumer Protection NRW (from 2012: 84-02.05.2012.123) and were performed 
according to current animal welfare guidelines. All mice were genotyped by polymerase 
chain reaction (PCR) before the experiments to confirm KO and WT animals. Genotyping 
was performed byJana Welzig or Dr. Otto Lindemann. 
Notably, TRPC1−/− and TRPC6−/− mice are viable and fertile with a normal life 
expectancy and no phenotypic changes. Fertility and litter sizes were like those of WT 
mice (Dietrich et al., 2007; Dietrich et al., 2005). However, TRPC1−/− mice have an 
increased body sizes and weights for unknown reasons (Dietrich et al., 2007). 
 
3.2.1 Pancreatic Stellate Cells 
Table 3.5: Primary Stellate Cells 
 
 
 
 
 
Nomenclature Description Culture Media 
mPSC Isolated from mice (see section 3.3.2) DMEM/F12 
RLT-PSC Immortalized human pancreatic stellate cell line 
(Jesnowski et al., 2005) 
DMEM/F12 
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3.3 Cell Biological Methods 
3.3.1 Reactivating Frozen RLT-PSCs 
Freshly thawed RLT-PSC cells were re-suspended in 37°C DMEM/F12 and 
centrifuged at 1000 rpm for 5 min at RT. The supernatant was removed and the pellet 
was re-suspended in 10 ml preheated DMEM/F12. Culture media was changed daily the 
following 1-2 days. From then on cell culturing was performed as described (section 
3.3.3).   
 
3.3.2 Isolation of Mice Pancreatic Stellate Cells  
The PSC isolation procedure was modified from Haanes et al. 2012. Mice were 
sacrificed by treating with Isoflurane followed by cervical dislocation. The pancreas was 
then removed and washed in cold GBSS before being cut into pieces with scissors and 
then transferred to a 15 ml Falcon-Tube containing 3 ml cold GBSS enzyme solution (2,5-3 
mg Collagenase P (Roche) in 3 ml cold GBSS per pancreas). The falcon tube was then 
incubated at 37 degrees for 25 min on a shaker. After incubation, the suspension was 
mixed carefully by pipetting up and down 2-3 times with a 5 ml pipette. Thereafter, 5 ml 
warm GBSS was added to give a final volume of 8 ml before centrifuging the content at 
1040 rpm for 8 min. During centrifugation a tissue culture dish (100 x 20 mm) was coated 
with 1 ml FCS Gold to make an adhesive surface for attachment of the PSCs (incubation 
time approx. 8-10 min). After centrifugation the supernatant was removed and the pellet 
re-suspended in 5 ml pre-warmed DMEM/F12 with a 5 ml pipette before an extra 5 ml 
DMEM/F12 were added to give a total volume of 10 ml. Then the mixture was transferred 
carefully to the pre -coated tissue culture dish and incubated for approx. 105 minutes. 
After incubation, the medium was removed and the bottom of the tissue culture dish 
forcefully washed 3-5 times with warm medium using a 10 ml pipette to remove other 
cells (e.g. duct cells) and cell debris. After each washing step cells were observed under 
the microscope to ensure optimal purity (figure 3.1). Next, the freshly isolated mPSCs 
were left in the incubator and media changed daily for 2 days.  After 5-6 days cells were 
split out in 1-3 tissue culture dishes depending on the isolation efficiency. From then on 
cells could be used for experiments (section 3.3.3). This type of isolation procedure 
utilizes the different adhesion time of different cell types. Pancreatic stellate cells adhere 
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Figure 3.1. Mouse Pancreatic Stellate Cell Isolation. The upper panel (A) shows the washing 
step and the subsequent removal of cell debris and excessive cells (primarily acinar and duct 
cells) be observed. Attached mPSCs could be visualized by the appearance of small dark dots. 
For clarity, some mPSCs have been pointed out in the upper right figure. Cell growth and 
morphology changes of the mPSCs could the following days be observed (B). Examples are 
given 1 and 2 days post isolation and after being passaged one time (day 9 post isolation) (the 
two upper images (A) were kindly provided by Benedikt Hild). 
earliest in this case, which allows the differentiation from other cells of the pancreas. 
After a few days in culture the contaminating cells detach, resulting in approx. 100% PSC 
population (Haanes et al., 2012).  
 
3.3.2.1 Identification of mPSCs 
Directly after isolation, mPSCs can be identified by the presence of Vitamin A 
droplets, indicating a state of quiescence (non-activated form). During culturing mPSCs 
gets activated, lose their Vitamin A droplets and can be stained for α-SMA and GFAP 
(Apte et al., 1998; Bachem et al., 1998). Validation of the isolation procedure of mPSCs 
was modified from Haanes et al. 2012 and further established in our laboratory prior to 
the start of this thesis by Benedikt Hild, a former medical student. I therefore refer to his 
dissertation for further reading regarding this subject (Hild, 2015). 
 
 
Before After wash 
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200 μm 
50 μm 50 μm 50 μm 
200 μm 
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3.3.3 Cell culture, Passaging and Cell Count 
mPSCs were cultured in tissue culture dishes (100 x 20 mm) supplied with 
DMEM/F12 in a humidified atmosphere of 5% CO2 and 95% air at 37°C. Under hypoxic 
conditions the O2 level was lowered to approx. 1%. mPSCs were not allowed to reach 
more than 90% confluence and were not passaged below 30%. For experimental use, 
mPSCs were always used at passage 2-3. Before passaging, cells were washed twice with 
sterile PBS at 37°C. Cells were then incubated at 37°C with 1 mL 0.05% trypsin-0.1% EDTA 
per tissue culture dish for 2-4 minutes, until the cells detached from the culture surface. 
The reaction was terminated with the addition of 10 mL culture medium. Then cells were 
harvested and then centrifuged at 1000 rpm for 4 minutes at RT. The pellet was 
resuspended in 1 mL of culture medium and mixed well. For standardized cell density 
within each experiment, an aliquot of 10 μL was removed for cell counting using a 
haemocytometer and following equation: 
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Q = Cell Number in a Large Quadrant 
 
3.4 Molecular Biological Methods 
3.4.1 Protein Biochemical Methods 
3.4.1.1 Protein Isolation and Estimation 
Protein isolation (section 3.4.1.1 – 3.4.1.2) was adapted and modified from Fabian 
et al. 2011. In brief, culture media was removed and cells were washed twice with cold 
PBS before 150-250 μl of freshly made lysis buffer were added (table 3.6 & 3.7). Lysis 
buffer was complemented with Complete mini (10x) and if required Phos-STOP (10x) (e.g. 
450 μl lysis buffer + 87.5 μl Complete Mini + 50 μl Phos-STOP). Cells were loosened by 
tapping the dish and collected with a cell scraper. The cell/protein solution was then 
transferred to a 1.5 ml Eppendorf tube on ice and incubated on a rotating wheel for 30 
min at 4°C. The solution was then centrifuged at 14.000 g for 15 min at 4°C and the 
supernatant transferred to a new 1.5 ml Eppendorf.  
 
3.4 Molecular Biological Methods 
 
40 
 
Table 3.6: RIPA Cell Lysis Buffer 
Reagent Volume (Total 500 ml) Final conc. 
1 M Tris-HCL pH 7.6 25 ml 25 mM 
5M NaCl 15 ml 150 mM 
NP-40 5 ml 1% 
10% SDS 5 ml 0.1% 
10% (240 mM) Sodium deoxycholate 50 ml 1% 
ddH2O up to 500 ml  
 
Table 3.7: RIPA Cell Lysis Buffer for HIF1-α 
Reagent Volume (Total 100 ml) Final conc. 
1 M Tris-HCL pH 7.5 5 ml 50 mM 
5M NaCl 3 ml 150 mM 
NP-40 0.5 ml 0.5% 
1% Triton X-100 1 ml 1% 
1M NaF 5 ml 50 mM 
ddH2O up to 100 ml  
 
An aliquot of the clear protein solution was used to measure protein concentration 
by the BCA Pierce® Protein Assay Kit (Thermo Scientific) according to the manufacturer’s 
instructions and the remaining solution stored at -80°C. Briefly, a standard curve was 
established with the addition of 10 μl BSA standard (25, 125, 250, 500, 750, 1000, 1500 
and 2000 μg/ml) into the wells of a 96 well plate to determine sample protein 
concentration. 10 μl of sample were added into the appropriate well together with 200 μl 
of the working reagent from the BCA kit. The plate was sealed and incubated at 37°C for 
30 minutes. Absorbance was measured at 562nm using a microplate reader (THERMO 
max) and analyzed with the SoftMax pro 3.1.2 software. Samples and standard protein 
concentration measurements were performed in duplicates.  
 
3.4.1.2 Protein Detection and Analysis  
7.5% SDS polyacrylamide gel electrophoresis (SDS-PAGE) was used to separate 
sample proteins. The 7.5% SDS polyacrylamide gel was composed of two different gels 
(stacking and running gel) (see table 3.8). Protein standards of known molecular weight 
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were run alongside the samples including a visible (PageRulerTM Plus prestained Protein 
ladder) and an immunofluorescence detection ladder (MagicMarkTM XP Western 
Standard). 
 
Table 3.8: Composition of 7.5 % SDS Polyacrylamide Gel 
 
Before electrophoresis, the protein samples were first mixed in 1:5 with Blue SDS 
sample buffer  (0.5 M Tris-HCL pH 7.6, 8.5% SDS, 27.5% Sucrose, 100 mM DTT, 0.003% 
Bromphenolblue) and preheated at 95°C for 5 min before loading to the gel. The amount 
of sample (μg protein) loaded per gel lane was dependent on the respective experiment. 
SDS-PAGE was performed in a gel chamber (BioRad) filled with running buffer (25 mM 
Tris, 200 mM Glycine, 1% SDS) and run for approximately 80-120 min at 100 V depending 
on the protein investigated. Thereafter, the proteins were transferred to a PVDF 
membrane using the Tank blotting method from Bio-Rad (Mini Trans-Blot® Cell). Prior to 
the transfer, the PVDF membrane was pre-activated in methanol for 5 min, before being 
put together in a sandwich like structure (composition from cathode: sponge – 2x filter 
paper – PVDF membrane – gel – 2x filter paper – sponge) and left to transfer overnight in 
a buffer tank at 4°C (transfer buffer: 10 mM Tris, 100 mM Glycine, 10% methanol). The 
PVDF membrane was then blocked in 5% milk PBS-tween (0.05%) for 2 h with rolling at RT 
to prevent non-specific binding of antibodies. Next, the membrane was incubated with 
the primary antibody of choice (table 3.9) diluted in 3-4 ml 5% milk PBS-tween (0.05%) 
overnight at 4°C on a tilting table. The following day the membrane was washed 4 times 
in PBS-tween (0.05%) for 10 min at RT and then incubated with the respective secondary 
antibody (table 3.9) diluted in approx. 10 ml 5% milk PBS-tween (0.05%) for 2 h at RT on a 
tilting table. This was followed by 4 washing steps again with PBS-tween (0.05%) as 
5% Stacker Gel  7.5% Running Gel 
ddH2O 1.3 ml ddH2O 1.3 ml  
Rotiphorese® Gel A 357 μl Rotiphorese® Gel A 357 μl 
Rotiphorese® Gel B 150 μl Rotiphorese® Gel B 150 μl 
0.5 M Tris/SDS, pH 8.8 500 μl 1.5 M Tris/SDS, pH 6.8 500 μl 
10% APS 25 μl 10% APS 25 μl 
Temed 2.5 μl  Temed 2.5 μl 
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described above. By using either the Super Signal West pico or West femto Luminol Kit 
(Thermo Scientific), depending on the protein analysed, relevant protein bands were 
detected in the gel documentations system (ChemiDocTM XRS, Bio-Rad) with the Quantity 
One Software, version 4.6.6 (Bio-Rad). 
 
Table 3.9: Antibodies and Ladders 
Antibody/Ladder Dilution  Protein size Origin Manufacturer Cat. Nr. 
Anti-β-Actin 1:15.000 45 kDa Mouse Sigma A5441 
Anti-CXCR2 1:300 55 kDa Rabbit Novus Biological NB300-696 
Anti-HIF1α 1:1000 120 kDa Mouse BD Transduction 610958 
Anti-TRPC1 1:500 90 kDa Mouse Neuromab  clone 1F1 
MagicMarkTM XP 
Western Standard 
   Invitrogen P/N LC5602 
Anti-mouse POD 1:50.000  Goat Dianova 115-035-003 
Anti-rabbit POD 1:10.000  Goat Sigma A0545 
PageRulerTM Plus 
Prestained Protein 
ladder 
   Thermo Scientific #26619 
 
When the same membrane was used to detect multiple proteins, the membrane 
was cut and antibody incubation performed in parallel, or the membrane stripped before 
incubation with the new antibody. This was performed by washing the membrane 3 times 
in ddH2O for 5 min after development, incubating it for 5-10 min in 0.2 M NaOH and then 
washing the membrane again 3 times in ddH2O for 5 min. The membrane was then ready 
for a new protein detection procedure starting from the blocking step with 5% milk PBS-
tween (0.05%). 
The program ImageJ was used to quantify the intensities protein bands in relation 
to that of the housekeeping gene (anti-β-Actin), thereby at the same time serving as a 
loading control. Secondly, background intensity was subtracted before band intensity was 
measured and calculated. For statistical reliability, Western Blots were performed at least 
3 times with protein lysates from different experiments and animals. 
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3.4.2 RNA Extraction and Purification from PSCs 
Total RNA was extracted from treated or non-treated mPSCs in passage 2. The 
supernatant was removed and cells were dissolved in 500 μl Trizol® Reagent (Invitrogen) 
on ice. Cell suspension was collected with a cell scraper, transferred to a 1.5 ml Eppendorf 
tube and incubated for 5 min at RT. 100 μl of chloroform were added and the suspension 
was vigorously shaken and further incubated for 2-3 min at RT. After incubation, the 
suspension was centrifuged at 12,000 g for 15 min at 4°C and the upper colourless liquid 
phase transferred to a new 1.5 ml Eppendorf tube. 250 μl of isopropanol was added and 
suspension mixed by inverting the tube 10-15 times. The suspension was then incubated 
for 10 min again at RT and then centrifuged at 12.000 g for 10 min at 4°C. The 
supernatant was discarded and the RNA pellet then washed two times with 500 μl of 70% 
ethanol by centrifugation at 7500 g for 5 min at 4°C. After the two washing steps the RNA 
pellet was air dried for 5-10 min before it was dissolved in 20 μl RNase free water on ice. 
RNA concentration was measured using a Bio photometer (Eppendorf). The RNA sample 
was then stored at -80°C or used directly in the RT-PCR reaction to make cDNA (section 
3.4.3). 
 
3.4.3 Reverse Transcriptase PCR 
Reverse transcriptase PCR was performed to synthesize cDNA from purified RNA 
(section 3.4.2), which was to be used in further mRNA quantification (section 3.4.6) and 
PCR experiments (section 3.4.4). The reverse transcriptase assay (Roche) was used 
according to the manufacturer’s instructions and reactions were mixed as shown in table 
3.10. A RT-minus control sample with no RNA was always performed simultaneously. The 
volume of the reaction mixture varied between the experiments due to variations in RNA 
concentration between individual experiments. The reverse transcriptase mixture was 
first incubated at RT for 10 min, followed by incubation for 45 min at 55°C before 
incubation for 5 min at 85°C to inactivate the reverse transcriptase. The mixture was 
stored on ice and a further 50 μl ddH2O added. The cDNA sample was stored at -20°C for 
further use in PCR. 
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Table 3.10: RT-PCR Reaction Composition 
Reagent Volume 
RNA Sample (~1 μg)* 1-2 μl 
5x RT Buffer 4 μl 
dNTP mix (10 mM) 2 μl 
RT Random Oligo dt-primers (10 μM)* 2 μl 
Reverse Transcriptase 0.5 μl 
RNase out 0.5 μl 
Nuclease Free Water 10 μl 
Total Volume 20 μl 
 
* To ensure denaturation of secondary structures, the RNA samples were first mixed with 
the oligo dt-primers and heated for 10 min at 60°C before being added to the RT-PCR 
reaction.  
 
3.4.4 Polymerase Chain Reaction (PCR) 
Primer pairs used for PCR and qPCR were selected from previously published data 
(primer pairs are shown in table 3.4) (Dietrich et al., 2005; Hill et al., 2013; Johnsen et al., 
2006; Liu et al., 2007; Storch et al., 2012; Varga-Szabo et al., 2008; Weissmann et al., 
2011). The specificity of primer pairs against target genes of interest in both WT and KO 
samples was tested and confirmed. For all PCR experiments the Taq DNA polymerase 
(Segenetic) was used. Taq DNA polymerase catalyses the polymerization of nucleotides 
into duplex DNA in the 5´-3´ direction. The composition and conditions of the PCR are 
given in table 3.11 and this reaction was performed in a Master Cycler (Eppendorf). After 
the PCR reaction had been completed the correct fragment size of amplified target genes 
was visualized by DNA electrophoresis (section 3.4.5). 
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Table 3.11: PCR Reaction Composition 
Reagent Volume  Reaction Step (35 cycles) Temp. Time 
DNA Sample (~20 ng) 1 μl  Initial Denaturation 94°C 5 min 
10x DNA Polymerase Buffer 2 μl  Denaturation 94°C 45 s 
dNTP mix (10 mM) 1 μl  Primer Annealing 50-55°C 15 s 
Forward Primer (10 μM)* 1 μl  DNA Synthesis 72°C 30 s 
Reverse Primer (10 μM)* 1 μl  Final Extension 72°C 10 min 
Taq DNA Polymerase 0.3 μl  Cooling 4°C ∞ 
5x Q Solution 4 μl   
ddH2O 9.7 μl  
Total Volume 20 μl  
 
3.4.5 DNA Electrophoresis  
DNA fragments were separated and visualized using agarose gel electrophoresis. 
The agarose concentration and DNA size markers were dependent on the predicted size 
of the DNA fragments under examination. For the preparation of 1% agarose gel, the 
appropriate amount of agarose (SERVA) was dissolved in 0.5x TBE buffer (45 mM 
Tris/HCL, 45 mM  Boric acid, 1 mM EDTA) by heating the gel solution in a microwave 
(Amica International GmbH, Germany). After cooling to ~60°C, the gel solution was 
transferred to a gel chamber and a comb added to create evenly-sized wells. When the 
gel had completely polymerized, the comb was removed and the gel transferred to a gel 
electrophoresis chamber containing 0.5x TBE buffer. DNA samples were mixed with 6x 
loading dye (New England BioLabs), loaded into the gel and DNA fragments separated by 
electrophoresis (Electrophoresis Power PAC 3000, Bio-Rad) at 80 volts for approx. 60 
minutes. After electrophoresis the gel was incubated with SYBR® Gold (Invitrogen) in 0.5x 
TBE buffer for 30 min with shaking. SYBR® Gold is a cyanine dye that stains nucleic acids 
and can therefore be used to visualize DNA fragments upon excitation with UV light in the 
agarose gel. The gel was visualized with the ChemiDocTM XRS Gel documentation system. 
A 100 bp DNA ladder (New England BioLabs) was run parallel to the samples for accurate 
prediction of the fragment sizes.  
 
 
3.4 Molecular Biological Methods 
 
46 
 
3.4.6 Quantitative Real-time PCR 
Quantitative real-time PCR (qRT-PCR) was performed at the University of Lille, 
France under supervision from Kateryna Kondratska. The qPCR procedure was adapted 
from Kondratska et al. 2014, also described in Lindemann et al. 2015. 
Total RNA was extracted as previously described (section 3.4.2). 5-10 μg RNA (total 
volume of 20 μl) was treated with DNase (Ambion) at 25°C for 30 min and purified using 
Phenol/Chloroform/Isoamyl (25:24:1), stabilized (Biosolve) with 5% 3 M Sodium Acetate 
(330 μl and 17.5 μl, respectively). Following centrifugation at 12.000g for 20 min the 
upper phase was collected and supplemented with 2.5x volume of ethanol and 10% 3 M 
Sodium Acetate. After overnight incubation at -20°C, the samples were washed with 70% 
ethanol, air dried and re-suspended in 15 μl ddH2O. RNA concentration was measured 
and purity determined by gel electrophoresis (section 3.4.5) through the identification of 
two clear bands (18S and 28S ribosomal RNA). 2 μg of total RNA were reverse transcribed 
into cDNA using random hexamer primers (Roche) and MuLV reverse transcriptase 
(Roche) (table 3.12). The reverse transcriptase mixture was incubated at room 
temperature for 15 min followed by incubation for 30 min at 42°C before inactivating the 
reverse transcriptase for 10 min at 70°C. The mixture was first put on ice and then stored 
at -20°C for further use in qRT-PCR. 
qRT-PCR is a method for DNA quantification where the amplification of a target 
sequence and its quantification are simultaneously performed. The reaction was carried 
out in a real-time thermal cycler Cfx C1000 (Bio-Rad). Quantification was performed by 
measuring fluorescence intensity after the extension step of each cycle using the cFX 96TM 
Real-Time system (Bio-Rad). The relative changes in gene expression were calculated by 
the 2-ΔΔCT method (Livak and Schmittgen, 2001). This method relies on the following two 
assumptions. (1) The PCR reaction occurs with 100% efficiency, which means that the 
amount of product doubles in each PCR round. (2) There is a gene that is expressed at a 
constant level in each sample to correct for any difference in the amount of sample used 
for the reaction (Livak and Schmittgen, 2001). The rise of fluorescence is assumed to be 
proportional to the generated PCR product and thereby measures the amount of target 
DNA. The threshold cycle (CT) was set to be automatically determined by the cFX 96TM 
Real-Time system. CT indicates the fractional PCR cycle number at which the amount of 
amplified target gene reaches a fixed threshold. 
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Table 3.12: RT-PCR Reaction Composition for qPCR 
Reagent Volume Total volume 
RNA Sample (~2 μg)* 1-8.4 μl 
9.6 μl Random hexamer primers (2.5 mM)* 1.2 μl 
Nuclease Free Water* Up to 9.6 μl 
10x RT Buffer (without Mg2+) 2 μl 
10.4 μl 
MuLV Reverse Transcriptase 1 μl 
dNTP mix (10 mM) 4 μl 
RNase inhibitor 1 μl 
Total Volume  20 μl 
 
* To ensure denaturation of secondary structures the RNA sample was first mixed with 
the hexamer primers and nuclease free water and then heated for 10 min at 70°C, before 
being added to the RT-PCR reaction mix.  
 
Ten picomoles of each primer pair and 0.2 μl of the synthesized cDNA (first-strand 
synthesis) were mixed with 2xSsoFastTMEvaGreen®Supermix (Bio-Rad) and qRT-PCR was 
carried out using following conditions: Initial denaturation activation step at 95°C for 30 s, 
followed by 41 cycles of 95°C for 5 s and 60°C for 30 s (for an overview, see table 3.13). To 
exclude fluorescence of primer dimers all primers were tested using diluted cDNA from 
the first-strand synthesis to confirm linearity of the reaction. Inclusion criteria for primers 
were an amplification efficiency of 90-110%, and an R2 value > 0.98 (parameter to 
evaluate PCR efficiency). A dissociation curve (melting curve analysis) was run for primers 
to exclude samples containing dimers using the following thermal profile: 95°C for 10 s, 
followed by a stepwise increase of temperature by 0.5°C every 5 s from 65°C to 95°C. 
Primer pairs that were used for the amplification of specific fragments from the first-
strand synthesis are listed in table 3.4. Note that primer set number 2 was used for 
amplification of TRPC1 in qRT-PCR. Both the Hypoxanthin phosphoribosyltransferase 1 
(hprt) gene and β-2 microglobulin (β-2M) were used as endogenous controls to normalize 
variations in RNA extractions, the degree of RNA degradation, variability in reverse 
transcription and qRT-PCR efficiency. All experiments were performed in triplicates and 
repeated three times.  
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Table 3.13: Composition of the qRT-PCR and Protocol Steps 
Reagent Volume  Reaction Step  
(41 cycles of step 2-3) 
Temp. Time 
2x SsoFastTM EvaGreen® 
Supermix  
7.5 μl  1) Initiating Step  95°C 30 sec 
Primer forward  
(10 μM) 
0.45 μl  2) Denaturation 95°C 5 sec 
Primer reverse  
(10 μM) 
0.45 μl  3) Annealing/Synthesis 60°C 30 sec 
ddH2O 1.6 μl   
cDNA Sample* 5 μl  Dissociation curve (melting curve analysis) 
Total Volume 15 μl  Increment steps 65°C → 95°C ↑0.5°C 5 sec 
 
* cDNA was taken from the dilution row 1/20 to 1/160 for the testing of primer efficiency. 
For quantification, the 1/40 dilution was found to be optimal. 
 
3.5 In Vitro Migration Assays 
To mimic tissue composition observed within the pancreas and in PDAC all 
migration experiments were performed with a matrix composed primarily of Collagen I 
(~90%) complemented with laminin, fibronectin, collagen III and IV, as observed in 
desmoplastic regions in PDAC. I will refer to this matrix as desmoplastic matrix. A detailed 
composition is given in table 3.14.   
 
3.5.1 Hypoxia treatment 
mPSCs were exposed to a hypoxic environment within the hypoxic CO2 incubator 
maintained at low oxygen tension (1% O2, 5% CO2 and 94% N2). The treatment was 
initiated by replacing the culture medium in the culture with deoxygenated DMEM/F12 
and incubating the mPSCs under hypoxic conditions. Deoxygenated medium was 
prepared prior to each experiment by equilibrating the medium within the hypoxic 
incubator for at least 5 h. The cell-permanent compound, dimethyloxalglycine (DMOG) 
(Frontier Scientific), was used to chemically induce hypoxia at a concentration of 0.5 mM 
with DMSO as control [1:10,000]. Different experiments were performed with DMOG: (1) 
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Figure 3.2. Schematic of the 2D Migration Setup. A 12.5 cm2 culture flask with seal cap was 
coated with approx. 200 μl desmoplastic matrix (table 3.14) and left for polymerization 
overnight in a CO2 incubator. The matrix should polymerize by the following day and be ready 
for experimental use. ~27.000 PSCs were then seeded out in 2.5 ml DMEM/F12 (plus FCS). 
After 6-7 h the cells should be firmly attached and ready for the experiment. 
Evaluation of the optimal concentration and chronic effect of DMOG (tested in 
concentrations at: [0.25 mM] [0.50 mM], [0.75 mM], [1.0 mM] and [1.5 mM]) and (2) 
assessing the acute effect of DMOG ([0.50 mM]).  
3.5.2 Two-Dimensional Migration 
Culture flasks (12.5 cm2) were coated with 150 μl desmoplastic matrix (pH 7.4) 
(table 3.14) and left overnight to polymerize (~14-18 h) in the CO2 incubator. mPSCs were 
seeded out (~27,000 mPSCs per flask) in 2.5 ml DMEM/F12 medium and left to attach for 
~6 h. A schematic is shown in figure 3.2. Hereafter, the medium was changed and flask 
incubated overnight (~20-24 h) under the appropriate conditions. The following day the 
caps of the flasks were closed quickly inside the incubator and transferred to pre-heated 
chambers (37°C) on stages of inverted microscopes (10x and 20x objectives). Cell 
migration was recorded for varying time periods in 5 min intervals using time-lapse video 
microscopy (program HiPic and Wasabi) as described previously (Fabian et al., 2012; 
Fabian et al., 2008). 
In the experiments with chemically-induced hypoxia the medium after PSC 
attachment was changed to fresh DMEM/F12 +/- DMOG or DMSO and incubated 
overnight (~20-22 h). Next day were the medium changed to RPMI/HEPES medium (minus 
FCS, pH 7.4, +/- DMSO or DMOG) and equilibrated in a heat closet for 30 min before 
transferring the closed flask to the microscope. This was performed to better mimic the 
conditions in the 3D migration experiment with the medium also being RPMI/HEPES 
minus FCS (see below).  
 
   
Before coating Matrix coated flask Polymerized matrix PSCs seeded on matrix 
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Figure 3.3. The 3D Migration Chamber. For 
clarity I omitted the Paraffin/Vaseline sealing 
of the chamber. (Top) A chamber was built 
onto a microscope slide out of 
paraffin/Vaseline (1:1) with a spacer (20 mm 
(L) x 20 mm (w) x 0.8 mm (h)). (Bottom) The 
matrix containing mPSCs was then loaded. 
After polymerization of the gel mPSC 
migration could be observed by means of 
time-lapse video microscopy.  
Table 3.14: Composition of 2D Matrix 
 Stock conc. Volume End Conc. % 
RPMI 5x 52 g/L 200 μl 10.4 g/l  
HEPES 10x 100 mmol/L 100 μl 10 mmol/l  
NaOH 1 M 4.8 μl pH = 7.4  
ddH2O  397 μl   
Laminin 1 mg/ml 40 μl 40 μg/ml 4.46% 
Fibronectin 1 mg/ml 40 μl 40 μg/ml 4.46% 
Collagen IV 0.9 mg/ml 6 μl 5.4 μg/ml 0.602% 
Collagen III 1.0 mg/ml 12 μl 12 μg/ml 1.34% 
Collagen I 4 mg/ml 200 μl 800 μg/ml 89.15% 
Total   1 ml 897.4 μg/ml 100% 
 
- Note: the given amounts in table 3.14 are for coating of approx. 5 migration flasks. 
 
3.5.3 Three-Dimensional Migration 
The 3D experimental migration setup is closely related to the one performed in 2D. 
The same matrix composition was used, but with an increased concentration of each 
individual component to achieve sufficient 
polymerization with embedded mPSCs.  
Initially, the migration chamber was built 
under semi-sterile conditions from a mixture of 
Paraffin and Vaseline (1:1) surrounding a 
spacer (l: 20 mm, w: 20 mm, h: 0.8 mm), 
3D Migration Chamber 
PSC Embedded in 3D Gel 
 
h 
L 
w 
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leaving one end open for loading (modified from (Stock et al., 2005)). Next, the 3D 
gel/+mPSCs mixture was made (~400 μl matrix, pH ≈ 7.35) (table 3.15), loaded and left 
upright for polymerization for 2.5 h at 37°C to prevent mPSCs from attaching to the 
side/bottom. An illustration of the 3D migration setup is shown in figure 3.3. After 
polymerization the chamber was sealed with paraffin/Vaseline (1:1) and transferred to 
pre-heated chambers (37°C) on stages of inverted microscopes and cell migration 
recorded for varying time periods using time-lapse video microscopy. The focus was set 
on mPSCs localized in the middle plane of the chamber to ensure 3D migratory 
conditions. Only mPSCs showing migratory activity within the first hour of the time-lapse 
video recording were used for further analysis (see section 3.5.6). mPSCs in focus and not 
moving in the Z direction were fully analysed (figure 4.3 D). mPSCs which were out of 
focus, but observed to be active, were only analysed for migration velocity and 
translocation (section 3.5.6). For time-lapse video microscopy of 3D migration the 
program HiPic was used with the following settings: 10x microscope objective, 5 min 
intervals.  
 
Table 3.15: Composition of 3D Matrix 
 Stock conc. Volume End conc.  
(300 μl matrix) 
End conc.  
(400 μl matrix) 
% 
RPMI 10x 104 g/L 30 μl 10.4 g/l 10.4 g/l  
HEPES 20x 200 mmol/L 30 μl 20 mmol/l 20 mmol/l  
NaOH 1 M 3.45 μl  pH = 7.4  
Laminin 1 mg/ml 30 μl 100 μg/ml 75 μg/ml 4.216% 
Fibronectin 1 mg/ml 30 μl 100 μg/ml 75 μg/ml 4.216% 
Collagen IV 0.9 mg/ml 5.4 μl 16.18 μg/ml 12.135 μg/ml 0.682% 
Collagen III 1.0 mg/ml 10.8 μl 36 μg/ml 27 μg/ml 1.516% 
Collagen I 4 mg/ml 159 μl 2120 μg/ml 1590 μg/ml 89.37% 
PDGF 10 μg/ml 2 μl 66.66 ng/ml 50 ng/ml  
mPSC In 1x RPMI/HEPES  
(20 mM, pH 7.4) 
100 μl 
 
90-100,000 cells 
 
Total    2372.18 μg/ml 1779.13 μg/ml 100% 
- Note that the given amounts in table 3.15 are for one 3D migration experiment.  
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Figure 3.4. Ibidi 2D Chemotaxis μ-Slide. The μ-Slide 
Chemotaxis2D from Ibidi consists of two large volume 
reservoirs (~40 μl) connected by a thin channel (1mm wide 
and 70 μm high). mPSCs are seeded into this channel. The two 
reservoirs can then be filled individually with a 
chemoattractant (shown in red) and cell- and 
chemoattractant-free medium (shown in blue). There is a 
linear and stable concentration gradient of the 
chemoattractant inside the connecting channel generated by 
diffusion (modified from www.Ibidi.com). 
Notation to 2D and 3D matrices: 
Bearing in mind that polymerization and self-assembly of collagen may be affected by 
free protons (Freire and Coelho-Sampaio, 2000; Williams et al., 1978), the pH values of 
the cell free 2D matrix composition (table 3.14) and the 3D matrix/+ mPSCs (table 3.15) 
were always adjusted to ≈ pH 7.4.  This ensured reproducible and consistently structured 
collagen polymerization, allowing for the exclusion of any effects based on pH-dependent 
differences in the matrix. The pH stability in the 3D chamber was in parallel to the time-
lapse recording by measuring the pH at different time points in an eppendorf tube, 
including the same amount of matrix and PSCs. 
 
3.5.4 Chemotaxis Assay 
For 2D chemotaxis experiments the μ-Slide Chemotaxis2D from Ibidi was used 
according to manufacturer’s guidelines (Application Note 14, Ibidi protocol) (figure 3.4) 
and as described previously (Fabian et al., 2011). First, the observation area (figure 3.4) of 
the chemotaxis μ-Slide was coated for 1 hour with the same desmoplastic matrix as used 
in the 2D migration experiments (table 3.14). Hereafter, the remaining matrix solution 
was aspirated to remove excessive coating and filled with 
RPMI (10mM HEPES, no FCS) before seeding ~5,000-7,500 
mPSCs into the channel. The mPSCs were allowed to attach 
for 5-7 h in a humid atmosphere at 37°C. Then the medium 
in the μ-Slide was replaced with fresh RPMI (10mM HEPES, 
no FCS) to get rid of non-attached mPSCs. The stimulant 
was then applied in one of the reservoirs to establish a 
gradient and mPSC chemotaxis/directionality was 
Chemoattractant  
1 mm 
70 μm
 
Free medium 
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monitored by time-lapse video microscopy for 15 h using the program HiPic and Wasabi 
with following settings: 5x and 10x microscope objectives, 5 min intervals. The following 
stimulants were used (end concentration in the chemoattractant reservoir is shown):  
PDGF (800 ng/ml), VEGF (400 – 1600 ng/ml) and KC (10 – 10.000 ng/ml).  
 
3.5.5 Autocrine Stimulation Assay 
WT, TRPC1-/- and TRPC6-/- mPSCs (passage 2) were cultured under hypoxic 
conditions (1% O2, 5% CO2 and 94% N2) in normal culture medium for 6 h before media 
was replaced with serum-free DMEM/F12 and further incubated for 18-24 h. The 
conditioned media were harvested, sterile filtered and applied to WT mPSCs pre-seeded 
on a desmoplastic matrix within 2D migration flasks (see section 3.5.2) for further 
evaluation of migration stimulation. Normoxically equilibrated culture media (DMEM/F12 
minus FCS) were used as control. 
 
3.5.6 Analysis of Migration Data 
For quantification and tracking of 2D/3D mPSC migration and chemotaxis the Amira 
Imaging Software was used to label the circumferences of the cells as previously 
described (Fabian et al., 2012; Fabian et al., 2008). The individual cell contours or cell 
center were manually determined frame-by-frame over the entire migration movie, 
which then served as the basis for further analysis. Every other image of the time-lapse 
video was selected for analysis giving intervals of 10 min duration. The duration of the 
migration movie analyzed was between 4-18 h. Usig a Java-based Plugin for ImageJ 
individual data files could be obtained for each segmented mPSC. This data file was then 
imported into Microsoft Excel and the following parameters were determined: 
 
1) Migration velocity [μm/min]:  
Calculated from the movement of the cell center per unit time.  
 
2) Translocation [μm]:  
Defined by the distance from start to end position. 
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Figure 3.5. Definitions of Directionality and Chemotactic Index. (A) The directionality of 
migration is calculated by the translocation from start to end (y) divided by the total distance 
covered (d). Changes in the directionality can point toward difficulties in the cells steering 
capabilities. (B) The chemotactic index (CI) is calculated by the distance covered toward a 
gradient (y) divided by the total distance covered (d). The CI thereby provides information 
about cells’ chemotaxis capabilities. 
 
 
3) Total path length [μm]:  
Defined by the total distance covered (from start to end position) during the 
migration movie. Calculated from mean velocity multiplied with the duration of the 
movie in minutes. 
 
4) Chemotactic index (CI): 
Indicates efficiency of cell chemotaxis toward a given stimulant. The chemotactic 
index (CI) is defined by the net distance covered towards the gradient in y-
direction(y) divided by the total path length (d) (figure 3.5). Cells moving in a direct 
line towards the gradient will give the value “1”, whereas cells changing direction 
often will give lower values, or even negative, when moving against the gradient.  
 
5) Directionality: 
The ability of the cell to move in a direct line from A to B. Calculated by the 
translocation (start to end point) (y) divided by the total path length (d) (figure 
3.5). Cells moving in a direct line give values close to “1”, whereas cells changing 
direction give lower values.  
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6) Cell Area [μm2]: 
Defined by the projected area covered by the cell. Not applicable to cells 
followed/marked only with a dot (cell center). 
 
7) Structure Index [SI]: 
The structure index defines cell morphology. Spherical cell shape structures give 
values close to “1”, whereas values closer to “0” indicate a more star-shape and 
extended structure/morphology. SI was calculated  as follows: 
  
 SI = (4*π*A)/ƿ2  
 
- “A” is the area covered by the cell and ƿ is the perimeter of A. 
 
3.6 Oxygen Consumption and Extracellular Acidification 
Measurements  
Oxygen consumption and extracellular acidification measurements of mPSCs were 
performed at Bayer A/G, Berlin, Germany under supervision from PhD student Ilya 
Kovalenko.  
The Seahorse Extracellular Flux Analyser XF96 (Bioscience) was used to profile the 
metabolic activity of WT, TRPC1-/- and TRPC6-/- mPSCs under normoxia and chemically-
induced hypoxia according to manufacturer’s guidelines (Installation and Operation 
Manual, Software Version 1.3, revision 12/21/10, www.seahorse.bio.com). This was 
performed by measuring O2 concentration and pH, which are estimates of the two major 
energy producing pathways, mitochondrial respiration and glycolysis. The XF96 analyzer 
converts these measurements into oxygen consumption rate (OCR) in pmol/min, 
extracellular acidification rate (ECAR) in mpH/min and proton production rate (PPR) at 
intervals of approx. 2-5 minutes. OCR is an indicator of mitochondrial respiration, 
whereas both ECAR and PPR are measured from pH and are predominately the result of 
glycolysis. As cells change metabolic pathways e.g. under hypoxic conditions, the 
relationship between OCR and ECAR changes. This is also known as the Warburg effect 
(Asgari et al., 2015; Upadhyay et al., 2013). The OCR/ECAR (estimated metabolic index) 
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was also calculated. If this index changes from “high” to “low” e.g. normoxia vs. hypoxia, 
it indicates prevalence to glycolysis above oxygen and thereby a more anaerobic than 
aerobic metabolic phenotype. In this experiment we used DMOG [0.50 mM] to simulate 
and induce hypoxic conditions. Both the acute (1 hour) and chronic (18-22 h) effect of 
DMOG was measured. 
The experiment was performed according to the manufacturer’s instructions. 
Briefly, on day one 25,000 mPSCs per well were seeded on a Seahorse 96-well cell culture 
plate and left to adhere for 3 h before DMOG or DMSO (control) were applied for the 
chronic experiments. Further, the Seahorse cartridge was equilibrated in Seahorse 
Bioscience XF96 Calibrant buffer overnight at 37°C in the Seahorse Prep station. In the 
acute DMOG experiment mPSCs were left in normal culture media overnight and 
DMOG/DMSO applied the next day to run the experiment simultaneously with the 
chronic DMOG treated mPSCs. At day 2 mPSC culture medium was replaced by XF 
Seahorse Assay medium (modified DMEM, pH 7.4, + 5 mM glucose, + 2 mM sodium 
pyruvate) +/- DMOG [0.50 mM] or DMSO and incubated for 60 min in a heating closet at 
37°C prior to running the assay. The equilibrated Seahorse cartridge was placed together 
with a utility plate with calibration buffer in the XF96 Analyzer for calibration. After 
incubation the Seahorse 96-well cell culture plate with treated mPSCs was loaded into the 
XF96 Analyzer and the assay was performed. The measurements were performed in 
triplicates in 9 min steps. A baseline of 4 measurements was made and the mean of these 
then calculated.  For further details about experimental instructions, I refer to the XF96 
Extracellular Flux Analyzer and Prep Station, Installation and operation Manual (Seahorse 
Bioscience). 
 
3.6.1 Estimation of Oxygen consumption in 3D chamber 
Known volume in chamber: 350 μl  =   0.35 ml 
Number of PSCs in chamber: 85.000 cells 
Oxygen capacity at 37°C:  7 mg/l 
1 mol oxygen:  32 g 
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Calculation of oxygen in chamber: 
?
?? ?
? ??????
???
?? ? ? ? ?????? ????
???
? ? ?????????? ???
???
? ???????? ? ? ???? ? ??????  
 mol oxygen in chamber: ???????
???
????????
? ????? ? ?????????????????
 
OCR readout (Seahorse): 
PSC WT readout:     (N = 3) 176.2 pmol/min 25,000 cells 
KO TRPC1 readout:  (N = 3) 182.1 pmol/min 25,000 cells 
KO TRPC6 readout:    (N = 3) 179.8 pmol/min 25,000 cells 
 
PSC WT:    
Oxygen consumption estimation in chamber  
?????????????????? ?????? ? ??????? ? ???? ? ???????? ??   for 25.000 cells 
            ? ?????? ??????? ???????    for 25.000 cells 
 
85.000 cells:     ???????????
???????????
? ??????? ? ???? ?? ???????? ??????? ???????? ?? 
          ? ???????? ??????? ???????? ?? 
????????????????????????????????????????????????????????????????????????????????? ????? ? ?????? ???????? 
 
Estimated hypoxia after: ????????
??????????????
?????????????? ???????
? ?????????? ? ???? ???  
 
PSC KO TRPC1:    
Oxygen consumption estimation in chamber  
?????????????????? ?????? ? ?????? ? ???? ? ???????? ??    for 25,000 cells 
            ? ?????? ??????? ???????    for 25,000 cells 
 
85.000 cells:    ????????????
???????????
? ?????? ? ???? ?? ???????? ??????? ???????? ??  
???????????????????????????????????????????????????????????????????????????????? ???????? ??????? ???????? ?? 
????????????????????????????????????????????????????????????????????????????????? ?????? ??????? ???????? 
 
Estimated hypoxia after: ????????
??????????????
??????????????? ???????
? ?????????? ? ???? ???  
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PSC KO TRPC6:    
Oxygen consumption estimation in chamber  
?????????????????? ?????? ? ??????? ? ???? ? ???????? ??    for 25,000 cells 
            ? ?????? ??????? ???????    for 25,000 cells 
 
85.000 cells:     ???????????
???????????
? ??????? ? ???? ?? ???????? ??????? ???????? ??  
????????????????????????????????????????????????????????????????????????????????? ???????? ??????? ???????? ?? 
????????????????????????????????????????????????????????????????????????????????? ?????? ??????? ???????? 
 
Estimated hypoxia after: ????????
??????????????
??????????????? ???????
? ?????????? ? ???? ???  
 
3.7 Manganese Quenching  
The Manganese (Mn2+) quenching method was used for indirectly measuring Ca2+ 
influx into Fura-2 (Calbiochem) loaded mPSCs (Fabian et al., 2011; Lindemann et al., 2013; 
Merritt et al., 1989). Mn2+ enters the cell via Ca2+ channels, binds with higher affinity than 
Ca2+ to the Ca2+ dye Fura-2 and thereby decreases the Ca2+-induced fluorescence 
intensity. The decrease of Ca2+-bound Fura-2 fluorescence intensity is thereby used as an 
indirect measure of Ca2+ influx. Fura-2 was excited at its isosbestic wavelength of 365 nm, 
where the emitted fluorescence at 500 nm is independent of changes in [Ca2+]i. 
Glass bottom cell culture dishes (CellviewTM, Greiner Bio-one) were coated with 0.8-
1.0 ml desmoplastic matrix (1:10 diluted) (table 3.14) for 30-45 min at RT. Hereafter 
20,00-25,000 mPSCs were seeded in a total volume of 2.5 ml and left to adhere for 4-6 h. 
mPSCs were then either incubated in 2.5 ml culture medium overnight (20-24 h) under 
hypoxic conditions (1% O2) or in chemically-induced hypoxia with DMOG [0.50 mM] 
together with their respective controls (normoxia and DMSO). The next day, 1 ml medium 
was removed and the normoxia- and hypoxia-treated mPSCs loaded for 30 min with 5 μM 
Fura-2-AM (total volume of 1 ml) within the CO2 incubator (no light). After incubation the 
cell dish was transferred to a 37°C heated inverted microscope (40x oil emission 
objective, Axiovert 200, Zeiss), and perfused for 5-10 min with Ringer’s solution (pH 7.4) 
prior to the measurements. The experiment was performed with perfusion of 37°C pre-
heated working solutions (given in table 3.16) and image sequences recorded in 5 s 
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Figure 3.6. Principle of the Manganese 
Quenching  Method. Representative 
graph showing an increased calcium 
influx in hypoxia stimulated mPSC (red 
slope, m2) compared to control (black 
slope, m2). Δm (m2 – m1) is giving a 
more negative value for hypoxia 
compared to normoxia treated mPSCs 
indicating a higher Ca2+ influx. 
intervals. The high speed poly chromator, camera and images were controlled by the 
Metaflour software (Visitron Systems). The experimental protocol was as follows: (1) 
Control period of 1.5-2.5 min in Ringer’s-solution, (2) 2-3 min in Mn2+ containing Ringer’s 
solution, (3) 2-3 min Ringer’s solution. For data analysis the perinuclear fluorescence 
intensity was quantified and corrected for background fluorescence. Afterwards, 
regression analysis of fluorescence intensity over time was performed to determine the 
change in fluorescence quenching. Mean Fura-2 fluorescence intensity excited at its 
isobestic wavelength 365 nm (F365) was normalized to the first stable values under control 
conditions. The corresponding mean change of the slope Δm (m2 – m1) was then 
calculated, with m1 equivalent to control conditions and m2 to Mn2+. A more negative 
value for Δm in treated PSCs would then indicate a higher Ca2+ influx within these cells. 
 
 
Table 3.16: Ringer’s Solutions for [Mn2+] Measurements 
Ringer-Solution, pH 7.4 at 37°C* Stock 
NaCl 122.5 mM 3M NaCl (157.32 g/l) 
KCl 5.4 mM 1M KCl (74.55 g/l) 
CaCl2 1.2 mM 0.1M (11.099 g/l) 
MgCl2 0.8 mM 0,1M (20.33 g/l) 
HEPES 10 mM  
Glucose 5.5 mM  
 
* For Mn2+ working solutions MnCl2 (125.84 g/mol) was applied to give a final conc. 
of [200 μM]. 
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3.8 Calcium Entry  
This experiment was performed in cooperation with Kateryna Kondratska, a PhD 
student from our cooperation partner from the University of Lille, France. Calcium 
imaging protocol was adapted and modified to our experimental setup from Kondratska 
et al. 2014. 
Freshly isolated mPSCs (described in section 3.3.2) were directly seeded on glass 
bottom cell culture dishes (CellviewTM, Greiner Bio-one) to carry out calcium imaging on 
non-culture-activated mPSCs, reflecting mPSCs in their quiescent state. We used mPSCs 
from passage 2 for calcium imaging on culture activated PSCs. The ratiometric dye Fura-
2/AM (Calbiochem) was used as a Ca2+ indicator. Cells were loaded with 2 μM Fura-2/AM 
for 45 min at 37°C and 5% CO2 in corresponding medium and subsequently washed three 
times with external solution containing: 140 mM NaCl, 5 mM KCl, 1mM MgCl2, 2 mM 
CaCl2, 5 mM glucose, 10  mM HEPES (pH 7.4). Experiments were carried out at room 
temperature. Excitation wavelength alternated between 340 and 380 nm, and the 
fluorescence emission was recorded at 500 nm. Images were aquired in 5-s intervals. High 
speed poly chromator, camera and images were controlled by the Metaflour software 
(Visitron Systems). Fluorescence intensity was measured over the whole cell area and was 
corrected for background fluorescence before [Ca2+]i was calculated by the ratio of the 
wavelengths 340 nm / 380 nm (f/f0) (Kondratska et al., 2014).  
 
3.9 Calpain Activity  
To determine calpain activity in single RLT-PSCs a so called Boc assay was modified 
and used according to previous published data (Glading et al., 2000; Rosser et al., 1993; 
Svensson et al., 2010). Glas bottom dishes (Greiner Bio-One, Frickenhausen, Germany) 
were coated for 30 min with 1:10 diluted basal lamina matrix (table 3.17), before 
~2.3*104 cells were plated in growth medium to attach for 3-4 h at 37°C and 5% CO2, 95% 
air. 5 min prior to the calpain experiment DMEM/F12 medium was replaced with Hepes-
buffered Ringer solution. Cells were then either treated in the presence or absence of 50 
ng/ml PDGF with DMSO (1:1000) or TRAM-34 (1-[(2-Chlorophenyl)diphenylmethyl]-1H-
pyrazole, 10 μmol/l), an inhibitor of KCa3.1 channels for 30 min. Thereafter, cells were 
transferred to the microscope stage (Axiovert 200) and the calpain substrate 7-amino-4-
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chloromethylcoumarin, t-BOC-L-leucyl-L-methionine amide (CMAC, t-BOC-Leu-Met; 10 
μM; Molecular Probes) was added. After 10 min at 37 °C fluorescence images were taken 
using a digital camera (model 9.0, RT-SE-Spot, Visitron Systems) and the MetaVue 
software (Visitron). At the end of the experiment cells were labelled with 2´,7´-bis-(2-
carboxyethyl)-5-(and-6)-carboxy-fluorescein (BCECF; 1.25 μg/ml) for 2 min in order to 
obtain a uniform labeling of the cytosol. The following filter sets were used: excitation 
365/12nm, beam splitter 395nm, emission 397nm (for CMAC, t-BOC-Leu-Met 
fluorescence) and excitation 470/40nm, beam splitter 510nm, emission 540/50nm (for 
BCECF-fluorescence). Image exposure settings were identical within each experiment: 100 
ms for CMAC, t-BOC-Leu-Met and 500 ms for BCECF. Fluorescence intensity was 
measured over the whole cell area and corrected for background fluorescence in ImageJ. 
When local calpain activities were determined, CMAC, t-BOC-Leu-Met fluorescence were 
normalized to that of BCECF. 
 
Table 3.17: Composition Basal Lamina Matrix 
 Stock conc. Volume End Conc. % 
RPMI 5x 52 g/L 104 μl 13.5 g/l  
HEPES 10x 100 mmol/L 52μl 12.99 mmol/l  
NaOH 1 M 7.5 μl pH = 7.4  
ddH2O  52 μl   
Laminin 1 mg/ml 12.5 μl 31.2 μg/ml 7.75% 
Fibronectin 1 mg/ml 12.5 μl 31.2 μg/ml 7.75% 
Collagen IV 0.9 mg/ml 160 μl 339 μg/ml 84.5% 
Total   400 μl 401.4 μg/ml 100% 
 
- Note: 1:10 (400 + 3600 μl ddH2O) was used for coating. 
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3.10 Statistical Analysis 
All experiments were repeated at least three times and tested for normal 
distribution by Shapiro-Wilk, Lilliefors and Kolmogorov Smirnov tests before performing 
any statistical analyses. For normally distributed data, statistical significance was 
determined using the Student t-test. Otherwise, the Mann-Whitney U test was used. Data 
are presented as means ± standard error of mean (SEM). Differences between 
experimental groups reaching p ≤ 0.05 were considered significantly different and 
presented as follows:  (*) = p ≤ 0.05. Non-significant data of interest were indicated as 
“n.s.” The number of experiments/replicates performed is given with by an “N” and 
number of data points with an “n”. 
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Figure 4.1. PSC Identification and Elevated Calcium Signalling in Activated mPSCs. (A) Mouse 
PSCs were identified directly after isolation through positive staining of Vitamin A, indicating a 
state of quiescence (non-activated form). (B) Upon culturing, mPSCs are activated, lose their 
vitamin A droplets and show positive staining for α-SMA (α-SMA staining after 5 days culturing 
is shown). (C) Store release and calcium influx were analysed by calcium imaging showing a 
higher calcium store release and influx in culture activated mPSCs compared to freshly isolated 
mPSCs. Data presented as means ± S.D. N = 3. (D) Representative gel (N = 3) documenting the 
expression level of TRPC1, ORAI1-3 and STIM1-2 assessed by semi-quantitative PCR. All target 
genes show elevated expression level in culture-activated mPSCs when compared to freshly 
isolated mPSCs. (Figure A and B were with permission adapted from Hild B. 2015, and 
experiments C and D were performed in cooperation with Kateryna Kondratska). 
Results 
4.1 mPSC Identification  
Freshly isolated mPSCs could be identified by the presence of Vitamin A droplets, 
indicating a state of quiescence (non-activated form). During culturing mPSCs lose their 
Vitamin A droplets and change to their activated form that expresses α-SMA (figure 4.1 A-
B). This transition can be observed after 2 days in culture. It is complete after approx. 5 
days and the first cell passaging. Therefore, mPSCs were used in passage 2 for all 
experiments. The processes used for identification and confirmation of isolated mPSCs 
were established and performed in our laboratory by Benedikt Hild, a former medical 
student, prior to the start of this project. I will therefore refer to his dissertation for 
20 μm 
Vitamin-A α-SMA 
50 μm 
50 μm 50 μm 
A 
B 
C 
Ra
tio
 f/
f 0
 
Ra
t
1.25 
1.00 
0.75 
f/
f 0 1.50 
1.75 
2.00 
0 
time (sec) 200 400 600 800 1000 
0 Ca
2+ 
2mM Ca
2+ 
2μM thapsigargin 
activated mPSCs 
non-activated mPSCs 
culture activated mPSC 
TR
PC
1 
200 bp –  500 bp –  
ac
tin
 
O
RA
I1
 
O
RA
I2
 
O
RA
I3
 
ST
IM
1 
ST
IM
2 
m
ar
ke
r 
TR
PC
1 
ac
tin
 
O
RA
I1
 
O
RA
I2
 
O
RA
I3
 
ST
IM
1 
ST
IM
2 
quiescent mPSC (non-activated) 
D 
am
850 bp –  
4.2 Quantitative Assessment of TRPC Channel Expression in mPSCs 
 
64 
 
further reading regarding this subject (Hild, 2015).  
Calcium signalling is important for cell migration and for PSC activation. It was 
therefore determined whether calcium levels were altered upon culture activation of 
mPSCs. Calcium store release and SOCE were elevated in activated mPSCs compared to 
freshly isolated mPSCs (figure 4.1 C). The mRNA expression level of important SOCE 
members (ORAI1-3, STIM1-2 and TRPC1) was assessed by semi-quantitative PCR showing 
a higher expression of all the analysed candidates (figure 4.1 D). This correlates with the 
elevated calcium influx, which suggests that calcium plays an important role in the 
activation process of mPSCs. These findings also implicate Ca2+ regulatory ion channels, 
including TRPC family members, in the activation of PSCs. 
  
4.2 Quantitative Assessment of TRPC Channel Expression 
in mPSCs 
Quantitative Real-time PCR was used to identify which of the TRPC family members 
(TRPC1-7) were expressed at the highest level in mPSCs. This was done to determine, if 
the expression of the two candidate genes (TRPC1 and TRPC6) were at a significant level. 
The level of expression was analysed in both WT, TRPC1-/- and TRPC6-/- mPSCs to 
determine if any compensatory differences were present. Both the hypoxanthin 
phosphoribosyltransferase 1 (hprt) and the β-2 microglobulin (β-2M) gene were used as 
Figure 4.2. TRPC1-7 Expression in mPSCs. TRPC1 and TRPC6 channels are more abundantly 
expressed in mPSCs compared to other TRPC members. (A) qPCR detection of mRNA 
expression of TRPC1-7 in WT, TRPC1-/- and TRPC6-/- mPSCs relative to the internal control gene 
hypoxanthin phosphoribosyltransferase 1 (hprt). Data presented as means of triplicates ± SEM, 
N = 3. (B) Representative gel showing primer specificity targeting TRPC1 and TRPC6 in mouse 
brain and WT, TRPC1-/- and TRPC6-/- mPSC. Band size depicted in base pairs. 
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endogenous controls and were unchanged for all samples tested. The data shown in 
figure 4.2 uses hprt as the endogenous control. In mPSCs, TRPC1 and TRPC6 were the 
predominantly expressed members of the of TRPC channel family. Smaller levels of 
TRPC2, 3 and 4 expression were detected, but no expression of TRPC5 and TRPC7 was 
found. There was no compensatory increase in expression of other TRPC members in 
TRPC1-/- and TRPC6-/- mPSCs (figure 4.2). These findings, together with substantial data 
linking TRPC channels to regulation of migratory events (Nielsen et al., 2014) lead to the 
interpretation that TRPC1 and TRPC6 channels in mPSCs may be involved in regulating the 
migration of mPSCs. It was postulated that the loss of either of these two channels could 
give rise to cellular functional defects visualized through inhibited mPSC motility. 
 
4.3 mPSC Migration in Three Dimensional Space  
In order to mimic the tissue composition observed within the pancreas and in 
desmoplastic regions in PDAC, all migration experiments were performed with a 
desmoplastic matrix composed primarily of Collagen I (~90%) complemented with 
laminin, fibronectin, collagen III and IV (composition is given in table 3.14 and 3.15). 
To confirm the physiological relevance of the loss of TRPC1 and TRPC6 channels, 
mPSCs were embedded in a desmoplastic matrix and loaded into a three dimensional 
migration chamber (modified from (Stock et al., 2005). To visualize 3D migration focus 
was set on mPSCs surrounded by matrix and having a spindle-shaped cell morphology 
which is characteristic for such conditions (figure 4.3, D). Time lapse video recording of 
cell migration was monitored over a time period of approx. 7 h. TRPC6-/- mPSCs showed a 
significant decrease of 14% in mean cell migration velocity (0.31±0.01 to 0.26±0.01 
μm/min, p = 0.00076) and 30% in mean cell translocation (38.5±3.9 to 26.9±3.2 μm, p = 
0.041) compared to corresponding WT values. In contrast, for TRPC1-/- mPSCs no change 
in velocity was observed compared to WT, although a significant decrease of 29% in mean 
cell translocation was detected (38.5±3.9 to 27.3±2.8 μm, p = 0.032) (figure 4.3 A-C). The 
directionality of TRPC1-/- mPSCs was therefore different from that of WT mPSCS (WT: 
0.28±0.03, TRPC1-/-: 0.21±0.02, p = 0.03). No differences in cell morphology and cell size 
were detected between the groups.  
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4.3.1 Oxidative Cell Stress in Three Dimensional mPSC Migration 
It was analysed whether additional factors have an impact on mPSC migration 
within the 3D migration setup. mPSC migration velocity and translocation were depicted 
over time and further divided into intervals of 2 h. As observed in figure 4.4 D-E, WT 
mPSCs showed 55% higher migration velocity (0.23±0.01 to 0.35±0.01 μm/min, p < 
0.0005) and translocation (13.6±1.3 to 21.2±2.1 μm, p = 0.0027) over the course of the 
experiment. This increase was absent in TRPC6-/- mPSCs, with their final migration velocity 
and cell translocation being significantly lower than that of WT mPSCs (-35% in velocity (p 
< 0.0005) and -59% in cell translocation (p = 0.0025)). In TRPC1-/- mPSCs, migration 
velocity increased by 27% (0.26±0.01 to 0.33±0.01 μm/min, p < 0.0005), but did not reach 
Figure 4.3. Three Dimensional Migration of mPSCs. mPSCs were embedded in a 3D migration 
chamber and cell migration was monitored with time-lapse video microscopy for 7 h. (A) 
Single cell trajectories were normalized to a common starting point and mean translocation 
determined from the radius of a circle. (B) Mean cell migration velocity was decreased in 
TRPC6-/- mPSCs compared to WT, but not that of TRPC1-/- mPSCs. (C) In contrast, both TRPC1-/- 
and TRPC6-/- mPSCs showed a decrease in mean translocation compared to that of WT mPSCs. 
(D) Representative phase contrast image of mPSC morphology in a 3D environment compared 
to that on a 2D surface. On a 2D surface one can clearly distinguish between cell front and 
trailing end. Values represent means ± SEM. n.s. = p > 0.05, (*) = p ≤ 0.05, Student t-test and 
Mann-Whitney U test. WT (N = 3, n = 52), TRPC1-/- (N = 3, n = 59), TRPC6-/- (N = 4, n=48). 
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the same level as that of WT mPSCs (-7%, p = 0.042). TRPC1-/- cell translocation remained 
unchanged overtime, and was not significantly different from that of WT mPSCs.  
The 3D migration chamber was assumed to be completely sealed from the outside, 
allowing for the point of “no” O2 present within the chamber to be calculated (for 
calculation see section 3.6.1 in materials and methods). In brief, this was estimated from 
oxygen consumption rate (OCR) (~180 pmol/min) and amount of O2 present at the 
beginning of the experiment (~7.7*10-8mol). In addition, parallel experiments determined 
Figure 4.4. Decreasing pO2 and pH Induce mPSC migration. WT mPSCs showed increased 
migration velocity and translocation to a higher level than both TRPC1-/- and TRPC6-/- mPSCs 
under decreasing pO2 and pH. (A) Migration velocity over time for WT, TRPC1-/- and TRPC6-/- 
mPSCs under decreasing pO2. The estimated time point at which all O2 within the chamber is 
consumed is depicted with a line. For this calculation it was assumed that the chamber was 
sealed for O2 from the environment. (B) Oxygen consumption rate (OCR) of WT, TRPC1-/- and 
TRPC6-/- mPSCs under normoxic conditions and after 1 and 18 h of chemically induced hypoxia 
with DMOG [0.50 mM], respectively. (C) Measurements of pH within the 3D cell-matrix 
mixture. (D) Migration velocity and (E) translocation over time in 2 h intervals. WT mPSCs 
showed an increase in migration velocity and translocation over the course of the experiment. 
This effect was completely absent in TRPC6-/- mPSCs, whereas TRPC1-/- mPSCs showed an 
increase in migration velocity, but not in translocation. Values represent means ± SEM. n.s. = p 
> 0.05, (*) = p ≤ 0.05, Student t-test and Mann-Whitney U test. WT (N = 3, n = 52), TRPC1-/- (N = 
3, n = 59), TRPC6-/- (N = 4, n = 48). 
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a concomitant drop in pH within the cell-matrix mixture (figure 4.4, C). Taken together, 
these data show that mPSCs demonstrate an increasing migratory activity under 
decreasing pO2 and acidosis, with TRPC6-/- mPSCs being unable to respond to these 
environmental cues.  
 
4.4 Hypoxia and mPSC Migration 
Hypoxia and oxidative stress are major stimulants of PSC activity, intensifying the 
mutual signalling between PSCs and PDAC cells, and consequently facilitating PDAC 
progression (section 1.3.3) (Eguchi et al., 2013; Erkan et al., 2009; Ide et al., 2006; 
Masamune et al., 2008a). Of note, the function of TRPC1 and TRPC6 channels is involved 
in the response of various cell types to hypoxia, giving rise to increased migratory activity 
(section 1.5.2). Therefore, as pointed out in the hypothesis (section 2.1), these two 
channels represent good candidates for mediating such cellular responses in PSCs.  
Due to uncontrollable external parameters (including pO2 and pH) in the 3D 
migration model, a simplified 2D model was introduced. This allowed more controlled 
investigation of the role of hypoxia as a major stimulating factor in mPSC migration. 
 
4.4.1 Chemically Induced Hypoxia Stimulates mPSC Migration 
4.4.1.1 DMOG Induces mPSC Migration in a Dose-Responsive Manner 
 DMOG acts to inhibit prolyl hydroxylases, preventing the degradation of HIF 
subunits to activate the HIF system and enhance transcription of target genes (Elvidge et 
al., 2006; Lum et al., 2007). In this way, it induces cell responses in high concordance to 
“real” hypoxic conditions (1% O2, 5% CO2 and 94% N2). DMOG has not been tested on 
isolated primary mPSCs before and a dose response curve was therefore established with 
concentrations of DMOG ranging from 0.25 – 1.50 mM. The stimulating effect of DMOG 
was assessed by its ability to increase 2D mPSC migration on a desmoplastic matrix. 
Preliminary data (N = 1, n = 18, data not shown) showed that applying DMOG acutely 
stimulated mPSC migration approx. after 12 h incubation. To investigate the chronic 
effect of DMOG-induced hypoxia on mPSC migration, 20 h of incubation time was 
selected. It is worth noting, that after 20 h of treatment in normal culture medium 
(+DMOG), the medium was changed to serum free HEPES buffered RPMI media (+DMOG) 
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Figure 4.5. DMOG Induces Migration of mPSCs in a Dose-Responsive Manner. mPSCs were pre-
activated with DMOG for 20 h before cell migration was monitored with time-lapse video 
microscopy for 8 h. DMOG increased mPSC migration velocity (A) and translocation (B) in a 
dose-responsive manner. The optimal level of activation was reached with 0.50 mM DMOG. 
Values represent means ± SEM. n.s. = p > 0.05, (*) = p ≤ 0.05, Student t-test. Control (N = 5, n = 
49), [0.25 mM DMOG] (N = 3, n = 28), [0.50 mM DMOG] (N = 4, n = 46), [0.75 mM DMOG] (N = 
3, n = 28).  
prior to the start of the experiment, as this was the condition used in the 3D model. The 
first 8 h of the time lapse video microscopy were analyzed with DMOG at concentrations 
from 0.25 – 0.75 mM. Higher concentrations induced cell death (1.0 and 1.5 mM DMOG) 
(data not shown). Figure 4.5 illustrates increased mPSC migration velocity and 
translocation at increasing concentrations of DMOG.  
The optimal level of mPSC migration activation was reached with a concentration of 
0.50 mM DMOG. mPSCs covered a mean distance of 73.6±6.5 μm at a velocity of 
0.27±0.02 μm/min. Under control conditions, mPSCs only covered a mean translocation of 
43.8±3.7 μm with a velocity of 0.18±0.02 μm/min. The increase in velocity and 
translocation was statistically significant (p < 0.05). All future experiments were conducted 
with 0.50 mM DMOG to investigate the hypoxic stimulation of mPSC migration.  
 
4.4.1.2 Chronic Treatment with DMOG Induces an Anaerobic mPSC Phenotype  
To verify that 0.50 mM DMOG induce an anaerobic phenotype with hypoxia characteristics, 
metabolic index was estimated for mPSCs treated under normoxic conditions and DMOG-induced 
hypoxia for 18-20 h. This was calculated by determining OCR and extracellular acidification rate 
(ECAR, pH related) of mPSCs. WT, TRPC1-/- and TRPC6-/- mPSCs showed significantly decreased 
OCR (p < 0.0005) and increased ECAR (p < 0.005) indicating a shift in the prevalence of glycolysis 
over oxygen, which is also known as the Warburg effect (Asgari et al., 2015; Upadhyay et al., 
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Figure 4.6. DMOG Induces an Anaerobic mPSC Phenotype Characteristic to Hypoxia. (A) mPSCs 
were pre-incubated for 1 or 18 hour(s) with DMOG to induce chemical hypoxia. OCR and ECAR 
show a well-known Warburg shift in the prevalence of glycolysis above oxygen (p < 0.0005). 
(B) An estimated metabolic index was calculated and represents a more anaerobic than 
aerobic metabolic phenotype (p < 0.0005). A difference in the metabolic index was found 
between WT and TRPC1-/- mPSCs (p = 0.011). (C) Representative Western blot showing 
elevated HIF-1α protein expression in mPSCs after 6 h of chemically induced hypoxia and 
hypoxia (1% pO2) compared to controls. Values represent means ± SEM. n.s. = p > 0.05, (*) = p 
≤ 0.05, Student t-test. All experiments were performed three times. 
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2013). The same effect was observed in the estimated metabolic index (OCR/ECAR) going from 
“high” to “low”, reflecting a more anaerobic than aerobic metabolic phenotype, when treated 
with DMOG (shown in figure 4.6). Surprisingly, a difference was detected between WT and TRPC1-
/- mPSCs (p < 0.05) indicative of a more anaerobic phenotype in WT than in TRPC1-/- mPSCs 
following DMOG treatment (figure 4.6, B). Furthermore, DMOG caused acute effects after 1 hour 
of treatment, lowering the OCR significantly in all mPSC groups (p < 0.05) (figure 4.4, B) in addition 
to the ECAR and the metabolic index (data not shown). The increase in HIF-1α protein expression 
served as further verification of hypoxic stress in mPSCs. As depicted in figure 4.6 C, the 
expression of HIF-1α increased in WT mPSCs after 6 h in both chemically induced hypoxia and in 
hypoxia treated (1% O2, 5% CO2 and 94% N2) mPSCs compared to controls. Overall, these data 
suggest that DMOG induces practically the same metabolic response in mPSCs as hypoxia. 
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4.4.2 mPSCs Morphology Upon Hypoxia Stimulation 
TRPC1-/- mPSCs appear larger in cell size than WT mPSCs. Chemical induction of 
hypoxia caused a morphological change in WT mPSCs to a smaller cell type (figure 4.7). 
Projected cell area of WT mPSCs is reduced by 15% upon chemically induced hypoxia 
(5074±219 to 4301±225 μm2, p = 0.016). TRPC1-/- mPSCs have a projected cell area of 
approx. 6000 μm2, which is significantly larger than that of WT mPSCs (+20% under 
control conditions (p = 0.015)). In contrast to WT mPSCs, projected cell area hardly 
decreased during hypoxia, such that the area of TRPC1-/- mPSCs was 37% larger than that 
of WT mPSCs under hypoxic conditions (p < 0.0005). In comparison, TRPC6-/- mPSCs have 
the same projected cell area as WT mPSCs (approx. 5100 μm2). However, they do not 
change their projected area upon chemically induced hypoxia as observed for WT mPSCs 
(p = 0.03). These data were partly inconsistent with those observed under hypoxia 
conditions (figure 4.7, B). WT mPSCs had a tendency to have a smaller projected cell area 
under hypoxic conditions (p = 0.08), which was significantly smaller than that of TRPC1-/- 
mPSCs (p = 0.041), but not than that of TRPC6-/- mPSCs. No tendency or significant change 
Figure 4.7. mPSCs Cell Size upon Hypoxic Stimulation. mPSCs were challenged with chemically 
induced hypoxia (A) or with hypoxic conditions (B) for 20 h before cell migration was 
monitored with time-lapse video microscopy for 8 h. The mean projected cell area was 
analyzed. WT mPSCs tend to display a smaller projected cell area upon hypoxic stimuli than 
TRPC1-/- and TRPC6-/- mPSCs. TRPC1-/- mPSCs appear to have a larger projected cell area 
compared to WT mPSCs, although this is not consistent in both experiment. Values represent 
means ± SEM. n.s. = p > 0.05, (*) = p ≤ 0.05, Student t-test. WT (control: N = 5, n = 49 and 
DMOG: N = 4, n = 46), TRPC1-/- (control: N = 3, n = 41 and DMOG: N = 4, n = 50) and TRPC6-/- 
(control: N = 3, n = 35 and DMOG: N = 4, n = 53). WT (normoxia: N = 4, n = 51 and hypoxia: N = 
4, n = 56), TRPC1-/- (normoxia: N = 4, n = 49 and hypoxia: N = 4, n = 53) and TRPC6-/- (normoxia: 
N = 4, n = 51 and hypoxia: N = 3, n = 53).   
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of projected cell area under hypoxia was observed for TRPC1-/- and TRPC6-/- mPSCs. This 
suggests that hypoxia induces morphological changes in mPSCs with TRPC1-/- and TRPC6-/- 
mPSCs responding differently, possibly with a different migratory behaviour as well.   
 
4.4.3 TRPC1-/- and TRPC6-/- mPSCs Display Diminished Motility Under 
Chemically Induced Hypoxia 
It was therefore next tested whether chemically induced hypoxia caused the same 
stimulatory effect of TRPC1-/- and TRPC6-/- mPSCs migration as observed for WT. mPSCs 
were incubated with DMOG for 20 h and cell migration was monitored with time-lapse 
video microscopy for 8 h. Figure 4.8 depicts cell trajectories normalized to the same 
starting point from all mPSC groups. These data clearly show a significant increase by 48% 
in the migration velocity  (0.18±0.01 μm/min to 0.27±0.02  μm/min, p < 0.0005) and 68% 
in translocation (43.8±3.7 μm to 73.6±6.5  μm, p < 0.0005) of WT mPSC under chemically 
induced hypoxia. TRPC1-/- mPSCs also showed increased migration velocity, +25% 
(0.16±0.01 μm/min to 0.20±0.01 μm/min, p = 0.009) and translocation, +50% (36.3±3.43 
μm to 54.12±4.34 μm, p = 0.01), but not to the same level as observed for WT mPSCs. In 
contrast, the stimulatory effect of chemically induced hypoxia was absent in TRPC6-/- 
mPSCs. Their migration velocity (0.16±0.01 μm/min to 0.19±0.08 μm/min, n.s.) and 
translocation (36.2±5.1 μm to 50.1±4.7 μm, n.s.) did not increase. This suggests a 
dominance of TRPC6 over TRPC1 channels in the PSC response to hypoxia. 
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Figure 4.8. mPSCs Migration Under Chemically Induced Hypoxia. (A) Single cell trajectories 
were normalized to a common starting point and mean translocation determined from the 
radius of a circle. DMOG increased mPSC migration velocity (B) and translocation (C) of both 
WT and TRPC1-/- but not that of TRPC6-/- mPSCs. The increase in migration velocity and 
translocation of TRPC1-/- mPSCs did not reach the level observed for WT. Values represent 
means ± SEM. n.s. = p > 0.05, (*) = p ≤ 0.05, Student t-test and Mann-Whitney U test. WT 
(control: N = 5, n = 49 and DMOG: N = 4, n = 46), TRPC1-/- (control: N = 3, n = 41 and DMOG: N 
= 4, n=50) and TRPC6-/- (control: N = 3, n = 35 and DMOG: N = 4, n = 53).  
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Figure 4.9. Indication of Autocrine Stimulation of mPSCs Under Chemically Induced Hypoxia. 
Following media change (wash-out) WT mPSCs increased their migration velocity (A) and 
translocation (B) over time (2 h intervals) under chemically induced hypoxia. This was not 
observed in TRPC1-/- and TRPC6-/- mPSCs. Moreover, the final migration velocity and 
translocation were significantly higher in WT compared to TRPC1-/- and TRPC6-/- mPSCs. Values 
represent means ± SEM. (*) = p ≤ 0.05, Student t-test and Mann-Whitney U test. WT (control: 
N = 5, n = 49 and DMOG: N = 4, n = 46), TRPC1-/- (control: N = 3, n = 41 and DMOG: N = 4, n = 
50) and TRPC6-/- (control: N = 3, n = 35 and DMOG: N = 4, n = 53).  
4.4.4 Attenuated Autocrine Stimulation of TRPC1-/- and TRPC6-/- mPSCs 
Under Chemically Induced Hypoxia 
Cell migration velocity and translocation were further plotted as a function of time 
and depicted in 2 h intervals (figure 4.9). This revealed an increasing migratory activity 
during the course of the experiment for the WT, but not for TRPC1-/- and TRPC6-/- mPSCs. 
Migration activity of WT mPSCs under chemically induced hypoxia increased to a final 
migration velocity of 0.30±0.02 μm/min and translocation of 26.5±2.5 μm. Neither  
TRPC1-/- (velocity: 0.20±0.01 μm/min, translocation: 18.7±1.7 μm) nor TRPC6-/- mPSCs 
(velocity: 0.19±0.01 μm/min, translocation: 16.3±1.7 μm) showed this dynamic behaviour 
(figure 4.9). Significance between the last intervals for the three groups is indicated. Note 
that the media were changed before cell migration recording, suggesting that WT mPSC 
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under chemical hypoxia secrete certain factors that likely lead to autocrine stimulation. 
The response to this stimulation or the degree of stimulation may be affected by the loss 
of TRPC1 and/or TRPC6.  
 
4.4.5 TRPC1-/- and TRPC6-/- mPSCs Display Diminished Motility Under 
Hypoxia Stimulation 
DMOG is a chemical compound primarily inducing hypoxia effects by preventing the 
degradation of HIF subunits, thereby activating the HIF system. Other pathways regulated 
by hypoxia can be independent of the HIF pathway and hypoxia often also leads to 
cellular stress, induction of ROS etc. (Elvidge et al., 2006; Lum et al., 2007). It was 
therefore tested whether the observed stimulatory effect with chemically induced 
hypoxia is in concordance to “real” hypoxia (pO2 < 1%). mPSCs were incubated for 22-24 h 
under hypoxic conditions (1% O2, 5% CO2 and 94% N2) before cell migration was 
monitored for 8 h with time-lapse video microscopy.  
In agreement with chemically induced hypoxia, incubation for 22-24 h under 
hypoxic conditions significantly increased WT mPSC migration velocity by 30% (0.23±0.01 
μm/min to 0.30±0.02 μm/min, p < 0.0005) and translocation by 51% (43.1±3.1 μm to 
65.3±6.8 μm, p = 0.02). TRPC1-/- mPSCs slightly increased their migration velocity by 16% 
from 0.21±0.01 μm/min to 0.24±0.01 μm/min (p = 0.04), which was significantly lower 
than that of WT (-21%, p = 0.002). However, the translocation (44.9±5.0 μm to 50.9±4.5 
μm, n.s.) was not statistically different from that of WT (-22%, p = 0.2, n.s.). Again the 
stimulating effect of hypoxia was absent in TRPC6-/- mPSCs showing migration velocity 
and translocation values of 0.21±0.01 μm/min to 0.20±0.01 μm/min (n.s.) and 49.1±3.8 
μm to 44.1±3.8 μm (n.s.), respectively (figure 4.10). This was in concordance with the 
observation detected under chemically induced hypoxia showing a more prominent effect 
on TRPC6-/- than TRPC1-/- mPSCs compared to corresponding WT values.  
As before, cell migration velocity and translocation were plotted in 2 h intervals 
(figure 4.11). Of note, no media change (wash-out) was conducted as in the experiment 
with chemically induced hypoxia. Migration activity of WT mPSCs under hypoxia 
stimulation increased to a final migration velocity of 0.30±0.02 μm/min and translocation 
of 24.4±2.3 μm versus that of TRPC1-/- (velocity: 0.26±0.02 μm/min, translocation: 
20.4±1.9 μm) and TRPC6-/- mPSCs (velocity: 0.19±0.01 μm/min, translocation: 15.0±1.4 
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μm) (figure 4.11). Significance between the last intervals for the three groups is indicated. 
Only TRPC6-/- mPSCs showed statistically lower levels of activation at the final interval 
when compared to WT values. The velocity and translocation values for WT mPSCs under 
chemically induced hypoxia (from figure 4.9) are illustrated in grey. This demonstrates 
that the migratory activity, under chemically induced hypoxia, is increased to the same 
Figure 4.10. mPSCs Migration Under Hypoxia Stimulation. (A) Single cell trajectories were 
normalized to a common starting point. Mean translocation determined from the radius of a 
circle. (B) Mean cell migration velocity. (C) Mean cell translocation. Hypoxia increased WT 
mPSC migration velocity and translocation. Only translocation of TRPC1-/- mPSCs was 
increased, but not to the same level as WT. Hypoxia stimulation was absent in TRPC6-/- mPSCs. 
Values represent means ± SEM. n.s. = p > 0.05, (*) = p ≤ 0.05, Student t-test and Mann-
Whitney U test . WT (normoxia: N = 4, n = 51 and hypoxia: N = 4, n = 56), TRPC1-/- (normoxia: N 
= 4, n = 49 and hypoxia: N = 4, n = 53) and TRPC6-/- (normoxia: N = 4, n = 51 and hypoxia: N = 3, 
n = 53).   
4.4 Hypoxia and mPSC Migration 
 
77 
 
Figure 4.11. Chronic Hypoxia Stimulates the Migratory Activity of mPSCs. Following 22-24 h of 
hypoxia incubation WT mPSCs have reached a steady level of migratory activity. This could be 
observed by displaying cell migration velocity (A) and cell translocation (B) over time in 2 h 
intervals. The final migration velocity and translocation were significantly higher in WT 
compared to TRPC6-/- mPSCs, but not that of TRPC1-/- mPSCs. Values represent means ± SEM. 
(*) = p ≤ 0.05, Student t-test and Mann-Whitney U test. WT (normoxia: N = 4, n = 51 and 
hypoxia: N = 4, n = 56), TRPC1-/- (normoxia: N = 4, n = 49 and hypoxia: N = 4, n = 53) and  
TRPC6-/- (normoxia: N = 4, n = 51 and hypoxia: N = 3, n = 53).   
level as observed for hypoxia via a possible autocrine stimulation mechanism (figure 
4.11). Taken together, these data demonstrate that the TRPC1 and TRPC6 channel are 
important for mPSCs response to hypoxia stimulation by affecting cell motility. Thus the 
defect of TRPC6-/- mPSCs is more pronounced than that of TRPC1-/- mPSCs. 
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4.5 TRPC Channel Expression in mPSCs under Hypoxia 
TRPC1 and TRPC6 channel expression have previously been described to be 
elevated in various cell types in response to hypoxia and oxidative stress which 
demonstrated their role in regulatory mechanisms in sensing and/or responding to such 
changes (reviewed in (Dietrich et al., 2014; Dietrich and Gudermann, 2014; Faouzi and 
Penner, 2014; Nesin and Tsiokas, 2014)). It was therefore tested whether the lower 
migratory activity of TRPC1-/- and TRPC6-/- mPSCs under hypoxia stimulation correlated 
with the two channels being differently expressed. This would give further information 
about TRPC1 and TRPC6 being involved in downstream sensing mechanism to hypoxia in 
accordance to the postulated hypothesis ① (section 2.1).  
WT mPSCs were incubated under hypoxic conditions (1% O2, 5% CO2 and 94% N2), 
or chemically induced hypoxia (DMOG [0.50 mM]) for 24 h before protein lysates were 
harvested or RNA isolated and reverse transcribed. A 1.5 fold increase in TRPC1 protein 
expression could be confirmed by WB analysis. Specificity of antibody was proven by the 
use of protein lysates from TRPC1-/- mPSCs and human PSCs (figure 4.12 A-B). mRNA 
quantification of all seven TRPC channel members (TRPC1-7) was performed. The level of 
mRNA expression from each TRPC channel member was normalized to that under control 
conditions. No expression of TRPC5 and TRPC7 could be detected. A tendency to hypoxia-
induced up-regulation of TRPC1, TRPC2 and TRPC3 could be noticed together with a 
down-regulation of TRPC4 (figure 4.12 C-D). This points toward TRPC1-4, but not TRPC6 
being part of a possible downstream sensing mechanism to hypoxia through regulated 
expression levels. This further suggests that the TRPC6 channel is implicated in a possible 
modifier mechanism or elicits important transduction/effector functions in mPSCs upon 
hypoxic stimulation in accordance to the postulated hypothesis ② and ③ (section 2.1).  
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Figure 4.12. TRPC Channel Expression in mPSCs Under Hypoxia. (A) The protein expression of 
TRPC1 (~90 kDa) was increased 1.5 fold upon 24 h of hypoxic stimulation in mPSCs. Protein 
expression was normalized to the level of controls. Values represent means ± SEM (N ≥ 3). (B) 
Representative Western blot of TRPC1 protein expression and antibody specificity tested in 
human RLT-PSC cell line, TRPC1-/- mPSCs, and WT mPSCs of passage 2 and 3. (C) qPCR 
detection of TRPC1-7 mRNA expression in WT mPSCs relative to the internal control gene hprt. 
Data presented as means of triplicates ± SEM (N = 3), normalized to the expression level under 
control conditions. The relative fold change in relation to both internal control genes is 
depicted in the table underneath. (D) Representative gel of qPCR showing detectable bands of 
TRPC1-4 and TRPC6 but not of TRPC5 and TRPC7. (*) = p ≤ 0.05, Student t-test. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 TRPC1 TRPC2
 TRPC3 TRPC4 TRPC6 
 
 DMOG hypoxia DMOG hypoxia DMOG hypoxia DMOG hypoxia DMOG hypoxia 
hprt 
fold 
change 
1.98 1.14 1.78 1.74 2.18 1.70 0.21 0.22 0.58 1.00 
p value 0.0001(*) 0.44 0.04(*) 0.35 0.40 0.76 0.17 0.05(*) 0.49 0.51 
β-2M 
fold 
change 
2.02 1.36 4.45 1.95 2.07 2.59 0.22 0.23 0.87 2.20 
p value 0.04(*) 0.29 0.005(*) 0.12 0.07 0.06 0.02(*) 0.02(*) 0.68 0.11 
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4.6 Assessment of Autocrine Stimulation of mPSCs under 
Hypoxia 
In relation to the lacking autocrine stimulation detected in figure 4.9 and to the 
hypothesized modifier mechanism of TRPC1 and TRPC6 channels of the microenvironment 
② (section 2.1), their role in the regulation of important hypoxia-mediated autocrine 
stimulants was tested. The stimulatory effect of hypoxia conditioned medium (18 h and 
no FCS added) from WT, TRPC1-/- and TRPC6-/- mPSCs on WT mPSC migration was 
investigated (figure 4.13 F). Normoxically equilibrated culture medium served as control 
(no FCS and no cell contact). Cell migration was monitored with time-lapse video 
microscopy for 4 h. As shown in figure 4.13 A and B, WT and TRPC1-/- mPSCs secrete 
autocrine stimulants upon hypoxia stimulation. The conditioned medium from both 
increased migration velocity by 34% and 33% (WT: 0.18±0.01 μm/min, p = 0.0003,   
TRPC1-/-: 0.18±0.01 μm/min, p = 0.0001) as well as translocation by 40% and 32% (WT: 
23.7±2.0, p = 0.02, TRPC1-/-: 22.4±2.0 μm, p = 0.05), respectively. In contrast, the 
migration of WT mPSCs was significantly attenuated using conditioned medium from 
hypoxia treated TRPC6-/- mPSCs. Migration velocity slightly increased by 7% (0.14±0.01 
μm/min, n.s.) and translocation decreased by 6% (15.8±2.3, n.s.). Tendency to lower 
projected cell area was observed using conditioned medium from WT and TRPC1-/- 
mPSCs, but not from TRPC6-/- mPSCs (figure 1.13, C). The cell structure index (SI) was 
lowered (p < 0.05) with hypoxic conditioned medium from both WT, TRPC1-/- and TRPC6-/- 
mPSCs compared to the control value (figure 1.13, D). More, directional cell migration of 
WT mPSCs was lowered with conditioned medium from TRPC6-/- mPSCs (figure 1.13, E). 
This suggests, that WT mPSCs respond to some secreted stimulants from TRPC6-/- mPSCs 
by adapting a more elongated cell shape and/or having more cell protrusions, but the 
major stimulants for inducing mPSC migration together with a smaller projected cell area 
is lacking. From this the following can be concluded: (i) mPSCs secrete autocrine factors 
under hypoxia which stimulate mPSC migration, (ii) the TRPC1 channel is not implicated in 
the secretion of autocrine stimulants and (iii) the TRPC6 channel is implicated in the 
production and/or secretion of autocrine factors under hypoxia, thereby eliciting a 
modifying mechanism with respect to the microenvironment and PSC activation. Possibly, 
this is due to TRPC6-/- mPSCs having a lower status of activation under hypoxia because of 
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Figure 4.13. Autocrine Stimulation of mPSCs under Hypoxia. Hypoxically conditioned medium 
from WT, TRPC1-/- and TRPC6-/- mPSCs was used to stimulate WT mPSC migration and thereby 
determine any differences in secreted stimulants. Mean values of (A) cell migration velocity, 
(B) cell translocation, (C) cell area, (D) cell structure index and (E) directionality. (F) 
Experimental illustration. mPSCs secreted autocrine stimulants upon hypoxia stimulation. This 
response is attenuated in TRPC6-/- mPSCs. Hypoxically conditioned medium mediated 
morphological changes in mPSCs by inducing a more elongated cell shape (lower SI value) and 
tendency to smaller cell size. Values represent means ± SEM. (*) = p ≤ 0.05. Student t-test and 
Mann-Whitney U test. (control media: N = 4, n = 51 , WT hypoxia media: N = 3, n = 38, TRPC1-/- 
hypoxia media: N = 3, n = 35, TRPC6-/- hypoxia media: N = 3, n = 39).  
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attenuated growth factor/cytokine signaling via a TRPC6-mediated transduction/effector 
pathway. This can lead to lower levels of secreted autocrine stimulants important for 
further stimulation in a loop sequence. 
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Figure 4.14. Hypoxia-Mediated Calcium Influx in mPSCs. Calcium influx is increased in WT 
mPSCs but not in TRPC6-/- mPSCs when pre-activated by chronic hypoxia (A) Time course of 
mean Fura-2 fluorescence (F365) when excited at its isosbestic wavelength of 365 nm for WT 
and TRPC6-/- mPSCs. F365 is normalized to the first value under stable control conditions. (B) 
The corresponding mean change of the slope (Δm: m2 – m1). Values of graphs are represented 
as mean values and values of Δm as means ± SEM. (*) = p ≤ 0.05, Student t-test. WT mPSCs 
(normoxia: N = 4, n = 30, DMSO: N = 3, n = 28, hypoxia: N = 4, n = 35 and DMOG: N = 4, n = 35) 
and TRPC6-/- mPSCs (normoxia: N = 3, n = 36, DMSO: N = 3, n = 26, hypoxia: N = 3, n = 29 and 
DMOG: N = 3, n = 29).   
4.7 Calcium Influx in Hypoxia Stimulated mPSCs  
In order to test if TRPC6 channels are part of transduction/effector pathways in 
mPSCs upon hypoxic stimulation (hypothesis ③, section 2.1), the level of hypoxia-
mediated calcium influx was investigated using the manganese quenching method. The 
decrease in Fura-2 fluorescence following the addition of Mn2+ is an indirect measure of 
calcium influx (Fabian et al., 2011; Lindemann et al., 2013; Merritt et al., 1989). Figure 
4.14 A illustrates the mean decrease of intensity (F365) in percentage in hypoxically 
activated WT and TRPC6-/- mPSCs before and after addition of Mn2+. In figure 4.14 B the 
mean delta slope (Δm) is depicted, which corresponds to the difference between the 
slopes before (m1) and after (m2) Mn2+ addition. Both hypoxia and chemically induced 
hypoxia elicited a higher quenching rate of the fluorescence compared to normoxic 
conditions in WT mPSCs of 43% (DMOSO vs. DMOG, p = 0.002) and 39% (normoxia vs. 
hypoxia, p = 0.0005). This was not observed for TRPC6-/- mPSCs being significantly 
different from that of WT mPSCs (p < 0.05). These results support the hypothesis of 
TRPC6 channels functioning in hypoxia-mediated transduction/effector mechanisms. Loss 
of TRPC6 leads to decreased calcium influx under hypoxic conditions, which may have 
profound effects on downstream signalling cascades important for mPSC migration. 
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Figure 4.15. The Effect of KCa3.1 Inhibition on Calpain Activity. Inhibition of KCa3.1 activity with 
TRAM-34 decreased calpain activity in RLT-PSCs stimulated with PDGF (50 ng/ml). (A) Calpain 
activity was indirectly measured using the CMAC peptidase substrate, t-BOC-Leu-Met. Whole 
cell fluorescence intensity was measured, corrected for background fluorescence and depicted 
in abitrary unit (a.u.). (B) Representative pseudo colour image of calpain activity under PDGF 
stimulation ± TRAM-34. Values represent means ± SEM. (*) = p ≤ 0.05, Mann-Whitney U test. 
(PDGF: N = 3, n = 35 and PDGF + TRAM-34: N = 3, n = 31).  
4.7.1 Calpain – a Downstream Effector in PSC Migration 
Calpain is a calcium dependent proteolytic enzyme known to be active in processes 
related to cell migration in various cell types including integrin-mediated cell migration, 
cytoskeletal remodeling and cell adhesion (Glading et al., 2000; Saraiva et al., 2013; 
Svensson et al., 2010). It was therefore hypothesized that calpain could be a major 
effector downstream of hypoxia-mediated calcium signaling through TRPC channels.  
This was addressed in an entirely different experimental setup. Unpublished data 
(manuscript in revision) have shown that TRPC3-mediated calcium influx, following PDGF 
stimulation (50 ng/ml) in the human established PSC line (RLT-PSC) is important for PSC 
migration, possibly via a mechanism involving calpain activity. Briefly, the calcium influx 
through TRPC3 channels was found to be coupled to the activity of the calcium-activated 
potassium channel (KCa3.1). Activation of KCa3.1 is followed by membrane 
hyperpolarization, which promotes calcium influx, in this context via TRPC3. Inhibition of 
KCa3.1 with TRAM-34 led to a decrease in TRPC3-mediated calcium entry and lower PSC 
migratory activity. Moreover, this was coupled to a lower activity of calpain. This suggests 
that calpain is a downstream effector of PDGF mediated PSC migration (figure 4.15). As 
illustrated in figure 4.15 B, the CMAC peptidase substrate, t-BOC-Leu-Met, was used to 
indirectly measure calpain activity in live RLT-PSCs stimulated with PDGF ± TRAM-34. 
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Whole cell  fluorescence intensity was measured and corrected for background 
fluorescence. Addition of TRAM-34 decreased the calpain activity by 32% (308.1±20.5 to 
210.7±24.9 a.u., p < 0.0005) demonstrating the mechanistic coupling of KCa3.1 mediated 
calcium influx through TRPC3 channels to calpain as regulator of PSC migration. Future 
experiments may elucidate whether calpain activity is decreased in hypoxia activated 
TRPC6-/- mPSCs.  
 
4.8 PDGF Stimulation of mPSC Migration 
PDGF is known to be one of the main stimulants of PSC activity inducing both 
chemokinetic and chemotactic effects (Hild, 2015; Luttenberger et al., 2000; Phillips et al., 
2003b). Furthermore, PDGF is secreted by PSCs upon activation and could thereby be one 
of the autocrine stimulants secreted by hypoxia-stimulated PSCs. Many downstream 
members of the PDGF receptor signaling pathway are Ca2+ dependent (see section 1.3.2). 
It was therefore tested whether TRPC1 and TRPC6 channels are involved in a downstream 
effector mechanism in the response of mPSCs to PDGF. In the human RLT-PSC line PDGF 
elicited a Ca2+ signaling cascade involving the activity of KCa3.1, TRPC3 channels and 
calpain (section 4.7.1). 
 
4.8.1 PDGF Stimulates mPSC Migration in Three Dimensional Space 
In a 3D model (described in section 4.3) the effect of PDGF was addressed in WT, 
TRPC1-/- and TRPC6-/- mPSCs. Time lapse video recording of cell migration was monitored 
over a time period of 7 h in the presence of PDGF (50 ng/ml) and mean migration velocity 
and cell translocation were calculated. PDGF significantly increased mean cell migration 
velocity and cell translocation compared to controls in all groups except the migration 
velocity of TRPC1-/- mPSCs (figure 4.16, table). No significant difference between the 
groups was observed in the presence of PDGF, beside a tendency to lower migration 
velocity and translocation in TRPC6-/- mPSCs (figure 4.16 B-C). Furthermore, the migration 
velocity and translocation were depicted over time in 2 h intervals (figure 4.16 D).  
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Figure 4.16. PDGF Stimulation of mPSC in Three dimensional Space. The addition of PDGF (50 
ng/ml) cannot overcome the loss of activation in TRPC6-/- mPSCs.  mPSCs were embedded in a 
3D migration chamber and cell migration was monitored with time-lapse video microscopy for 
7 h. (A) Single cell trajectories were normalized to a common starting point and mean 
translocation determined from the radius of a circle. (B) Mean cell migration velocity. (C) 
Mean cell translocation. (D) Cell migration and translocation in 2 h intervals in the presence of 
PDGF. All groups significantly increased their migration velocity and translocation from the 
first to the last interval. TRPC1-/- and TRPC6-/- mPSCs did not reach the same level of activation 
as observed for WT mPSCs with the defect being more pronounced for that of TRPC6-/- mPSCs. 
Values represent means ± SEM. In the table the mean migration values under control 
conditions (from figure 4.3) and in the presence of PDGF are depicted. n.s. = p > 0.05, (*) = p ≤ 
0.05, Student t-test and Mann-Whitney U test. WT (N = 3, n = 53), TRPC1-/- (N = 3, n = 72) and 
TRPC6-/- (N = 4, n = 59).  
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 PSC WT PSC TRPC1-/- PSC TRPC6-/- 
MEAN control PDGF control PDGF control PDGF 
Translocation (μm) 38.5±3.9 69.1±6.1(*) 27.3±2.8 65.7±5.2(*) 26.9±3.2 60.3±4.6(*) 
Velocity (μm/min) 0.31±0.01 0.34±0.02(*) 0.30±0.01 0.33±0.01(n.s.) 0.26±0.01 0.31±0.01(*) 
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All groups significantly increased their migration velocity and translocation from the 
first to the last interval. WT mPSCs increased their migration velocity by 55% (0.26±0.01 
to 0.41±0.01 μm/min, p < 0.0005) and translocation by 67% (19.4±1.7 to 32.6±3.5 μm, p = 
0.001), whereas TRPC1-/- increased their migration velocity by 41% (0.26±0.01 to 
0.37±0.01 μm/min, p < 0.0005) and translocation by 59% (18.3±1.4 to 29.1±2.9 μm, p = 
0.001). Although not reaching the same level in migration velocity as WT mPSCs (p = 
0.0003), TRPC6-/- mPSCs increased their migration velocity by 31% (0.24±0.01 to 
0.32±0.01 μm/min, p < 0.0005) and translocation by 36% (16.8±1.5 to 22.9±2.1 μm, p = 
0.02). Both values are far from the corresponding WT values. Velocity was 22% lower (p < 
0.0005) and translocation 30% lower (p = 0.02) (figure 4.16 D).  
 No other cell morphological changes were detected between and within individual 
groups. Therefore, it can be concluded, that TRPC1-/- and TRPC6-/- mPSCs have not lost 
their ability to respond to the chemokinetic stimulation by PDGF. However, keeping in 
mind the decreasing pO2 and/or increasing cellular stress and acidosis throughout the 
experiment, the addition of PDGF could not overcome the loss of activation in TRPC6-/- 
mPSCs.  
 
4.8.2 PDGF Chemotaxis 
PDGF is also known to elicit chemotaxis in PSCs through specific receptor binding 
(Hild, 2015; Phillips et al., 2003b) possibly leading to the activation of Ca2+ permeable 
channels involved in directed cell migration. The role of TRPC1 and TRPC6 channels in 
PDGF mediated chemotaxis of mPSCs was investigated using 2D ibidi chemotaxis slides 
coated with the same desmoplastic matrix used in previous migration experiments. 
Migrating in a PDGF gradient WT, TRPC1-/- and TRPC6-/- mPSCs significantly increased their 
migration velocity by 29%, 38% and 39% (p < 0.0005), respectively, and more than 
doubled their translocation rate (p < 0.0005) (figure 4.17 A-B). However, a 12-16% lower 
cell migration velocity (p < 0.05) was detected under control conditions in both TRPC1-/- 
and TRPC6-/- mPSCs versus that of WT. Additionally, TRPC6-/- mPSCs showed a slightly 
diminished migration velocity of 11% (p = 0.043) during PDGF chemotaxis when compared 
to that of WT mPSCs. The chemotactic index of WT, TRPC1-/- and TRPC6-/- mPSCs was 
almost identical (0.44-0.49, p > 0.05, n.s.) (figure 4.17 C). These findings indicate that 
neither TRPC1 nor TRPC6 play a role in directed cell migration toward PDGF.  
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 PSC WT PSC TRPC1-/- PSC TRPC6-/- 
 control PDGF control PDGF control PDGF 
Translocation (μm) 92.5±6.0 190.7±10.5(*) 85.5±6.1 204.0±10.4(*) 78.2±6.7 184.8±12.1(*) 
Figure 4.17. PDGF Chemotaxis. WT, TRPC1-/- and TRPC6-/- mPSCs efficiently chemotax in a 
gradient of PDGF. mPSCs were seeded into 2D Ibidi slides, PDGF was applied and chemotaxis 
monitored for 15 h using time-lapse video microscopy. (A) Single cell trajectories were 
normalized to a common starting point. Mean translocation values are given in the table. (B) 
Mean cell migration velocity was decreased in TRPC1-/- and TRPC6-/- mPSCs under control 
conditions and in TRPC6-/- mPSCs upon PDGF stimuli. (C) Mean directed cell migration 
efficiency toward higher concentration of PDGF was increased in all groups, displayed by a 
chemotactic index (see figure 3.5, materials and methods, section 3.5.6). Values represent 
means ± SEM. n.s. = p > 0.05, (*) = p ≤ 0.05, Student t-test. WT (control: N = 3, n = 95, PDGF: N 
= 3, n = 98), TRPC1-/- (control: N = 3, n = 64, PDGF: N = 3, n = 69) and TRPC6-/- (control: N = 3, n 
= 60, PDGF: N = 3, n = 70).  
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Discussion 
A link between TRP channel-mediated Ca2+ influx in cell migration is confirmed in 
various cell types (Fiorio Pla and Gkika, 2013; Nielsen et al., 2014; Schwab et al., 2012; 
Stock et al., 2013), however their role in PSC migration was completely unknown before 
the beginning of this thesis. Only the TRPV4 channel is demonstrated in PSC activation. 
This channel is implicated in reactive calcium responses in high fat and alcohol activated 
PSCs (Zhang et al., 2013). Similarly, not much is known about the role of TRP channel-
mediated calcium signalling in the closely related HSCs. Only recently, the TRPM7 channel 
was reported to regulate PDGF-BB-induced HSC proliferation via PI3K and ERK signalling 
(Fang et al., 2013) and the TRPV4 channel to be involved in regulating TGF-β1-induced 
HSC proliferation (Song et al., 2014).  
The present study showed that SOC is transcriptionally and functionally upregulated 
in culture activated mPSCs compared to quiescent mPSCs (figure 4.1). This is in 
accordance to Won et al. who showed that Ca2+ signalling is elevated in activated 
compared to quiescent PSCs (Won et al., 2010). It demonstrates the importance of Ca2+ 
signalling in activated PSCs. In addition, the TRPC1 and TRPC6 channel are the 
predominantly expressed members of the of TRPC channel family in culture activated 
mPSCs (figure 4.2). Furthermore, TRPC1 and TRPC6 channels are recognized as 
transducers of chemically mediated Ca2+ signalling as well as sensors and modifiers of a 
wide variety of microenvironmental changes related to cell migration (Nielsen et al., 
2014). However, their exact functional role in the response of PSCs to hypoxia remains 
elusive. The overall aim of this study was therefore to identify TRPC1 and TRPC6 channels 
as potential sensors, modifiers or transducers/effectors of hypoxia-mediated activation of 
PSCs (depicted in figure 2.1).  
 The key observations found in this study were as followed: (1) the mode of cell 
migration and involved proteins may diverge between 2D and 3D migration. (2) Hypoxia 
induces a migratory phenotype in mPSCs with smaller cell size. (3) Hypoxia-mediated 
increase of TRPC1 channel expression in mPSCs is coupled to elevated cell motility, 
potentially via a sensor mechanism that is also important for correct cell size regulation. 
(4) TRPC6 channels are part of a modifier mechanism in mPSC under hypoxic conditions 
through growth factor/cytokine secretion. (5) TRPC6 channels are part of a 
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transduction/effector pathway by mediating increased calcium influx during hypoxia 
required for stimulation of cell motility. 
 
5.1 The “Ideal” Migration Setup 
The ECM is a complex meshwork of fibrous proteins that provide a physical scaffold 
for cells to move. It provides guiding cues during development, wound repair together 
with support and maintenance of normal tissue architecture. Furthermore, the ECM is 
involved in coordinating cellular migratory functions by the activation of intracellular 
signalling pathways controlling cell motility (Doyle et al., 2013; Grinnell, 2008; Keren et 
al., 2008). Cells react to distinct physical and biochemical characteristics of the ECM (i.e. 
content and arrangement of the matrix). This highlights the importance of using 
experimental models mimicking 3D tissue networks and microenvironments observed 
both in healthy tissues and under pathological conditions (Doyle et al., 2013; Friedl and 
Wolf, 2009a; Petrie et al., 2009).  
To investigate TRPC1 and TRPC6 channels’ role in PSC migration, a 3D experimental 
model was modified and established from Stock et al. 2005. PSC migration could thereby 
be visualized in a microenvironment closely related to that observed within desmoplastic 
regions of pancreatic cancer. Accordingly, it has been observed that the overall mode of 
cell migration and signalling pathways involved may diverge between 2D and 3D 
migration. For example, a higher migration rate was detected for fibroblasts in a 3D 
environment compared to the corresponding 2D ECM. This further depended on ECM 
composition (Hakkinen et al., 2011). This is in agreement with data from this study, 
showing a higher final migration velocity for WT mPSCs migrating in a confined and 
dynamic 3D microenvironment with evolving increasing acidosis and hypoxia than for 
stimulated WT mPSCs migrating on a 2D ECM. However, the relative increase in mPSC 
migration activity upon stimulation (2D versus 3D) was more or less the same compared 
to their respective controls. Furthermore, consistent with previously published data, 
mPSCs spread to a flattened morphology when cultivated on 2D-surfaces (Apte et al., 
1998; Bachem et al., 1998), whereas mPSCs surrounded by a 3D-fibrous matrix assumed 
an elongated cell shape that seemed to mimic that observed in vivo (Apte et al., 2004; 
Apte et al., 2012) (figure 4.3 D).  
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5.2 Hypoxia in mPSC Activation 
As pointed out earlier, hypoxia is a potent stimulator of PSC activity, which also 
promotes inflammatory responses that lead to production and secretion of autocrine 
stimulants (see section 1.3.3). Moreover, it seems that hypoxia-mediated stimulation of 
PSC motility as present in this study and demonstrated previously by Erkan et al., 2009, 
Masamune et al., 2008a and Rebours et al., 2013, is not a universal cell response. In 
contrast to pancreatic and hepatic stellate cells (Novo et al., 2007; Novo et al., 2012; 
Wang et al., 2013), immune cells and (myo)fibroblast migration is inhibited by hypoxia 
(Qu et al., 2005; Riches et al., 2009; Turner et al., 1999; Vogler et al., 2013). The reasons 
for this discrepancy are not yet known. Despite the advantage of the 3D migration model 
to expose PSCs to conditions similar to that in PDAC, it has some disadvantages. While the 
initial physicochemical conditions can be controlled, this is not the case during the course 
of the experiment. A more simplified 2D model was therefore used to analyse the chronic 
effect of hypoxia on mPSC activation. 
WT mPSCs decreased their projected cell area in response to hypoxia stimulation 
(figure 4.7). This is in contrast to that of mice L929 fibrosarcoma fibroblasts which 
increase their cell area and volume under hypoxia stimulation (Vogler et al., 2013). In a 
rat HSC line (HSC-T6) hypoxia induces and an elongated cell structure through a HIF-1α 
dependent pathway. Whether the rat HSCs also changed their cell size is unknown (Wang 
et al., 2013). This morphological response to hypoxia was not detected in TRPC1-/- mPSCs, 
suggesting a role of TRPC1 in cell size regulation. This is further supported by the fact, 
that TRPC1-/- mPSCs generally displayed a larger projected cell area than WT mPSCs 
(figure 4.7). More, previously published data from our group and by others have shown 
that functional expression of the TRPC1 channel is involved in cell size regulation. Chen et 
al. showed that a downregulation of TRPC1 in rat liver hepatoma cells (H4-IIE cells) 
increased cell area and volume (Chen and Barritt, 2003). Fabian et al. could later support 
these findings by showing larger projected cell area and cell volume in murine TRPC1-/- 
fibroblast and siTRPC1 treated Madin–Darby canine kidney focus cells (Fabian et al., 
2012). Thus, the failure of TRPC1-/- mPSCs to increase their activity under hypoxia 
stimulation could be due to a defect in cell size regulation. 
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5.3 TRPC1 and TRPC6 Channels in the Hypoxia-Mediated 
Activation of mPSCs 
Generally, there are two major ways in which TRP channels can sense pO2: 1. 
through direct alteration of the redox status of the channel proteins themselves via 
modification of Cys residues. 2. through an indirect pathway via interaction with pO2 
sensitive complexes or the involvement in pathways of proteins carrying O2 sensor 
domains (Numata et al., 2013). So far, however, only TRPA1 channels are known to sense 
pO2 directly (Takahashi et al., 2011). 
This study demonstrates for the first time, that TRPC1 and TRPC6 channels are 
important for mPSCs response to hypoxia stimulation by affecting cell motility. This is 
further suggested to be mediated by their contribution to distinct mechanisms underlying 
sensor, modifier and transduction/effector pathways of microenvironmental cues.  
 
5.3.1 TRPC1 Channel: Part of an Indirect Sensor Mechanism to Hypoxia in 
mPSCs 
The TRPC1 channel is predominantly viewed as a SOCE channel, although this 
property is still controversially discussed (Ambudkar, 2007; DeHaven et al., 2009; Dietrich 
et al., 2014; Nesin and Tsiokas, 2014). It is connected to the cytoskeleton in a bidirectional 
interplay, linking the channel directly to the migration machinery of the cell (Clark et al., 
2008; Nielsen et al., 2014; Smani et al., 2013). An increase in TRPC1 function can lead to 
elevated Ca2+ influx important for the activation of Ca2+-dependent signalling effectors 
coupled to cell migration. The understanding of the TRPC1 channel function in response 
to hypoxia, however, is only starting to emerge, mostly implicating the channel in an 
indirect sensing mechanism.  
In this study it could be shown that TRPC1-/- mPSCs have an attenuated migratory 
response to hypoxic stimulation when migrating on a 2D surface compared to WT mPSCs 
(figure 4.8 and 4.10). In contrast, under increasing acidosis and hypoxia, the loss of TRPC1 
showed less pronounced effects when mPSCs were migrating in a 3D matrix (figure 4.3 
and 4.4). This indicates that the impact of TRPC1 channels on mPSC depends on the used 
migration model, 2D versus 3D. There is limited information regarding TRPC1 channels as 
mechanosensors in 3D cell migration. In contrast, TRPC1 channels are linked to 
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mechanosignalling during 2D cell migration. In human bone osteosarcoma (Weihuang et 
al., 2015) and primary cultures of synovial fibroblasts (Fabian et al., 2012) membrane 
stretch and substrate stiffness induced TRPC1-mediated SOCE, respectively. Hence, a loss 
of directionality in TRPC1-/- mPSCs was found compared to that of WT mPSCs when 
migrating in a 3D environment (WT: 0.28±0.03, TRPC1-/-: 0.21±0.02, p = 0.03) (data not 
shown). This is in accordance to Weihuang et al. In a 2D migration model they found that 
TRPC1-mediated SOCE and cytoskeleton architecture plays a critical role in the formation 
of cell polarity during directional cell migration (Weihuang et al., 2015). This indicates a 
dependence of the constitutive “steering” mechanism of mPSCs migrating in a 3D matrix. 
However, this effect could be rescued by the application of PDGF. Curiously, the 
difference in in directionality was not observed when mPSCs were migrating on a 2D 
surface. TRPC1-/- mPSCs were even capable of efficient chemotaxis in a PDGF gradient 
(figure 4.17). This differential response appears to be PSC specific since TRPC1 channels 
are implicated in the response to PDGF in rat hippocampal neuronal progenitor cells (Yao 
et al., 2012). Moreover, TRPC1 channels are involved in the response to other stimulants 
such as EGF, FGF-2, TGF-β and fMLP (Bomben et al., 2011; Dong et al., 2010; Fabian et al., 
2011; Fiorio Pla et al., 2005; Lindemann et al., 2015; Tajeddine and Gailly, 2012).  
Hypoxia increased the protein expression of TRPC1 by 1.5 fold, which could partly 
be confirmed by qPCR. This is in accordance to other published data. In smooth muscle 
cells, hypoxia increases TRPC1 channel expression in a HIF-1α dependent manner, further 
leading to elevated SOCE (Jiang et al., 2014; Li et al., 2010; Wang et al., 2006; Yang et al., 
2015). From this it can be suggested, that the hypoxia-mediated increase of TRPC1 
channel expression is part of a sensor mechanism in mPSCs, possibly regulated by 
upstream hypoxia sensitive proteins such as HIF-1α (figure 5.1). Surprisingly, hypoxia also 
regulated the mRNA expression of TRPC2, TRPC3 and TRPC4 channels in WT mPSCs 
(figure 4.12). Additional studies have to determine if this is also the case in TRPC1-/- 
mPSCs and if any possible compensatory effects could be present.  
 In line with these observations it is tempting to speculate that the TRPC1 channel is 
an important contributor to hypoxia-mediated calcium influx in mPSCs needed for 
elevated cell motility in response to hypoxia. Furthermore, efficient TRPC1 channel 
interaction with STIM1 and ORAI1 is needed for SOCE in hypoxically stimulated 
pulmonary arterial smooth muscle cells of both rats and mice (Lu et al., 2008; Ng et al., 
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Figure 5.1. Illustration of the Role of TRPC1 Channels in mPSCs Under Hypoxic Stimulation. The 
TRPC1 channel is part of an indirect sensor mechanism to hypoxia in mPSCs by expression 
regulation. O2 sensitive proteins such as HIF-1α can increase the functional expression of 
TRPC1 leading to a possible elevation in Ca2+ influx. This mobilization of Ca2+ promotes the 
activation of other signaling proteins important for cell migration. Hypoxia and oxidative stress 
can also promote the secretion of autocrine stimulants binding to GPCRs leading to activation 
of PLC and formation of IP3. IP3 mediate Ca2+ efflux from the ER activating SOCE. TRPC1 
channels can be part of the SOCE complex through interactions with STIM1 and ORAI. 
2012). This is interesting as the response of TRPC1-/- mPSCs to hypoxia is not completely 
absent, indicating that the TRPC1 channel is not the only regulator of this process. One 
possible explanation for this could be that hypoxia-mediated ROS production in mPSCs 
(see section 1.3.3 -1.3.4) modifies the Cys residue on either STIM1 or TRPC1, thereby 
altering their functional interaction in the TRPC1-STIM1-ORAI1 complex (Ng et al., 2012; 
Numata et al., 2013; Shimizu et al., 2014). Hence, the TRPC1 channel can function as part 
of a SOCE complex with STIM and ORAI in response to hypoxia (illustrated in figure 5.1). It 
would therefore be interesting to investigate SOCE in hypoxia-stimulated mPSCs and 
decipher the role of TRPC1 played therein. TRPC1 channels could also be part of GPCR-
triggered pathways responding to autocrine stimulants. Frequently these signalling 
cascades also lead to SOCE activation (Clapham, 2003; Minke and Cook, 2002) (figure 5.1). 
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Along these lines the diminished migratory activity of TRPC1-/- mPSCs could be explained 
by altered activity of Ca2+ dependent effectors needed for cell migration. 
 Additionally, TRPC1 channel function is related to inflammatory responses through 
its impact on NAPDH oxidase mediated ROS production (Brechard et al., 2008). NAPDH 
oxidase activity is known to be involved in PSC activation (Asaumi et al., 2007; Masamune 
et al., 2008b). This couples the TRPC1 channel to PSC activation under hypoxia by 
regulating such a process. The model in figure 5.1, illustrates the signalling cascade, which 
link TRPC1 channels to the hypoxia-induced activation of PSCs. This model provides a 
framework to be further validated experimentally. 
  
5.3.1.1 The TRPC1 Channel is not Implicated in the Secretion of Autocrine Stimulants 
Indication of an autocrine stimulation defect in TRPC1-/- mPSCs was detected under 
chemically induced hypoxia (figure 4.9). It was therefore tested whether the TRPC1 
channel was implicated in a modifying mechanism by secretion of autocrine stimulants 
upon hypoxic stimulation. However, no difference in the secretion of autocrine stimulants 
was observed between WT and TRPC1-/- mPSCs. Hypoxia conditioned media from WT and 
TRPC1-/- mPSCs showed the same level of stimulation of WT mPSC migration (figure 4.13). 
Interestingly, the conditioned media induced a smaller and more elongated cell 
morphology (figure 4.13, D). Since this behaviour was detected with conditioned media 
from both genotypes it is proposed that TRPC1 channels are not part of a modifier 
mechanism of the microenvironment. However, at present moment the possibility that 
TRPC1 channels could be involved in the secretion of other stimulants having paracrine 
effects on cancer cells or other stroma host cells such as immune cells, epithelial cells and 
fibroblast cannot be excluded. 
 
5.3.2 TRPC6 Channel: A Central Component in the Response of mPSCs to 
Hypoxia 
The TRPC6 channel is viewed as a ROCE channel, thereby being part of a direct 
transduction/effector pathway downstream of the activation of growth factor or 
chemoattractant receptors (GPCR and RTK) (Dietrich and Gudermann, 2014). Hypoxia-
induced Ca2+ signalling mediated by TRPC6 channels has been pointed out in section 
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1.5.2.2. It was therefore speculated whether TRPC6 channel activity is important for 
regulating responses to hypoxia leading to an elevated migratory activity.  
This study shows convincing data that TRPC6 channels play an important role in the 
migratory response of mPSCs to hypoxia. Thus, in contrast to that of WT mPSCs, TRPC6-/- 
mPSCs did not increase their level of motility under hypoxic stimulation. This was 
observed both when migrating on a 2D desmoplastic surface under hypoxia conditions 
(figure 4.8-4.11) and in a 3D matrix under increasing acidosis and hypoxia (figure 4.3-4.4). 
This is in concordance with other observations. For example, TRPC6 channel activity is 
important for migration of podocytes and fibroblasts (Tian et al., 2010), neutrophils 
(Damann et al., 2009; Lindemann et al., 2013; McMeekin et al., 2006), endothelial cells 
(Hamdollah Zadeh et al., 2008), head and neck squamous cell carcinomas (Bernaldo de 
Quiros et al., 2013) and glioblastoma (Chigurupati et al., 2010). Application of PDGF could 
not overcome the defect induced by the loss of TRPC6 in the 3D model (figure 4.16). 
More, TRPC6 is required for optimal PDGF induced migratory stimulation when migrating 
in a gradient of PDGF (figure 4.17). However, the ability to sense the directional cue 
imposed by a PDGF gradient was not affected suggesting a role of TRPC6 channels in 
regulation of the migration machinery and not a general defect in the steering 
mechanism, too. 
Despite substantial data showing hypoxia-mediated up-regulation of TRPC6 channel 
expression in other cell types such as mesangial cells (Liao et al., 2012), venous smooth 
muscle cells (Li et al., 2010; Wang et al., 2006; Xu et al., 2014), arterial smooth muscle 
cells (Jiang et al., 2014; Yang et al., 2015) and in glioblastoma (Chigurupati et al., 2010), no 
such difference in TRPC6 channel mRNA expression was detected in mPSCs (figure 4.12). 
Different antibodies were tested to verify this on the protein level. However, unspecific 
binding of the antibody (WT versus KO) resulted in high uncertainty of the data. Protein 
analysis of TRPC6 channel expression is therefore not present in this study. Taken 
together, this finding excludes the TRPC6 channel to be part of a hypoxia-mediated sensor 
mechanism.  
 
5.3.2.1 The TRPC6 Channel in a Modifier Mechanism 
Not much is known about TRPC6-mediated production and secretion of stimulants 
under hypoxia. Such mechanisms have mostly been related to the activity of other TRP 
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channels, thus demonstrating the role of Ca2+ signalling in growth factor/cytokine 
secretion. TRPM2 channels underlie enhanced cytokine/chemokine production in 
activated T-lymphocytes (Melzer et al., 2012), monocytes and neutrophils (Knowles et al., 
2011; Wehrhahn et al., 2010; Yamamoto et al., 2008) and pancreatic cancer cells (Bauer 
et al., 2012). TRPM4 channels regulate interleukin production in Jurkat T-cells (Launay et 
al., 2004) and mouse T-cells (Weber et al., 2010), TRPV2 channels that of macrophages 
(Yamashiro et al., 2010) and TRPC5 channel activation induces NO production in 
endothelial cells (Takahashi et al., 2012b; Yoshida et al., 2006). The inflammatory process 
of NADPH oxidase-mediated superoxide production is related to TRPC1, TRPC3, TRPC6 
and ORAI1 channel activity in granulocytes (Brechard et al., 2008). More, NAPDH oxidase-
mediated generation of ROS is important for PSC activation (Asaumi et al., 2007; 
Masamune et al., 2008b). TRPC6 channels could therefore indirectly play a role in 
perpetuating PSC activation through NAPDH oxidase activity regulation. Furthermore, the 
observation of TGF-β signalling in fibroblasts leading to elevated Ca2+ signalling through 
TRPC6 channels important for αSMA positive stress fibers (activation marker) is also of 
great interest (Davis et al., 2012). This is related to the activation of PSCs. First, αSMA is a 
marker of activation in PSCs and second, TGF-β is an important (autocrine) stimulant of 
PSC activity (section 1.3.4). TGF-β could be a TRPC6-dependent expressed stimulant under 
hypoxia in mPSCs and thereby explain the diminished autocrine effect observed in   
TRPC6-/- mPSCs. 
This study provides evidence for an autocrine stimulation defect in TRPC6-/- mPSCs 
when hypoxia was induced chemically with DMOG (figure 4.9). This was confirmed by 
showing that conditioned medium from TRPC6-/- mPSCs kept under hypoxic conditions 
was less potent in stimulating migration of WT mPSCs than that of WT cells (figure 4.13 A-
B). More, it did not induce a smaller projected cell area as detected with conditioned 
medium from WT mPSCs and directional cell migration was diminished. However, it could 
induce the same elongated cell morphology (figure 4.13, C-E). This suggests, that some 
autocrine stimulants are secreted, but the major stimulants of mPSC migration are 
lacking. TRPC6 channels are therefore required for perpetuating mPSC activity under 
hypoxia by a modifier mechanism (illustrated in figure 5.2). This can either be elicited by: 
(i) a direct role of the TRPC6 channel in hypoxia-mediated growth factor/cytokine 
production and secretion or, (ii) loss of the TRPC6 channel leads to a lower activation 
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Figure 5.2. Illustration of the Role of TRPC6 Channels in mPSCs Under Hypoxic Stimulation. The 
TRPC6 channel is part of a possibly coupled modifier and transduction/effector mechanism 
activated in response to hypoxia in mPSCs. Hypoxia and oxidative stress can promote the 
secretion of autocrine stimulants binding to GPCR’s leading to activation of PLC and formation 
of DAG and IP3. IP3 mediates Ca2+ efflux from the ER, whereas DAG directly binds to TRPC6 
channels which promote Ca2+ influx (ROCE). The resulting increase of [Ca2+]i induces the 
activation of signalling proteins important for cell migration. In addition, it drives the secretion 
of autocrine stimulants further stimulating PSC activity in a loop sequence. If these stimulants 
also elicit paracrine effects on PDAC cells remains elusive. 
status under hypoxia, possibly by attenuated growth factor/cytokine signalling via a TRPC6 
mediated transduction/effector pathway. This leads to lower levels of secreted autocrine 
stimulants important for stimulating PSC activation in a loop sequence. It could be 
interesting to determine if any paracrine signalling with PDAC cells is affected (figure 5.2). 
This would determine a role of TRPC6 channels in regulating the mutual signalling with 
PDAC cells, conclusively attenuating PDAC development and progression. 
 
5.3.2.2 TRPC6 Channel: Important for Hypoxia-mediated Calcium Entry 
It was investigated whether TRPC6 channels were required for mediating increased 
calcium influx during hypoxia in mPSCs. In hypoxically preconditioned WT mPSCs, the 
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level of calcium influx was increased (figure 4.14). This elevation in calcium influx, which 
was essentially absent in TRPC6-/- mPSCs, may be important for the activation of Ca2+ 
sensitive effector proteins of the cellular migration machinery demonstrating a role of the 
TRPC6 channel in a transduction/effector pathway (illustrated in figure 5.2). For example, 
TRPC6-mediated reorganization of the cytoskeleton affecting cell migration is shown in 
neutrophils (Lindemann et al., 2013), glioblastoma (Chigurupati et al., 2010) and 
fibroblasts (Davis et al., 2012). This may also explain the attenuated morphological 
response to hypoxia, as WT mPSCs decreased their projected cell area under hypoxia 
stimulation, whereas TRPC6-/- did not (figure 4.7).  
It is not yet known, which mechanism lies behind the elevated TRPC6-dependent 
calcium influx under hypoxia in mPSCs. Since TRPC6 channel expression is unaffected, 
other mechanisms may be more relevant. SOCE members can interact and regulate 
TRPC6 function either directly or indirectly via the formation of heteromeric complexes 
including TRPC1 and STIM1 (Albarran et al., 2014; Yuan et al., 2007) and the STIM/ORAI 
complex (Jardin et al., 2009). Moreover, the functional expression of TRPC6 channels is 
coupled to SOCE (Chigurupati et al., 2010; Xu et al., 2014). Thus, additional studies 
measuring Ca2+ store-release and SOCE are needed to clarify whether TRPC6-mediated 
calcium influx is also a part of SOCE.  
Accumulating evidence indicates that TRPC6 is involved in ROCE, and that it is 
activated directly by DAG via a PKC-independent mechanism (Dietrich and Gudermann, 
2014; Hofmann et al., 1999). It has also been suggested that a stimulation of DAG 
production by GPCRs or RTKs is a prerequisite for oxygen sensing and signal transduction 
through TRPC6 channels in smooth muscle cells (Fuchs et al., 2011). Such a view supports 
the concept that hypoxia-induced TRPC6 activation is mediated by DAG accumulation, 
probably by activated phospholipases (Weissmann et al., 2006; Weissmann et al., 2011). 
However, Tang et al. could not verify such a role of DAG (Tang et al., 2010). They 
suggested instead, that the activation of TRPC6 is independent of PLC, but subsequent to 
an elevation in cellular AMP-activated kinase (AMPK) during hypoxia (Tang et al., 2010). 
The role of DAG in TRPC6 activation is therefore not definitive. Additional experiments 
with a DAG kinase inhibitor would clarify this mechanism in hypoxia activated mPSCs. 
Recent studies have also demonstrated that the TRPC6 channel represents a target of 
ROS (Graham et al., 2010; Wang et al., 2009; Wuensch et al., 2010), which is linked to PSC 
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activation (section 1.3.4). In all these scenarios the TRPC6 channel would function as 
transducer/effector and not as the primary hypoxia-sensor in mPSCs.  
TRPC6 channels are non-selective cation channels that are also permeable for Na+. 
In rat aortic smooth muscle cells both global monotonic and localized transient [Na+]i 
elevations were TRPC6-dependent (Poburko et al., 2007). The authors suggested, that Na+ 
entry via TRPC6-containing channels is a common response to a variety of phospholipase 
C–coupled receptors (Poburko et al., 2007). This can be a preserved mechanism in other 
cells such as PSCs. In this context it is interesting to note that Na+ is important for correct 
GPCR function. GPCRs contain a specific allosteric binding site for Na+, which can 
modulate agonist binding and thereby GPCR signal transduction (Katritch et al., 2014; 
Muller et al., 2012; Parker et al., 2008). From this it can be speculated that TRPC6-
mediated Na+ entry could contribute to the correct function of GPCR receptors linked to 
autocrine stimulation pathways in PSC activation. In turn, GPCR induced DAG production 
activates TRPC6 channel activity. Loss of TRPC6 would therefore inhibit this loop of 
activation.  
 
5.4 Future Objectives 
The current study demonstrates that TRPC1 and TRPC6 channels are important for 
the response of mPSCs to hypoxia by contributing to distinct mechanisms underlying 
sensor, modifier and transduction/effector pathways regulating mPSC activation. 
However, some questions remain open. One of the future objectives is to further clarify 
the role of TRPC1 channels. This could be achieved by measuring SOCE in hypoxia-
stimulated mPSCs in order to confirm a possible role of TRPC1 channels in this process. 
Moreover, it is not yet known which TRPC6-dependent autocrine stimulants are secreted 
by mPSCs and if these can also have paracrine effects on PDAC cells. Once the autocrine 
factors are identified, one could determine whether TRPC1 and TRPC6 channels are part 
of the intracellular effector pathways. These pieces of information are the final data sets 
needed for clarifying the role of the TRPC6 channel as modifier and/or transducer in 
hypoxia-stimulated migration of mPSCs.  
The present study shows that TRPC1 and TRPC6 channels are not central 
components in the response of mPSCs to PDGF. Their involvement in the response to 
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other known stimulants of PSC activity such as EGF, FGF, TGF-β, VEGF, CTGF, ROS and 
several ILs is not yet known. However, many of these stimulants elicit their effects 
through GPCRs and RTKs leading to the activation of TRPC1 and TRPC6 channels 
(reviewed in (Dietrich and Gudermann, 2014; Nesin and Tsiokas, 2014)). For example, 
TRPC1 regulates cellular responses to EGF and fMLP (Bomben et al., 2011; Lindemann et 
al., 2015; Tajeddine and Gailly, 2012) and TRPC6 regulates responses to KC, VEGF and 
TGF-β (Davis et al., 2012; Hamdollah Zadeh et al., 2008; Lindemann et al., 2013). One way 
to identify TRPC6-dependent secreted growth factors and cytokines could be by 
comparing the supernatants from WT and TRPC6-/- mPSCs. The most prominent candidate 
protein could then be tested in migration experiments. Comparing its stimulatory effect 
in WT and TRPC6-/- mPSCs will show whether TRPC6 channels are – in addition to 
regulating growth factor/cytokine secretion – also play a role in its transducer/effector 
pathway. 
The TRPC1- and TRPC6-mediated Ca2+ influx can regulate the reorganization of the 
cytoskeleton in cell movement and volume control. The identification of activated 
cytoskeletal effector proteins would thereby shed light upon the lacking morphological 
changes in TRPC1-/- and TRPC6-/- mPSCs under hypoxia stimulation. This regulation is 
primarily demonstrated by their effect on important signalling cascades including PI3K, 
MAPK and Rho, almost all of which depend on Ca2+ and affect cell migration (Falke and 
Ziemba, 2014). Activated PI3K generates PIP3 from PIP2. PIP3 activates the activity of Rac 
or Cdc42 via Guanine Nucleotide Exchange Factors (GEFs) such as Vav, Tiam1, PIX and p-
REX (Benard et al., 1999; Fukata et al., 2003). The importance of GEF and Rho A signalling 
in actin dynamics and migration has been identified (Etienne-Manneville and Hall, 2002). 
MAPK signalling regulates the actomyosin network by activation of Rho and myosin-II (Li 
et al., 2013). In line with this, several studies showed that TRP channels elicit their effect 
on migration via these pathways. Examples include TRPM7-dependent polarization and 
migration of fibroblasts (Su et al., 2011) and TRPC1- and TRPC6-dependent chemotaxis of 
neutrophils (Damann et al., 2009; Lindemann et al., 2013). TRPC6 activity induces RhoA 
activation in smooth muscle cells (Jiang et al., 2014) and endothelial cells (Singh et al., 
2007), which is important for cytoskeletal rearrangements. Moreover, TRPC6-mediated 
calcium influx increase RhoA activity which regulate fibroblast migration (Tian et al., 
2010). 
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Many of these signalling cascades are implicated in PSC activation (section 1.3.2). 
Identification of a TRPC1- and/or TRPC6-dependent activation of such signalling cascades 
can improve the understanding of the mechanism by which these channels regulate mPSC 
migration under hypoxia. Preliminary studies have shown that WT mPSCs elicit elevated 
migratory activity in response to the GPCR CXCR2 ligand KC. A link is shown between KC, 
CXCR2 and TRPC6 activity in chemotaxis of murine neutrophils (Lindemann et al., 2013). 
Interestingly, KC (CXCL1) is upregulated in PDAC and mediates stimulating effects on 
pancreatic stromal fibroblasts leading to enhanced tumour growth. Inhibition of this KC-
CXCR2 axis had a significant antitumor effect (Ijichi et al., 2011). These results suggest 
that inhibiting tumour-stromal interactions could be a promising therapeutic strategy for 
PDAC. This mechanism may be preserved in mPSCs as well. Moreover, in an entirely 
different experimental setup, inhibition of KCa3.1 led to a decrease in TRPC3-mediated 
calcium entry and lower PSC migratory activity. This TRPC3-mediated calcium influx was 
found to be required for calpain activity, thereby acting as the downstream Ca2+ effector 
in cell migration. Accordingly, calpain activity is also needed for efficient migration of 
fibroblasts (Glading et al., 2000), lymphocytes (Svensson et al., 2010), cervical cancer cells 
(Saraiva et al., 2013) and glioblastoma cells (Jang et al., 2010). This suggests that calpain 
may be a downstream effector of TRPC1- and/or TRPC6-mediated calcium entry in mPSCs 
migration under hypoxia stimulation. 
Until now, most studies performed in other tumour stroma cells rely on ‘proof of 
principle’ experiments in ‘normal’ stroma cells showing that TRP channels are central for 
migration and/or growth factor secretion. Future experiments could therefore include in 
vivo experiments for further validation of the roles of TRPC1 and TRPC6 channels in PSC 
function in PDAC. Co-injection of TRPC1-/- or TRPC6-/- PSCs with PDAC cells into a murine 
PDAC model would clarify whether the two channels are required for PSCs to co-
metastasise with PDAC cells. Furthermore, any signs of slower tumour progression, 
reduced tumour size or metastasis would indicate an important role of TRPC1 and/or 
TRPC6 channels in PSC function in PDAC. Such a finding would also argue for a protective 
role of inhibiting PSC function in PDAC.  
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Concluding Remarks and Perspectives 
6.1 Conclusions 
Cell migration is fundamental to cell and tissue homeostasis and therefore plays a 
vital role in many physiological and pathophysiological processes. On the other hand, 
uncontrolled migration or migration of an incorrect cell type can endanger the well-being 
of our body as observed in tumour metastasis and in the activation of stroma cells such as 
PSCs (Hanahan and Weinberg, 2011; Nielsen et al., 2014). Sustained PSC activation in 
PDAC leads to disturbance of the tissue architecture, primarily through increased 
deposition of connective tissue. This further leads to poor vascularization and thereby to 
the development of a progressively hypoxic and acidic TME (Apte et al., 2004; Vonlaufen 
et al., 2008b). In the view of PSCs, migration is a consequence of their activated state and 
a requirement for mutual signalling with cancer cells permissive for PDAC progression 
(Phillips et al., 2003b). Growing evidence supports a role of TRP channels in sensing and 
modifying the (tumour) microenvironment. More, by acting as Ca2+ permeable channels 
they are closely connected to cell migration as this is recognized as a Ca2+ dependent 
mechanism (Nielsen et al., 2014).  
The overall aim for the studies described in this thesis was to decipher the role of 
TRPC1 and TRPC6 channels in regulating the responses of PSCs to hypoxia. This was 
postulated to occur through a sensor, modifier and/or effector mechanism mediated 
intracellular Ca2+ transients during hypoxic stimulation. This in turn could activate 
signalling pathways linked to cell migration and/or secretion of growth factors/cytokines 
that promote autocrine stimulation of PSCs. These data demonstrate for the first time 
that hypoxia-mediated increase of TRPC1 channel expression in mPSCs is coupled to 
elevated cell motility, possibly via a sensor mechanism. In addition, it seems TRPC1 is 
implicated in cell size regulation. Finally, TRPC6 channels are part of a modifier 
mechanism in mPSCs by being involved in efficient autocrine growth factor/cytokine 
secretion under hypoxia stimulation. More, TRPC6 channels are part of a 
transduction/effector pathway as they are required for increased calcium influx during 
hypoxia, which possibly activate Ca2+ sensitive effector proteins important for the cellular 
migration machinery.  
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Figure 6.1. Overview of TRPC1 and TRPC6 Channels Functional Mechanism in mPSCs Under  
Hypoxic Stimulation. TRP channels are important components of cellular responses to the 
microenvironment and vice versa. Based on data in the present work the following 
mechanisms could be predicted for the role of TRPC1 and TRPC6 channels in the response of 
mPSCs to hypoxia: (1) The TRPC1 channel is part of an indirect sensor mechanism to hypoxia, 
(2) whereas the TRPC6 channels is part of a coupled modifier and transduction/effector 
mechanism by being involved in secretion of autocrine stimulants and mediating elevated 
calcium responses upon hypoxia stimulation (modified from figure 1.8 in introduction). 
In conclusion, the work described in this thesis supports the hypothesis TRPC1 and 
TRPC6 channels are important for the response of PSCs to hypoxia by contributing to 
distinct mechanisms underlying a sensor, modifier and transduction/effector pathways 
(illustrated in figure 6.1). 
The results show a clear direction for future studies to further characterize the 
mechanistic role of TRPC1 and TRPC6 channels in mPSCs response to hypoxia. It is of great 
interest to: (i) determine which autocrine stimulants are secreted hypoxia- and TRPC6-
dependently by mPSCs and whether TRPC6 channels are part of the intracellular effector 
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pathways of these stimulants, (ii) identify TPRC1 channels contribution to calcium influx 
under hypoxia and (iii) determine TRPC1- and TRPC6-dependent downstream effector 
proteins important for cell migration. 
 
6.2 Perspectives 
It is logical that PSCs and the PDAC stroma are seen as important alternative 
therapeutic targets (Farrow et al., 2008; Feig et al., 2012). This is further highlighted by 
the observation that PSCs remain activated after in vivo chemoradiation (Cabrera et al., 
2014) and perpetuate supporting microenvironments for PDAC stem cells survival 
(Lonardo et al., 2012). Thus, PDAC stem cells are shown to be major players in promoting 
PDAC formation and resistance (Hermann et al., 2007; Li et al., 2007a). Reprogramming 
PSCs and consequently the tumour stroma represents therefore a new paradigm that 
may be exploited to improve the outcome of PDAC therapy (Schober et al., 2014; 
Stromnes et al., 2014).  
Promising results have been achieved in reprogramming PSCs to reprise their 
quiescent state, with increases in PDAC response to cancer therapy. Sherman et al. 
demonstrated that activation of the vitamin D receptor in PSCs acts as a genomic 
suppressor and inhibited PSC activation (Sherman et al., 2014). Retinoic acid induces 
quiescence and reduces PSC motility slowing tumour progression (Froeling et al., 2011). 
However, two recent publications question a tumour protective role of PSCs (Ozdemir et 
al., 2014; Rhim et al., 2014). Rhim et al. and Ozdemir et al. documented that removal of 
stroma promoting hedgehog signalling and depletion of PSCs, respectively, led to 
acceleration of PDAC progression in GEMMs. This was postulated to be caused by a 
decrease in desmoplasia subsequently leading to a more vascularized tumour, 
accelerated growth and metastasis, ultimately leading to poor survival (Coleman and 
Rhim, 2014; Ozdemir et al., 2014). These data underscore the complex role of PSCs in 
PDAC biology and demonstrate that their function is far from being completely 
understood. However, with the overall recognition of the tumour stroma role in PDAC 
progression, there has been a shift in the way treatment of advanced PDAC is viewed. For 
a long time gemcitabine has been the drug of choice (reviewed in (Jones et al., 2014; 
Oettle, 2014). A recent phase III trial has shown convincing results that pave the way for 
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future treatment regimens that target not only the primary tumour but the surrounding 
stroma as well. A combination of Nab-paclitaxel (a stroma-targeted drug) plus 
gemcitabine (targeting PDAC cells) shows an increased survival rate (p < 0.001) compared 
to gemcitabine alone. The 1-year survival rate were 35% vs. 22%, and 9% vs. 4% at 2 
years, respectively (Frese et al., 2012; Haqq et al., 2014; Oettle, 2014; Von Hoff et al., 
2013; Von Hoff et al., 2011).  
The prominent role of TRP channels in cancer can be related to the fact that the 
expression of TRP channels is frequently dysregulated in cancer in a stage and cancer 
type-dependent manner (Ouadid-Ahidouch et al., 2013; Santoni and Farfariello, 2011; 
Van Haute et al., 2010). This property is shared with many other ion channels such as K+, 
Na+ or Cl– (Prevarskaya et al., 2010; Stock and Schwab, 2014). So far, there is relatively 
limited information about TRP channels in tumour stroma cells. Furthermore, as 
membrane proteins, TRPC channels are accessible from the extracellular side, which 
reduces the risk of multidrug resistance due to drug export from the cytoplasm. Targeting 
TRPC1 and TRPC6 channels expressed in both PDAC cells (unknown) and PSCs would offer 
the potential for a ‘double hit’ and break the vicious cycle of mutual PDAC and PSC cell 
stimulation. This is highlighted by the fact that these channels are not only involved in cell 
migration but also in other functions critical for cancer progression such as tumour cell 
proliferation. This has, among others, been observed for TRPC1 and TRPC6 in 
glioblastoma (Bomben and Sontheimer, 2010; Bomben et al., 2011; Chigurupati et al., 
2010; Ding et al., 2010). Moreover, TRP channels are implicated in important functions of 
endothelial cells such as angiogenesis and vascularization of the tumour (Fiorio Pla et al., 
2008; Fiorio Pla et al., 2012; Lodola et al., 2012) (reviewed in (Fioro Pla and Gkika, 2013).  
Hypoxia and PSC activation are typical features of the PDAC stroma (Erkan et al., 
2009; Fabian et al., 2012). The data present in this study identify a specific role of TRPC1 
and/or TRPC6 channels in hypoxia-mediated activation of PSCs by distinct mechanisms. 
This brings new insights into several aspects of PSC biology and PDAC. Thus, further 
elucidation and identification of the functional role of TRP channels in hypoxia activated 
PSCs may lead to the development of new innovative tumour markers. Moreover, 
targeting PSCs and inhibiting their activity will indirectly also affect PDAC cells: (i) The 
mutual activation of PSCs and PDAC cells will be attenuated and (ii) inhibiting the PSC-
mediated desmoplastic reaction will slow down tumour progression. Furthermore, it 
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highlights the importance of TRP channels in sensing (tumour) micoenvironmental 
changes and in transducing the respective cellular responses in both tumour and stroma 
cells. This study therefore expands the knowledge and understanding of the functional 
diversity of TRP channels. 
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